,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"Sustainability ReportMaking a World of Difference2022 Hologic Sustainability Report From Our CEO   .
","('Business_Model_Resilience', 0.2714112102985382)","('Product_Design_And_Lifecycle_Management', 0.16043776273727417)","('Supply_Chain_Management', 0.11376193910837173)","('NON-ESG', 0.2714112102985382)","('NON-ESG', 0.16043776273727417)","('NON-ESG', 0.11376193910837173)"
Line 2,"A M essage From   Our Chairman,   President and CEO    .
","('Director_Removal', 0.7284752130508423)","('Management_Of_Legal_And_Regulatory_Framework', 0.03799736499786377)","('Business_Ethics', 0.023802997544407845)","(['Anti-Crime Policy & Measures'], 0.7284752130508423)","('NON-ESG', 0.03799736499786377)","('NON-ESG', 0.023802997544407845)"
Line 3,"Our Purpose   .
","('Human_Rights_And_Community_Relations', 0.25142717361450195)","('Business_Model_Resilience', 0.08536763489246368)","('Employee_Engagement_Inclusion_And_Diversity', 0.06764070689678192)","('NON-ESG', 0.25142717361450195)","('NON-ESG', 0.08536763489246368)","('NON-ESG', 0.06764070689678192)"
Line 4,"H ologic Overview  .
","('Access_And_Affordability', 0.20901571214199066)","('Customer_Welfare', 0.08957088738679886)","('Product_Design_And_Lifecycle_Management', 0.07554112374782562)","('NON-ESG', 0.20901571214199066)","('NON-ESG', 0.08957088738679886)","('NON-ESG', 0.07554112374782562)"
Line 5,"H ologic at a Glance    .
","('Customer_Welfare', 0.16706162691116333)","('Competitive_Behavior', 0.1219303086400032)","('Access_And_Affordability', 0.10790184885263443)","('NON-ESG', 0.16706162691116333)","('NON-ESG', 0.1219303086400032)","('NON-ESG', 0.10790184885263443)"
Line 6,"R&D Spotlight   .
","('Business_Model_Resilience', 0.2798764705657959)","('Supply_Chain_Management', 0.17355400323867798)","('Product_Design_And_Lifecycle_Management', 0.1077256053686142)","('NON-ESG', 0.2798764705657959)","('NON-ESG', 0.17355400323867798)","('NON-ESG', 0.1077256053686142)"
Line 7,"History of Innovation   .
","('Business_Model_Resilience', 0.17174836993217468)","('Product_Design_And_Lifecycle_Management', 0.1471058577299118)","('Employee_Engagement_Inclusion_And_Diversity', 0.12236158549785614)","('NON-ESG', 0.17174836993217468)","('NON-ESG', 0.1471058577299118)","('NON-ESG', 0.12236158549785614)"
Line 8,"9  Shingo Prize: A World-Class  Culture of Excellence .
","('Business_Ethics', 0.1570734977722168)","('Management_Of_Legal_And_Regulatory_Framework', 0.11852454394102097)","('Competitive_Behavior', 0.10320335626602173)","('NON-ESG', 0.1570734977722168)","('NON-ESG', 0.11852454394102097)","('NON-ESG', 0.10320335626602173)"
Line 9,"10  Materiality Assessment    .
","('Business_Model_Resilience', 0.2784676253795624)","('Systemic_Risk_Management', 0.14056582748889923)","('Management_Of_Legal_And_Regulatory_Framework', 0.07145129889249802)","('NON-ESG', 0.2784676253795624)","('NON-ESG', 0.14056582748889923)","('NON-ESG', 0.07145129889249802)"
Line 10,"11  U.N. Sustainable  Development Goals    .
","('Human_Rights_And_Community_Relations', 0.6057009696960449)","('Business_Model_Resilience', 0.077064648270607)","('Ecological_Impacts', 0.045815858989953995)","(['Community Relations'], 0.6057009696960449)","('NON-ESG', 0.077064648270607)","('NON-ESG', 0.045815858989953995)"
Line 11,"A Discussion With Our CFO: Our Sustainability Strategy    .
","('Business_Model_Resilience', 0.6645469665527344)","('Systemic_Risk_Management', 0.0840299054980278)","('Supply_Chain_Management', 0.04244492948055267)","(['Codes of Business Conduct'], 0.6645469665527344)","('NON-ESG', 0.0840299054980278)","('NON-ESG', 0.04244492948055267)"
Line 12,"13Championing Women   .
","('Employee_Engagement_Inclusion_And_Diversity', 0.36319440603256226)","('Director_Removal', 0.08449321240186691)","('Labor_Practices', 0.06733069568872452)","('NON-ESG', 0.36319440603256226)","('NON-ESG', 0.08449321240186691)","('NON-ESG', 0.06733069568872452)"
Line 13,"14  Hologic Global Women’s  Health Index    .
","('Employee_Health_And_Safety', 0.240494966506958)","('Employee_Engagement_Inclusion_And_Diversity', 0.12871097028255463)","('Access_And_Affordability', 0.11339972913265228)","('NON-ESG', 0.240494966506958)","('NON-ESG', 0.12871097028255463)","('NON-ESG', 0.11339972913265228)"
Line 14,"15  Serving the Greater Good With  the WTA    .
","('Access_And_Affordability', 0.22292418777942657)","('Human_Rights_And_Community_Relations', 0.17093582451343536)","('Product_Design_And_Lifecycle_Management', 0.08943435549736023)","('NON-ESG', 0.22292418777942657)","('NON-ESG', 0.17093582451343536)","('NON-ESG', 0.08943435549736023)"
Line 15,"18  Global Access Initiative    .
","('Access_And_Affordability', 0.5052722096443176)","('Management_Of_Legal_And_Regulatory_Framework', 0.08823321759700775)","('Human_Rights_And_Community_Relations', 0.08587273210287094)","(['Health Outcome Contribution'], 0.5052722096443176)","('NON-ESG', 0.08823321759700775)","('NON-ESG', 0.08587273210287094)"
Line 16,"20  Project Health Equality    .
","('Human_Rights_And_Community_Relations', 0.529636800289154)","('Employee_Engagement_Inclusion_And_Diversity', 0.09733501821756363)","('Access_And_Affordability', 0.09547434002161026)","(['Community Relations'], 0.529636800289154)","('NON-ESG', 0.09733501821756363)","('NON-ESG', 0.09547434002161026)"
Line 17,"Helping Underserved  Women Worldwide    .
","('Access_And_Affordability', 0.934110164642334)","('Critical_Incident_Risk_Management', 0.00757948262616992)","('Human_Rights_And_Community_Relations', 0.005976839456707239)","(['Health Outcome Contribution'], 0.934110164642334)","('NON-ESG', 0.00757948262616992)","('NON-ESG', 0.005976839456707239)"
Line 18,"Our People   .
","('Human_Rights_And_Community_Relations', 0.4915091395378113)","('Employee_Engagement_Inclusion_And_Diversity', 0.14478391408920288)","('Business_Model_Resilience', 0.055221762508153915)","('NON-ESG', 0.4915091395378113)","('NON-ESG', 0.14478391408920288)","('NON-ESG', 0.055221762508153915)"
Line 19,"P eople First    .
","('Competitive_Behavior', 0.5420197248458862)","('Business_Ethics', 0.049711138010025024)","('Systemic_Risk_Management', 0.048999518156051636)","(['Business Ethics'], 0.5420197248458862)","('NON-ESG', 0.049711138010025024)","('NON-ESG', 0.048999518156051636)"
Line 20,"Key Indicators of  Engagement    .
","('Human_Rights_And_Community_Relations', 0.5564277768135071)","('Business_Model_Resilience', 0.10496503114700317)","('Management_Of_Legal_And_Regulatory_Framework', 0.044812217354774475)","(['Community Relations'], 0.5564277768135071)","('NON-ESG', 0.10496503114700317)","('NON-ESG', 0.044812217354774475)"
Line 21,"Our People Drive  Our Passion    .
","('Employee_Engagement_Inclusion_And_Diversity', 0.22082504630088806)","('Human_Rights_And_Community_Relations', 0.21965357661247253)","('Business_Model_Resilience', 0.13893316686153412)","('NON-ESG', 0.22082504630088806)","('NON-ESG', 0.21965357661247253)","('NON-ESG', 0.13893316686153412)"
Line 22,"Our People Deliver  Our Promise    .
","('Human_Rights_And_Community_Relations', 0.3213636577129364)","('Employee_Engagement_Inclusion_And_Diversity', 0.18537552654743195)","('Business_Model_Resilience', 0.10227951407432556)","('NON-ESG', 0.3213636577129364)","('NON-ESG', 0.18537552654743195)","('NON-ESG', 0.10227951407432556)"
Line 23,"Raising the Bar: Championing  World-Class Managers    .
","('Competitive_Behavior', 0.5526652336120605)","('Business_Ethics', 0.07190944254398346)","('Systemic_Risk_Management', 0.04167407751083374)","(['Business Ethics'], 0.5526652336120605)","('NON-ESG', 0.07190944254398346)","('NON-ESG', 0.04167407751083374)"
Line 24,"Employee Workforce  Composition    .
","('Employee_Engagement_Inclusion_And_Diversity', 0.9320091605186462)","('Labor_Practices', 0.014642306603491306)","('Employee_Health_And_Safety', 0.006965104956179857)","(['Human Capital Development'], 0.9320091605186462)","('NON-ESG', 0.014642306603491306)","('NON-ESG', 0.006965104956179857)"
Line 25,"39Good Governance   .
","('Business_Model_Resilience', 0.16087192296981812)","('Systemic_Risk_Management', 0.1346915364265442)","('Competitive_Behavior', 0.11128739267587662)","('NON-ESG', 0.16087192296981812)","('NON-ESG', 0.1346915364265442)","('NON-ESG', 0.11128739267587662)"
Line 26,"44  Governance and Shareholder   Engagement    .
","('Business_Model_Resilience', 0.35248735547065735)","('Management_Of_Legal_And_Regulatory_Framework', 0.11973124742507935)","('Competitive_Behavior', 0.0818830356001854)","('NON-ESG', 0.35248735547065735)","('NON-ESG', 0.11973124742507935)","('NON-ESG', 0.0818830356001854)"
Line 27,"Clinical Trial Governance    .
","('Competitive_Behavior', 0.337955117225647)","('Management_Of_Legal_And_Regulatory_Framework', 0.280245840549469)","('Business_Ethics', 0.09206981956958771)","('NON-ESG', 0.337955117225647)","('NON-ESG', 0.280245840549469)","('NON-ESG', 0.09206981956958771)"
Line 28,"48  Supply Chain Management    .
","('Supply_Chain_Management', 0.9439929127693176)","('Physical_Impacts_Of_Climate_Change', 0.005229755770415068)","('Product_Design_And_Lifecycle_Management', 0.0039370679296553135)","(['Supply Chain Management'], 0.9439929127693176)","('NON-ESG', 0.005229755770415068)","('NON-ESG', 0.0039370679296553135)"
Line 29,"49  Supplier Risk Management    .
","('Supply_Chain_Management', 0.9359897971153259)","('Physical_Impacts_Of_Climate_Change', 0.005884972866624594)","('Systemic_Risk_Management', 0.005087980534881353)","(['Supply Chain Management'], 0.9359897971153259)","('NON-ESG', 0.005884972866624594)","('NON-ESG', 0.005087980534881353)"
Line 30,"50  Quality Management Systems    .
","('Product_Quality_And_Safety', 0.2533518373966217)","('Supply_Chain_Management', 0.13355180621147156)","('Product_Design_And_Lifecycle_Management', 0.09672540426254272)","('NON-ESG', 0.2533518373966217)","('NON-ESG', 0.13355180621147156)","('NON-ESG', 0.09672540426254272)"
Line 31,"51  Workplace Health  and Safety    .
","('Employee_Health_And_Safety', 0.9792328476905823)","('Critical_Incident_Risk_Management', 0.004921154584735632)","('Employee_Engagement_Inclusion_And_Diversity', 0.001761132851243019)","(['Operational Eco-Efficiency'], 0.9792328476905823)","('NON-ESG', 0.004921154584735632)","('NON-ESG', 0.001761132851243019)"
Line 32,"52  Information Security  Governance    .
","('Data_Security', 0.914284348487854)","('Systemic_Risk_Management', 0.009492163546383381)","('Management_Of_Legal_And_Regulatory_Framework', 0.00646494934335351)","(['Information Security/Cybersecurity & System Availability'], 0.914284348487854)","('NON-ESG', 0.009492163546383381)","('NON-ESG', 0.00646494934335351)"
Line 33,"Governance Policies   and Procedures    .
","('Management_Of_Legal_And_Regulatory_Framework', 0.7486196160316467)","('Human_Rights_And_Community_Relations', 0.061292342841625214)","('Business_Ethics', 0.03845022991299629)","(['Corporate Governance'], 0.7486196160316467)","('NON-ESG', 0.061292342841625214)","('NON-ESG', 0.03845022991299629)"
Line 34,"Reporting Frameworks    .
","('Management_Of_Legal_And_Regulatory_Framework', 0.6491971015930176)","('Human_Rights_And_Community_Relations', 0.0611192025244236)","('Access_And_Affordability', 0.032138314098119736)","(['Corporate Governance'], 0.6491971015930176)","('NON-ESG', 0.0611192025244236)","('NON-ESG', 0.032138314098119736)"
Line 35,"Sustainability Accounting   Standards    .
","('Management_Of_Legal_And_Regulatory_Framework', 0.22625166177749634)","('Product_Quality_And_Safety', 0.10509209334850311)","('Director_Removal', 0.09181080013513565)","('NON-ESG', 0.22625166177749634)","('NON-ESG', 0.10509209334850311)","('NON-ESG', 0.09181080013513565)"
Line 36,"Task Force on Climate-Related  Financial Disclosures    .
","('Physical_Impacts_Of_Climate_Change', 0.924232006072998)","('Business_Model_Resilience', 0.018597841262817383)","('GHG_Emissions', 0.010513108223676682)","(['Climate Change'], 0.924232006072998)","('NON-ESG', 0.018597841262817383)","('NON-ESG', 0.010513108223676682)"
Line 37,"Safe Harbor Statement    .
","('Customer_Privacy', 0.37226951122283936)","('Data_Security', 0.30447152256965637)","('Business_Model_Resilience', 0.03302910923957825)","('NON-ESG', 0.37226951122283936)","('NON-ESG', 0.30447152256965637)","('NON-ESG', 0.03302910923957825)"
Line 38,"60Table of  Contents Our Communities   .
","('Human_Rights_And_Community_Relations', 0.42101332545280457)","('Business_Model_Resilience', 0.07801471650600433)","('Employee_Engagement_Inclusion_And_Diversity', 0.0755675882101059)","('NON-ESG', 0.42101332545280457)","('NON-ESG', 0.07801471650600433)","('NON-ESG', 0.0755675882101059)"
Line 39,"2 Strengthening Communities   Through Philanthropy    .
","('Human_Rights_And_Community_Relations', 0.8232394456863403)","('Access_And_Affordability', 0.05327595770359039)","('Critical_Incident_Risk_Management', 0.014638681896030903)","(['Community Relations'], 0.8232394456863403)","('NON-ESG', 0.05327595770359039)","('NON-ESG', 0.014638681896030903)"
Line 40,"Supporting a Diverse   Range of Causes    .
","('Human_Rights_And_Community_Relations', 0.656360924243927)","('Access_And_Affordability', 0.10252001881599426)","('Management_Of_Legal_And_Regulatory_Framework', 0.03813844174146652)","(['Community Relations'], 0.656360924243927)","('NON-ESG', 0.10252001881599426)","('NON-ESG', 0.03813844174146652)"
Line 41,"26The Environment   .
","('Ecological_Impacts', 0.6209879517555237)","('GHG_Emissions', 0.15424519777297974)","('Water_And_Wastewater_Management', 0.038609154522418976)","(['Natural Capital'], 0.6209879517555237)","('NON-ESG', 0.15424519777297974)","('NON-ESG', 0.038609154522418976)"
Line 42,"2 Environmental Goals    .
","('Human_Rights_And_Community_Relations', 0.7261773943901062)","('Ecological_Impacts', 0.0376683846116066)","('GHG_Emissions', 0.030809132382273674)","(['Community Relations'], 0.7261773943901062)","('NON-ESG', 0.0376683846116066)","('NON-ESG', 0.030809132382273674)"
Line 43,"Hologic Costa Rica's Climate Leadership    .
","('Physical_Impacts_Of_Climate_Change', 0.915200412273407)","('Business_Model_Resilience', 0.016797469928860664)","('GHG_Emissions', 0.010658040642738342)","(['Climate Change'], 0.915200412273407)","('NON-ESG', 0.016797469928860664)","('NON-ESG', 0.010658040642738342)"
Line 44,"Environmental Initiatives in  Our Diagnostics Division    .
","('Human_Rights_And_Community_Relations', 0.1182086393237114)","('Management_Of_Legal_And_Regulatory_Framework', 0.10981602221727371)","('Access_And_Affordability', 0.10860225558280945)","('NON-ESG', 0.1182086393237114)","('NON-ESG', 0.10981602221727371)","('NON-ESG', 0.10860225558280945)"
Line 45,"Climate Risks  and Opportunities    .
","('Physical_Impacts_Of_Climate_Change', 0.9217859506607056)","('Business_Model_Resilience', 0.014471305534243584)","('GHG_Emissions', 0.011922153644263744)","(['Climate Change'], 0.9217859506607056)","('NON-ESG', 0.014471305534243584)","('NON-ESG', 0.011922153644263744)"
Line 46,"322022 Hologic Sustainability Report 2 2022 Hologic Sustainability Report 2From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  A Message From  Our Chairman,   President and CEO 2Hologic's virtuous circle represents our corporate objectives.
","('Human_Rights_And_Community_Relations', 0.7682762742042542)","('Business_Model_Resilience', 0.04999247193336487)","('Ecological_Impacts', 0.019080406054854393)","(['Community Relations'], 0.7682762742042542)","('NON-ESG', 0.04999247193336487)","('NON-ESG', 0.019080406054854393)"
Line 47,"Dear Hologic Stakeholders, Thanks to all of you for taking an interest in our sustainability journey.
","('Business_Model_Resilience', 0.5698546171188354)","('Product_Design_And_Lifecycle_Management', 0.06269521266222)","('Supply_Chain_Management', 0.04686688259243965)","(['Codes of Business Conduct'], 0.5698546171188354)","('NON-ESG', 0.06269521266222)","('NON-ESG', 0.04686688259243965)"
Line 48,"We are excited to showcase our 2022 report and the progress we  continue to make living into our purpose, passion and promise: • Our purpose  is to enable healthier lives everywhere, every day.
","('Employee_Health_And_Safety', 0.5805941224098206)","('Access_And_Affordability', 0.13292089104652405)","('Product_Design_And_Lifecycle_Management', 0.04668015241622925)","(['Operational Eco-Efficiency'], 0.5805941224098206)","('NON-ESG', 0.13292089104652405)","('NON-ESG', 0.04668015241622925)"
Line 49,"• Our passion  is to champion women’s health globally.
","('Employee_Health_And_Safety', 0.7503848671913147)","('Employee_Engagement_Inclusion_And_Diversity', 0.06359675526618958)","('Access_And_Affordability', 0.033958565443754196)","(['Operational Eco-Efficiency'], 0.7503848671913147)","('NON-ESG', 0.06359675526618958)","('NON-ESG', 0.033958565443754196)"
Line 50,"•    Our promise  is The Science of Sure® , a commitment to provide healthcare  professionals clinically differentiated, high-quality products.
","('Product_Design_And_Lifecycle_Management', 0.5091868042945862)","('Customer_Welfare', 0.22215299308300018)","('Product_Quality_And_Safety', 0.04776950925588608)","(['Product Stewardship'], 0.5091868042945862)","('NON-ESG', 0.22215299308300018)","('NON-ESG', 0.04776950925588608)"
Line 51,"Before diving into the highlights of this year’s report, I’d like to reflect on the theme of false  choices raised in the introduction letter  to last year’s Sustainability Report.
","('Business_Model_Resilience', 0.5071892142295837)","('Systemic_Risk_Management', 0.10484545677900314)","('Physical_Impacts_Of_Climate_Change', 0.07557674497365952)","(['Codes of Business Conduct'], 0.5071892142295837)","('NON-ESG', 0.10484545677900314)","('NON-ESG', 0.07557674497365952)"
Line 52,"These false   choices, in which something is presented as undoubtedly true or false, have defined   much of today’s discourse — from politics to business to everyday conversations at the   dinner table.
","('Business_Ethics', 0.6994437575340271)","('Competitive_Behavior', 0.11530211567878723)","('Systemic_Risk_Management', 0.04018860682845116)","(['Business Ethics'], 0.6994437575340271)","('NON-ESG', 0.11530211567878723)","('NON-ESG', 0.04018860682845116)"
Line 53,"Perhaps inevitably, the framing of false choices has also made its way into   environmental, social and governance matters.
","('Human_Rights_And_Community_Relations', 0.400888055562973)","('Management_Of_Legal_And_Regulatory_Framework', 0.23249119520187378)","('Business_Model_Resilience', 0.0650777742266655)","('NON-ESG', 0.400888055562973)","('NON-ESG', 0.23249119520187378)","('NON-ESG', 0.0650777742266655)"
Line 54,"At Hologic, we believe the best companies don’t have to choose between sustainability   and maximizing performance.
","('Business_Model_Resilience', 0.496989369392395)","('Product_Design_And_Lifecycle_Management', 0.09182728826999664)","('Systemic_Risk_Management', 0.08513546735048294)","('NON-ESG', 0.496989369392395)","('NON-ESG', 0.09182728826999664)","('NON-ESG', 0.08513546735048294)"
Line 55,"We commit to elevating women’s health worldwide while   generating strong financial returns for our shareholders.
","('Employee_Health_And_Safety', 0.6314142346382141)","('Access_And_Affordability', 0.12575648725032806)","('Employee_Engagement_Inclusion_And_Diversity', 0.05782578885555267)","(['Operational Eco-Efficiency'], 0.6314142346382141)","('NON-ESG', 0.12575648725032806)","('NON-ESG', 0.05782578885555267)"
Line 56,"As you will see from the breadth   and depth of our initiatives, each objective is intimately connected to our business strategy  because doing the right thing is fundamental to who we are.
","('Business_Model_Resilience', 0.3638952672481537)","('Human_Rights_And_Community_Relations', 0.23703472316265106)","('Director_Removal', 0.04925241693854332)","('NON-ESG', 0.3638952672481537)","('NON-ESG', 0.23703472316265106)","('NON-ESG', 0.04925241693854332)"
Line 57,"Our financial success, sustainability strategy, commitment to helping more women — all while  reducing our carbon footprint and acting ethically in all matters with our stakeholders — are intertwined.
","('Business_Model_Resilience', 0.3411079943180084)","('Human_Rights_And_Community_Relations', 0.14597831666469574)","('Business_Ethics', 0.0834762305021286)","('NON-ESG', 0.3411079943180084)","('NON-ESG', 0.14597831666469574)","('NON-ESG', 0.0834762305021286)"
Line 58,"This relationship led to the creation of our virtuous circle.
","('Employee_Engagement_Inclusion_And_Diversity', 0.22455844283103943)","('Competitive_Behavior', 0.09244035184383392)","('Business_Ethics', 0.08030171692371368)","('NON-ESG', 0.22455844283103943)","('NON-ESG', 0.09244035184383392)","('NON-ESG', 0.08030171692371368)"
Line 59,"Through our deep focus on innovation and The Science of Sure , we generate financial returns and leverage these benefits to  invest in groundbreaking women’s health initiatives like the Hologic Global Women’s Health Index, Project Health Equality and work with the World Economic Forum.
","('Human_Rights_And_Community_Relations', 0.34032347798347473)","('Employee_Engagement_Inclusion_And_Diversity', 0.1653873473405838)","('Employee_Health_And_Safety', 0.14700593054294586)","('NON-ESG', 0.34032347798347473)","('NON-ESG', 0.1653873473405838)","('NON-ESG', 0.14700593054294586)"
Line 60,"These achievements enable us to elevate women’s health globally by advancing access, policy and awareness.2022 Hologic Sustainability Report 3 2022 Hologic Sustainability Report 3From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  Steve MacMillan at the World Economic Forum gathering in May 2022.
","('Human_Rights_And_Community_Relations', 0.8811913132667542)","('Access_And_Affordability', 0.026637207716703415)","('Employee_Engagement_Inclusion_And_Diversity', 0.0133499251678586)","(['Community Relations'], 0.8811913132667542)","('NON-ESG', 0.026637207716703415)","('NON-ESG', 0.0133499251678586)"
Line 61,"While we have made meaningful progress, our sustainability journey is by no means  complete.
","('Business_Model_Resilience', 0.43184006214141846)","('Human_Rights_And_Community_Relations', 0.0872010588645935)","('Director_Removal', 0.060680218040943146)","('NON-ESG', 0.43184006214141846)","('NON-ESG', 0.0872010588645935)","('NON-ESG', 0.060680218040943146)"
Line 62,"Every day, we seek to improve and refine our strategy with heartfelt purpose, passion and promise.
","('Business_Model_Resilience', 0.31770166754722595)","('Human_Rights_And_Community_Relations', 0.20522849261760712)","('Employee_Engagement_Inclusion_And_Diversity', 0.0939532145857811)","('NON-ESG', 0.31770166754722595)","('NON-ESG', 0.20522849261760712)","('NON-ESG', 0.0939532145857811)"
Line 63,"The women of the world deserve nothing less.
","('Business_Ethics', 0.19853460788726807)","('Labor_Practices', 0.18601353466510773)","('Human_Rights_And_Community_Relations', 0.0857895165681839)","('NON-ESG', 0.19853460788726807)","('NON-ESG', 0.18601353466510773)","('NON-ESG', 0.0857895165681839)"
Line 64,"First, the Hologic Global Women’s Health Index , conducted annually in partnership with   Gallup®, reveals unique insights directly from the experiences of women and provides a framework for making progress.
","('Employee_Health_And_Safety', 0.32697048783302307)","('Employee_Engagement_Inclusion_And_Diversity', 0.18828919529914856)","('Access_And_Affordability', 0.0909176617860794)","('NON-ESG', 0.32697048783302307)","('NON-ESG', 0.18828919529914856)","('NON-ESG', 0.0909176617860794)"
Line 65,"As we highlight on page 15, the Index’s results underscore  that prioritizing women’s health is more critical now than ever.
","('Employee_Health_And_Safety', 0.5775136351585388)","('Access_And_Affordability', 0.09952051192522049)","('Human_Rights_And_Community_Relations', 0.05478661507368088)","(['Operational Eco-Efficiency'], 0.5775136351585388)","('NON-ESG', 0.09952051192522049)","('NON-ESG', 0.05478661507368088)"
Line 66,"It is striking and disheartening  that even in developed economies, women’s health has taken a step back in the past year.
","('Employee_Health_And_Safety', 0.931125283241272)","('Employee_Engagement_Inclusion_And_Diversity', 0.007952681742608547)","('Critical_Incident_Risk_Management', 0.0073682451620697975)","(['Operational Eco-Efficiency'], 0.931125283241272)","('NON-ESG', 0.007952681742608547)","('NON-ESG', 0.0073682451620697975)"
Line 67,"For example, more than 1.5 billion women worldwide lacked essential health screenings for cancer, heart disease, diabetes and sexually transmitted infections.
","('Employee_Health_And_Safety', 0.43098142743110657)","('Access_And_Affordability', 0.28217265009880066)","('Product_Quality_And_Safety', 0.040591660887002945)","('NON-ESG', 0.43098142743110657)","('NON-ESG', 0.28217265009880066)","('NON-ESG', 0.040591660887002945)"
Line 68,"This is unacceptable.
","('Business_Ethics', 0.46601489186286926)","('Labor_Practices', 0.062189724296331406)","('Customer_Privacy', 0.04221232235431671)","('NON-ESG', 0.46601489186286926)","('NON-ESG', 0.062189724296331406)","('NON-ESG', 0.04221232235431671)"
Line 69,"With the multiyear Index initiative, we will continue to bring awareness to women’s health  at the highest levels, as evidenced by our inaugural participation at the 2022 World Economic Forum’s gathering in Davos, Switzerland.
","('Employee_Health_And_Safety', 0.7204841375350952)","('Access_And_Affordability', 0.10536845773458481)","('Human_Rights_And_Community_Relations', 0.03375723585486412)","(['Operational Eco-Efficiency'], 0.7204841375350952)","('NON-ESG', 0.10536845773458481)","('NON-ESG', 0.03375723585486412)"
Line 70,"We will relentlessly engage policymakers, business leaders, scholars, nonprofit advocates and others to join us in helping women around the  world live longer and better.
","('Human_Rights_And_Community_Relations', 0.4119740426540375)","('Employee_Engagement_Inclusion_And_Diversity', 0.2436329424381256)","('Access_And_Affordability', 0.08107142150402069)","('NON-ESG', 0.4119740426540375)","('NON-ESG', 0.2436329424381256)","('NON-ESG', 0.08107142150402069)"
Line 71,"Second, with Project Health Equality , we collaborate with our partners to reduce the healthcare  disparities gap that underserved women face.
","('Access_And_Affordability', 0.9389599561691284)","('Human_Rights_And_Community_Relations', 0.006848739925771952)","('Critical_Incident_Risk_Management', 0.005429066717624664)","(['Health Outcome Contribution'], 0.9389599561691284)","('NON-ESG', 0.006848739925771952)","('NON-ESG', 0.005429066717624664)"
Line 72,"Research shows, for example, that Black women  are almost 40% more likely to die from breast cancer compared to non-Hispanic white women.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9091225862503052)","('Employee_Health_And_Safety', 0.018718142062425613)","('Access_And_Affordability', 0.007863017730414867)","(['Human Capital Development'], 0.9091225862503052)","('NON-ESG', 0.018718142062425613)","('NON-ESG', 0.007863017730414867)"
Line 73,"Together with our Project Health Equality partners, we aim to change these statistics.
","('Employee_Engagement_Inclusion_And_Diversity', 0.20575056970119476)","('Access_And_Affordability', 0.12556254863739014)","('Labor_Practices', 0.11094535887241364)","('NON-ESG', 0.20575056970119476)","('NON-ESG', 0.12556254863739014)","('NON-ESG', 0.11094535887241364)"
Line 74,"On page 21, we proudly highlight events, partnerships and programs that help women overcome systemic hurdles to high-quality healthcare.
","('Systemic_Risk_Management', 0.6108612418174744)","('Supply_Chain_Management', 0.07586279511451721)","('Access_And_Affordability', 0.07060191035270691)","(['Risk & Crisis Management'], 0.6108612418174744)","('NON-ESG', 0.07586279511451721)","('NON-ESG', 0.07060191035270691)"
Line 75,"Third, our global alliance with the  Women’s Tennis Association  (WTA) creates what WTA   President Micky Lawler describes as a “fantastic partnership — couldn’t have asked for a   better team of people, a better brand and a better shared mission.” We and the WTA, two champions for women, have joined forces to realize further progress.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3474777936935425)","('Business_Model_Resilience', 0.1621997207403183)","('Human_Rights_And_Community_Relations', 0.07509678602218628)","('NON-ESG', 0.3474777936935425)","('NON-ESG', 0.1621997207403183)","('NON-ESG', 0.07509678602218628)"
Line 76,"As the WTA’s lead sponsor, Hologic works with the sport’s legends and athletes to increase  awareness of preventive care, advance equality for women on and off the court as well as raise money for the charitable ACEing Cancer program to fund researchers and nonprofit groups battling women's cancers (page 18).
","('Access_And_Affordability', 0.6100847721099854)","('Employee_Health_And_Safety', 0.0651911124587059)","('Employee_Engagement_Inclusion_And_Diversity', 0.06498808413743973)","(['Health Outcome Contribution'], 0.6100847721099854)","('NON-ESG', 0.0651911124587059)","('NON-ESG', 0.06498808413743973)"
Line 77,"Fourth, as detailed on pages 34-35, our employee engagement is best-in-class.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8049430251121521)","('Employee_Health_And_Safety', 0.05120044946670532)","('Human_Rights_And_Community_Relations', 0.022295711562037468)","(['Human Capital Development'], 0.8049430251121521)","('NON-ESG', 0.05120044946670532)","('NON-ESG', 0.022295711562037468)"
Line 78,"It is a direct   reflection of our vibrant culture, created by teams of people committed to living our   organization’s purpose.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6638585925102234)","('Human_Rights_And_Community_Relations', 0.10411092638969421)","('Business_Model_Resilience', 0.03485606610774994)","(['Human Capital Development'], 0.6638585925102234)","('NON-ESG', 0.10411092638969421)","('NON-ESG', 0.03485606610774994)"
Line 79,"In 2022, Hologic received Gallup’s Exceptional Workplace   Award for the second year in a row.
","('Employee_Engagement_Inclusion_And_Diversity', 0.26430967450141907)","('Employee_Health_And_Safety', 0.20326751470565796)","('Product_Design_And_Lifecycle_Management', 0.0767783671617508)","('NON-ESG', 0.26430967450141907)","('NON-ESG', 0.20326751470565796)","('NON-ESG', 0.0767783671617508)"
Line 80,"As I speak with both long-serving and new employees,   our purpose shines through as a strong motivator for continued success.
","('Employee_Engagement_Inclusion_And_Diversity', 0.24093618988990784)","('Human_Rights_And_Community_Relations', 0.1734868288040161)","('Business_Model_Resilience', 0.09997980296611786)","('NON-ESG', 0.24093618988990784)","('NON-ESG', 0.1734868288040161)","('NON-ESG', 0.09997980296611786)"
Line 81,"Steve MacMillan   Hologic Chairman, President and CEOOn that note, we are excited to share four highlights and key initiatives that illustrate our commitment to helping improve women’s health, as well as the lives of those who live in communities where Hologic conducts business:2022 Hologic Sustainability Report 4From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Our Purpose Hologic Overview  .
","('Human_Rights_And_Community_Relations', 0.8362919688224792)","('Employee_Health_And_Safety', 0.03622543066740036)","('Access_And_Affordability', 0.03184737637639046)","(['Community Relations'], 0.8362919688224792)","('NON-ESG', 0.03622543066740036)","('NON-ESG', 0.03184737637639046)"
Line 82,"H ologic at a Glance   .
","('Customer_Welfare', 0.16706162691116333)","('Competitive_Behavior', 0.1219303086400032)","('Access_And_Affordability', 0.10790184885263443)","('NON-ESG', 0.16706162691116333)","('NON-ESG', 0.1219303086400032)","('NON-ESG', 0.10790184885263443)"
Line 83,"R&D Spotlight   .
","('Business_Model_Resilience', 0.2798764705657959)","('Supply_Chain_Management', 0.17355400323867798)","('Product_Design_And_Lifecycle_Management', 0.1077256053686142)","('NON-ESG', 0.2798764705657959)","('NON-ESG', 0.17355400323867798)","('NON-ESG', 0.1077256053686142)"
Line 84,"History of Innovation    .
","('Business_Model_Resilience', 0.17174836993217468)","('Product_Design_And_Lifecycle_Management', 0.1471058577299118)","('Employee_Engagement_Inclusion_And_Diversity', 0.12236158549785614)","('NON-ESG', 0.17174836993217468)","('NON-ESG', 0.1471058577299118)","('NON-ESG', 0.12236158549785614)"
Line 85,"9  Shingo Prize:   A World-Class Culture of Excellence   .
","('Business_Ethics', 0.1570734977722168)","('Management_Of_Legal_And_Regulatory_Framework', 0.11852454394102097)","('Competitive_Behavior', 0.10320335626602173)","('NON-ESG', 0.1570734977722168)","('NON-ESG', 0.11852454394102097)","('NON-ESG', 0.10320335626602173)"
Line 86,"Materiality Assessment    .
","('Systemic_Risk_Management', 0.20669075846672058)","('Business_Model_Resilience', 0.17345742881298065)","('Business_Ethics', 0.12025893479585648)","('NON-ESG', 0.20669075846672058)","('NON-ESG', 0.17345742881298065)","('NON-ESG', 0.12025893479585648)"
Line 87,"11  U.N. Sustainable Development Goals    .
","('Human_Rights_And_Community_Relations', 0.6057009696960449)","('Business_Model_Resilience', 0.077064648270607)","('Ecological_Impacts', 0.045815858989953995)","(['Community Relations'], 0.6057009696960449)","('NON-ESG', 0.077064648270607)","('NON-ESG', 0.045815858989953995)"
Line 88,"A Sustainability Discussion With Our  CFO, Karleen Oberton   .
","('Business_Model_Resilience', 0.5963677167892456)","('Director_Removal', 0.0626494511961937)","('Supply_Chain_Management', 0.05095037445425987)","(['Codes of Business Conduct'], 0.5963677167892456)","('NON-ESG', 0.0626494511961937)","('NON-ESG', 0.05095037445425987)"
Line 89,"13At Hologic, we live our purpose — to enable  healthier lives everywhere, every day — bringing our virtuous circle to life.
","('Employee_Health_And_Safety', 0.30420753359794617)","('Product_Design_And_Lifecycle_Management', 0.20797322690486908)","('Employee_Engagement_Inclusion_And_Diversity', 0.061815667897462845)","('NON-ESG', 0.30420753359794617)","('NON-ESG', 0.20797322690486908)","('NON-ESG', 0.061815667897462845)"
Line 90,"Our innovative, life-changing technologies lead to continuous   business growth and financial success.
","('Business_Model_Resilience', 0.6529591083526611)","('Product_Design_And_Lifecycle_Management', 0.12885110080242157)","('Supply_Chain_Management', 0.029963940382003784)","(['Codes of Business Conduct'], 0.6529591083526611)","('NON-ESG', 0.12885110080242157)","('NON-ESG', 0.029963940382003784)"
Line 91,"These   gains allow us to reinvest in programs and   initiatives designed to nurture and support women’s health globally.2022 Hologic Sustainability Report 5From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  From the day we opened our doors in 1985,   Hologic has consistently introduced clinical advances that transform the delivery   of healthcare: •    W e developed the first dual-energy   X-ray absorptiometry system  for   evaluating osteoporosis.
","('Access_And_Affordability', 0.40715086460113525)","('Human_Rights_And_Community_Relations', 0.3254461884498596)","('Employee_Engagement_Inclusion_And_Diversity', 0.03745941072702408)","('NON-ESG', 0.40715086460113525)","('NON-ESG', 0.3254461884498596)","('NON-ESG', 0.03745941072702408)"
Line 92,"These   gains allow us to reinvest in programs and   initiatives designed to nurture and support women’s health globally.2022 Hologic Sustainability Report 5From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  From the day we opened our doors in 1985,   Hologic has consistently introduced clinical advances that transform the delivery   of healthcare: •    W e developed the first dual-energy   X-ray absorptiometry system  for   evaluating osteoporosis.
","('Employee_Health_And_Safety', 0.10539712011814117)","('Ecological_Impacts', 0.09694598615169525)","('Customer_Welfare', 0.08360166102647781)","('NON-ESG', 0.10539712011814117)","('NON-ESG', 0.09694598615169525)","('NON-ESG', 0.08360166102647781)"
Line 93,"•    Our ThinPrep® Pap  technology is used to  detect abnormal cells on the cervix, often  before they develop into cervical disease.
","('Employee_Health_And_Safety', 0.2587399184703827)","('Ecological_Impacts', 0.07454872131347656)","('Employee_Engagement_Inclusion_And_Diversity', 0.07444474846124649)","('NON-ESG', 0.2587399184703827)","('NON-ESG', 0.07454872131347656)","('NON-ESG', 0.07444474846124649)"
Line 94,"•    Our Genius® 3D Mammography™  exam has  revolutionized breast cancer detection for women of all ages and breast densities.
","('Employee_Health_And_Safety', 0.3627874255180359)","('Employee_Engagement_Inclusion_And_Diversity', 0.1534479856491089)","('Customer_Welfare', 0.05896291881799698)","('NON-ESG', 0.3627874255180359)","('NON-ESG', 0.1534479856491089)","('NON-ESG', 0.05896291881799698)"
Line 95,"•    Our minimally invasive treatment options   restore quality of life for women facing uterine fibroids and abnormal uterine bleeding.
","('Employee_Health_And_Safety', 0.7554150223731995)","('Employee_Engagement_Inclusion_And_Diversity', 0.03832991421222687)","('Access_And_Affordability', 0.026442652568221092)","(['Operational Eco-Efficiency'], 0.7554150223731995)","('NON-ESG', 0.03832991421222687)","('NON-ESG', 0.026442652568221092)"
Line 96,"•   T o help fight COVID-19, we developed   the Panther Fusion® SARS-CoV-2 Assay  and the Aptima® SARS-CoV-2  Assay ,  molecular diagnostic tests to detect the  novel coronavirus.
","('Customer_Welfare', 0.13187362253665924)","('Ecological_Impacts', 0.11352778226137161)","('Competitive_Behavior', 0.09749945253133774)","('NON-ESG', 0.13187362253665924)","('NON-ESG', 0.11352778226137161)","('NON-ESG', 0.09749945253133774)"
Line 97,"•   K ey assays in our Aptima®  portfolio, which  run on our Panther®  molecular diagnostics  system, have a proven record for accurate detection of sexually transmitted infections (STIs) including chlamydia, gonorrhea, human papillomavirus (HPV), trichomoniasis and vaginitis (BV and CV/TV — detailed on page 8), among other diseases.Hologic Overview — The Science of Sure® Hologic delivers detection, diagnostic and surgical innovations rooted in science, driven by technology and inspired by a desire to improve the health   of millions of people everywhere around the world.
","('Access_And_Affordability', 0.15893779695034027)","('Product_Quality_And_Safety', 0.13176824152469635)","('Employee_Health_And_Safety', 0.10802264511585236)","('NON-ESG', 0.15893779695034027)","('NON-ESG', 0.13176824152469635)","('NON-ESG', 0.10802264511585236)"
Line 98,"•   K ey assays in our Aptima®  portfolio, which  run on our Panther®  molecular diagnostics  system, have a proven record for accurate detection of sexually transmitted infections (STIs) including chlamydia, gonorrhea, human papillomavirus (HPV), trichomoniasis and vaginitis (BV and CV/TV — detailed on page 8), among other diseases.Hologic Overview — The Science of Sure® Hologic delivers detection, diagnostic and surgical innovations rooted in science, driven by technology and inspired by a desire to improve the health   of millions of people everywhere around the world.
","('Employee_Health_And_Safety', 0.494194358587265)","('Critical_Incident_Risk_Management', 0.08451758325099945)","('Access_And_Affordability', 0.06789654493331909)","('NON-ESG', 0.494194358587265)","('NON-ESG', 0.08451758325099945)","('NON-ESG', 0.06789654493331909)"
Line 99,"Our solutions help healthcare professionals diagnose and treat their patients with ever-greater   certainty and peace of mind.2022 Hologic Sustainability Report 6From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic at a Glance 12%  Capital 74%  Consumables14%  ServiceBY TYPE2022 RevenueFounded:   1985  by Jay Stein and David EllenbogenFast Facts  NASDAQ Stock Exchange:  HOLXChairman, President and CEO:  Steve MacMillan Global Patents:  4,100+ Global Headquarters:  Marlborough, MassachusettsEmployees:  ~7,000 worldwideFiscal 2022 Revenue:  $4.86 billion Estimated Number of Lives Impacted: 300+ million in fiscal 2022Hologic is a fundamentally different company than it was prior to the pandemic.
","('Access_And_Affordability', 0.18877045810222626)","('Human_Rights_And_Community_Relations', 0.15422984957695007)","('Business_Model_Resilience', 0.13744652271270752)","('NON-ESG', 0.18877045810222626)","('NON-ESG', 0.15422984957695007)","('NON-ESG', 0.13744652271270752)"
Line 100,"Our solutions help healthcare professionals diagnose and treat their patients with ever-greater   certainty and peace of mind.2022 Hologic Sustainability Report 6From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic at a Glance 12%  Capital 74%  Consumables14%  ServiceBY TYPE2022 RevenueFounded:   1985  by Jay Stein and David EllenbogenFast Facts  NASDAQ Stock Exchange:  HOLXChairman, President and CEO:  Steve MacMillan Global Patents:  4,100+ Global Headquarters:  Marlborough, MassachusettsEmployees:  ~7,000 worldwideFiscal 2022 Revenue:  $4.86 billion Estimated Number of Lives Impacted: 300+ million in fiscal 2022Hologic is a fundamentally different company than it was prior to the pandemic.
","('Physical_Impacts_Of_Climate_Change', 0.3859322965145111)","('Systemic_Risk_Management', 0.15911151468753815)","('Critical_Incident_Risk_Management', 0.127019003033638)","('NON-ESG', 0.3859322965145111)","('NON-ESG', 0.15911151468753815)","('NON-ESG', 0.127019003033638)"
Line 101,"We are more purpose- driven, more global, with more diverse, recurring revenue.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3536739647388458)","('Business_Model_Resilience', 0.28715020418167114)","('Human_Rights_And_Community_Relations', 0.034686874598264694)","('NON-ESG', 0.3536739647388458)","('NON-ESG', 0.28715020418167114)","('NON-ESG', 0.034686874598264694)"
Line 102,"Our strength enables us to make a unique difference, with a core focus on helping more women around the world.
","('Human_Rights_And_Community_Relations', 0.45132261514663696)","('Employee_Engagement_Inclusion_And_Diversity', 0.30892765522003174)","('Employee_Health_And_Safety', 0.03693883493542671)","('NON-ESG', 0.45132261514663696)","('NON-ESG', 0.30892765522003174)","('NON-ESG', 0.03693883493542671)"
Line 103,"27%  Breast &  Skeletal11%   Surgical 62%  DiagnosticsBY DIVISION Awards Received:  •   D rucker Institute’s Best-Managed   Companies •   F ast Company’s 2022 List of World’s   Most Innovative Companies • Gallup Exceptional Workplace Award • IMV ServiceTrak Awards• LinkedIn 25 Top Healthcare Companies• NorthFace Service Award• Shingo Prize• The Boston Globe Top Places to Work•    T he San Diego Union-Tribune Top   Workplaces Global Reach:   Locations in 36+ countries with direct  staff and a market presence in more  than 100 countries71%  U.S.29%  Intl.BY GEOGRAPHY World-Class Employee Engagement  “My sister was diagnosed with terminal breast cancer at age   40, and she passed on eight years later.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4001373052597046)","('Employee_Health_And_Safety', 0.11856736242771149)","('Business_Model_Resilience', 0.0614396296441555)","('NON-ESG', 0.4001373052597046)","('NON-ESG', 0.11856736242771149)","('NON-ESG', 0.0614396296441555)"
Line 104,"27%  Breast &  Skeletal11%   Surgical 62%  DiagnosticsBY DIVISION Awards Received:  •   D rucker Institute’s Best-Managed   Companies •   F ast Company’s 2022 List of World’s   Most Innovative Companies • Gallup Exceptional Workplace Award • IMV ServiceTrak Awards• LinkedIn 25 Top Healthcare Companies• NorthFace Service Award• Shingo Prize• The Boston Globe Top Places to Work•    T he San Diego Union-Tribune Top   Workplaces Global Reach:   Locations in 36+ countries with direct  staff and a market presence in more  than 100 countries71%  U.S.29%  Intl.BY GEOGRAPHY World-Class Employee Engagement  “My sister was diagnosed with terminal breast cancer at age   40, and she passed on eight years later.
","('Employee_Health_And_Safety', 0.2552720308303833)","('Employee_Engagement_Inclusion_And_Diversity', 0.20761001110076904)","('Access_And_Affordability', 0.1576939970254898)","('NON-ESG', 0.2552720308303833)","('NON-ESG', 0.20761001110076904)","('NON-ESG', 0.1576939970254898)"
Line 105,"The world fell in   front me, and I told myself that this should not happen   to other women in this world.
","('Competitive_Behavior', 0.15945084393024445)","('Labor_Practices', 0.14221026003360748)","('Business_Ethics', 0.10405178368091583)","('NON-ESG', 0.15945084393024445)","('NON-ESG', 0.14221026003360748)","('NON-ESG', 0.10405178368091583)"
Line 106,"I wanted to make my sister   proud of my career choice.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5643247365951538)","('Director_Removal', 0.053336624056100845)","('Business_Model_Resilience', 0.05280465632677078)","(['Human Capital Development'], 0.5643247365951538)","('NON-ESG', 0.053336624056100845)","('NON-ESG', 0.05280465632677078)"
Line 107,"Hologic stands out because   of our focus on championing women’s health and preventive  care.
","('Employee_Health_And_Safety', 0.45651984214782715)","('Access_And_Affordability', 0.2662326395511627)","('Human_Rights_And_Community_Relations', 0.061794981360435486)","('NON-ESG', 0.45651984214782715)","('NON-ESG', 0.2662326395511627)","('NON-ESG', 0.061794981360435486)"
Line 108,"Hologic is the connection I need to make a difference   in women’s lives.” Linda Seah   Vice President, General Manager for Emerging Asia2022 Hologic Sustainability Report 7From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  1.
","('Human_Rights_And_Community_Relations', 0.9118617177009583)","('Employee_Engagement_Inclusion_And_Diversity', 0.013098658062517643)","('Access_And_Affordability', 0.009636126458644867)","(['Community Relations'], 0.9118617177009583)","('NON-ESG', 0.013098658062517643)","('NON-ESG', 0.009636126458644867)"
Line 109,"Year Ended Earnings per share (EPS) 9/24/22 9/25/21 9/26/20 9/28/19 9/29/18 9/30/17 9/24/16 9/26/15 9/27/GAAP earnings (loss) per share 5.13 7.21 4.21 (0.76) (0.40) 2.64 1.16 0.45 0.Non-GAAP adjustments 0.89 1.20 (0.23) 3.1912.632(0.61) 0.80 1.22 1.Adjusted EPS 6.02 8.41 3.98 2.43 2.23 2.03 1.96 1.67 1.5-year average adjusted EPS growth 33%$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 2022$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 *  T otal non-GAAP revenue growth in millions.
","('Systemic_Risk_Management', 0.5242308974266052)","('Business_Model_Resilience', 0.11858133226633072)","('Competitive_Behavior', 0.05231975018978119)","(['Risk & Crisis Management'], 0.5242308974266052)","('NON-ESG', 0.11858133226633072)","('NON-ESG', 0.05231975018978119)"
Line 110,"Year Ended Earnings per share (EPS) 9/24/22 9/25/21 9/26/20 9/28/19 9/29/18 9/30/17 9/24/16 9/26/15 9/27/GAAP earnings (loss) per share 5.13 7.21 4.21 (0.76) (0.40) 2.64 1.16 0.45 0.Non-GAAP adjustments 0.89 1.20 (0.23) 3.1912.632(0.61) 0.80 1.22 1.Adjusted EPS 6.02 8.41 3.98 2.43 2.23 2.03 1.96 1.67 1.5-year average adjusted EPS growth 33%$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 2022$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 *  T otal non-GAAP revenue growth in millions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17137077450752258)","('Business_Ethics', 0.0947469100356102)","('Business_Model_Resilience', 0.09035374969244003)","('NON-ESG', 0.17137077450752258)","('NON-ESG', 0.0947469100356102)","('NON-ESG', 0.09035374969244003)"
Line 111,"Year Ended Earnings per share (EPS) 9/24/22 9/25/21 9/26/20 9/28/19 9/29/18 9/30/17 9/24/16 9/26/15 9/27/GAAP earnings (loss) per share 5.13 7.21 4.21 (0.76) (0.40) 2.64 1.16 0.45 0.Non-GAAP adjustments 0.89 1.20 (0.23) 3.1912.632(0.61) 0.80 1.22 1.Adjusted EPS 6.02 8.41 3.98 2.43 2.23 2.03 1.96 1.67 1.5-year average adjusted EPS growth 33%$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 2022$2,511 $2,705 $2,833 $3,059 $3,218 $3,367 $2,847 $3,473 $3,433** $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02$929$2,$1,0.4%9.9% 5.4%8.3%4.3% 5.7%12.1%46.5% -12.3% -2.7%14.4% 17.4% 3.6% 9.9% 9.0%63.8%111.3% -28.4%**$5,$3,776$4,0$1,000$2,000$3,000$4,000$5,000$6,$0.00$1.00$2.00$3.00$4.00$5.00$6.00$7.00$8.00$9.2014 2015 2016 2017 2018 2019 2020 2021 2022 2014 2015 2016 2017 2018 2019 2020 2021 *  T otal non-GAAP revenue growth in millions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.278976708650589)","('Systemic_Risk_Management', 0.19127969443798065)","('Competitive_Behavior', 0.12023140490055084)","('NON-ESG', 0.278976708650589)","('NON-ESG', 0.19127969443798065)","('NON-ESG', 0.12023140490055084)"
Line 112,"Growth rates in constant currency.
","('Systemic_Risk_Management', 0.6495057344436646)","('Competitive_Behavior', 0.08077509701251984)","('Management_Of_Legal_And_Regulatory_Framework', 0.07362082600593567)","(['Risk & Crisis Management'], 0.6495057344436646)","('NON-ESG', 0.08077509701251984)","('NON-ESG', 0.07362082600593567)"
Line 113,"As reported except FY14, which excludes   ~$20 million one-time revenue from amending Roka license.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8710910081863403)","('Competitive_Behavior', 0.025053080171346664)","('Energy_Management', 0.014850782230496407)","(['Corporate Governance'], 0.8710910081863403)","('NON-ESG', 0.025053080171346664)","('NON-ESG', 0.014850782230496407)"
Line 114,"Results include contributions from the Blood Screening business  that was divested in 2017, the Medical Aesthetics business that was acquired in 2017 and divested in 2020, and other smaller acquisitions.
","('Systemic_Risk_Management', 0.1453002542257309)","('Customer_Welfare', 0.12078015506267548)","('Competitive_Behavior', 0.0917307510972023)","('NON-ESG', 0.1453002542257309)","('NON-ESG', 0.12078015506267548)","('NON-ESG', 0.0917307510972023)"
Line 115,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 116,"**  D ecline in Total Revenue excluding COVID Assays is driven by lower capital sales in our Breast Health business, as a result of  semiconductor supply chain shortages.*  N on-GAAP EPS as presented in our earnings releases except FY14, which excludes ~$0.05 one-time contribution from  amending Roka license.
","('Supply_Chain_Management', 0.9417749643325806)","('Labor_Practices', 0.005169741343706846)","('Employee_Health_And_Safety', 0.004716427531093359)","(['Supply Chain Management'], 0.9417749643325806)","('NON-ESG', 0.005169741343706846)","('NON-ESG', 0.004716427531093359)"
Line 117,"Results include contributions from the Blood Screening business divested in 2017, the Medical Aesthetics business acquired in 2017 and divested in 2020, and other smaller acquisitions.
","('Systemic_Risk_Management', 0.14468400180339813)","('Customer_Welfare', 0.1206866130232811)","('Access_And_Affordability', 0.0961906835436821)","('NON-ESG', 0.14468400180339813)","('NON-ESG', 0.1206866130232811)","('NON-ESG', 0.0961906835436821)"
Line 118,"**  D ecline in Non-GAAP EPS is driven by less COVID testing revenue and lower capital sales in our Breast Health business,   as a result of semiconductor supply chain shortages.Base Business ex.
","('Supply_Chain_Management', 0.9412223100662231)","('Employee_Health_And_Safety', 0.004649830982089043)","('Labor_Practices', 0.004601245746016502)","(['Supply Chain Management'], 0.9412223100662231)","('NON-ESG', 0.004649830982089043)","('NON-ESG', 0.004601245746016502)"
Line 119,"COVID Assays COVID AssaysHologic at a Glance (continued) Total Revenue* GAAP to Non-GAAP ReconciliationNon-GAAP EPS* Numbers may not foot due to rounding.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31426504254341125)","('Systemic_Risk_Management', 0.11690735071897507)","('GHG_Emissions', 0.10251279920339584)","('NON-ESG', 0.31426504254341125)","('NON-ESG', 0.11690735071897507)","('NON-ESG', 0.10251279920339584)"
Line 120,"1.
","('Competitive_Behavior', 0.08736830949783325)","('Energy_Management', 0.08274902403354645)","('Management_Of_Legal_And_Regulatory_Framework', 0.0740576833486557)","('NON-ESG', 0.08736830949783325)","('NON-ESG', 0.08274902403354645)","('NON-ESG', 0.0740576833486557)"
Line 121,"Assumes dilution of 1.9 million shares for the year ended September 28, 2019.
","('Systemic_Risk_Management', 0.32369816303253174)","('Business_Model_Resilience', 0.1279674470424652)","('Director_Removal', 0.09852386265993118)","('NON-ESG', 0.32369816303253174)","('NON-ESG', 0.1279674470424652)","('NON-ESG', 0.09852386265993118)"
Line 122,"2.
","('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 123,"Assumes dilution of 2.8 million shares for the year ended September 29, 2018.2022 Hologic Sustainability Report 8From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  R&D Spotlight: BV and CV/TV Aptima® Assays The healthcare markets we participate in are characterized by rapid technological change, frequent product introductions and evolving customer requirements.
","('Product_Design_And_Lifecycle_Management', 0.8087913393974304)","('Business_Model_Resilience', 0.06099840998649597)","('Supply_Chain_Management', 0.017239192500710487)","(['Product Stewardship'], 0.8087913393974304)","('NON-ESG', 0.06099840998649597)","('NON-ESG', 0.017239192500710487)"
Line 124,"Investment in research and development (R&D) is critical to driving our future growth.
","('Business_Model_Resilience', 0.3881809711456299)","('Ecological_Impacts', 0.06916598975658417)","('Management_Of_Legal_And_Regulatory_Framework', 0.06359446048736572)","('NON-ESG', 0.3881809711456299)","('NON-ESG', 0.06916598975658417)","('NON-ESG', 0.06359446048736572)"
Line 125,"Hologic's longstanding commitment to R&D across all divisions is clear: we've invested nearly $1.9 billion globally over the past eight years, including approximately $282 million in 2022.
","('Business_Model_Resilience', 0.5679770708084106)","('Systemic_Risk_Management', 0.09343644976615906)","('Supply_Chain_Management', 0.05187296122312546)","(['Codes of Business Conduct'], 0.5679770708084106)","('NON-ESG', 0.09343644976615906)","('NON-ESG', 0.05187296122312546)"
Line 126,"Hologic’s R&D pipeline remains robust, with strong product launches including our BV and CV/TV Aptima® assays, which diagnose 90% of vaginitis cases including bacterial vaginosis (BV),  candidiasis (CV) and trichomonas vaginalis (TV).
","('Employee_Health_And_Safety', 0.24083934724330902)","('Product_Quality_And_Safety', 0.18548867106437683)","('Customer_Welfare', 0.08886485546827316)","('NON-ESG', 0.24083934724330902)","('NON-ESG', 0.18548867106437683)","('NON-ESG', 0.08886485546827316)"
Line 127,"Vaginitis remains the leading reason why millions of women visit their OB/GYN each year, making the Aptima® BV and CV/TV assays a   game-changer in women's health.
","('Employee_Health_And_Safety', 0.7694721221923828)","('Employee_Engagement_Inclusion_And_Diversity', 0.0637311264872551)","('Access_And_Affordability', 0.020003128796815872)","(['Operational Eco-Efficiency'], 0.7694721221923828)","('NON-ESG', 0.0637311264872551)","('NON-ESG', 0.020003128796815872)"
Line 128,"What sparked the idea for these assays?
","('Competitive_Behavior', 0.7721419334411621)","('Management_Of_Legal_And_Regulatory_Framework', 0.03139710798859596)","('Systemic_Risk_Management', 0.028513764962553978)","(['Business Ethics'], 0.7721419334411621)","('NON-ESG', 0.03139710798859596)","('NON-ESG', 0.028513764962553978)"
Line 129,"Hologic is committed to developing innovative technology  grounded in evidence and clinical data.
","('Access_And_Affordability', 0.19702288508415222)","('Customer_Welfare', 0.1083245649933815)","('Competitive_Behavior', 0.07366318255662918)","('NON-ESG', 0.19702288508415222)","('NON-ESG', 0.1083245649933815)","('NON-ESG', 0.07366318255662918)"
Line 130,"This is how we deliver the best results for our patients.
","('Access_And_Affordability', 0.4082494378089905)","('Customer_Welfare', 0.06430096179246902)","('Product_Quality_And_Safety', 0.058186426758766174)","('NON-ESG', 0.4082494378089905)","('NON-ESG', 0.06430096179246902)","('NON-ESG', 0.058186426758766174)"
Line 131,"Vaginitis is a complex health issue impacting millions of women and can result in a long journey for patients seeking answers to their vaginal symptoms and discomfort.
","('Employee_Health_And_Safety', 0.9430615305900574)","('Employee_Engagement_Inclusion_And_Diversity', 0.00813212525099516)","('Product_Quality_And_Safety', 0.005608833394944668)","(['Operational Eco-Efficiency'], 0.9430615305900574)","('NON-ESG', 0.00813212525099516)","('NON-ESG', 0.005608833394944668)"
Line 132,"It’s incredibly personal.
","('Customer_Privacy', 0.34932243824005127)","('Business_Ethics', 0.07838741689920425)","('Business_Model_Resilience', 0.06392209231853485)","('NON-ESG', 0.34932243824005127)","('NON-ESG', 0.07838741689920425)","('NON-ESG', 0.06392209231853485)"
Line 133,"Many women feel embarrassed, self-conscious and frustrated by their symptoms.
","('Employee_Health_And_Safety', 0.1837175488471985)","('Business_Ethics', 0.1392483413219452)","('Labor_Practices', 0.1330585777759552)","('NON-ESG', 0.1837175488471985)","('NON-ESG', 0.1392483413219452)","('NON-ESG', 0.1330585777759552)"
Line 134,"New methods for diagnosing vaginitis infections were  needed.
","('Employee_Health_And_Safety', 0.5778334140777588)","('Product_Quality_And_Safety', 0.05428918078541756)","('Employee_Engagement_Inclusion_And_Diversity', 0.03850341960787773)","(['Operational Eco-Efficiency'], 0.5778334140777588)","('NON-ESG', 0.05428918078541756)","('NON-ESG', 0.03850341960787773)"
Line 135,"We developed these assays over a multi-year period that began by establishing close relationships  with experts in microbiology and clinical medicine from around the world.
","('Access_And_Affordability', 0.16077369451522827)","('Competitive_Behavior', 0.10313944518566132)","('Customer_Welfare', 0.09842082113027573)","('NON-ESG', 0.16077369451522827)","('NON-ESG', 0.10313944518566132)","('NON-ESG', 0.09842082113027573)"
Line 136,"We used these insights to develop our Aptima® BV and Aptima® CV/TV molecular assays, allowing for a more accurate vaginitis diagnosis, which  is essential to treat and help reduce the potential  for recurrent or persistent infections.
","('Employee_Health_And_Safety', 0.7960144281387329)","('Product_Quality_And_Safety', 0.03055262751877308)","('Business_Ethics', 0.01628423109650612)","(['Operational Eco-Efficiency'], 0.7960144281387329)","('NON-ESG', 0.03055262751877308)","('NON-ESG', 0.01628423109650612)"
Line 137,"Why is it so important for women to get tested  for BV and CV/TV?
","('Access_And_Affordability', 0.311806321144104)","('Product_Quality_And_Safety', 0.09958924353122711)","('Competitive_Behavior', 0.06213102489709854)","('NON-ESG', 0.311806321144104)","('NON-ESG', 0.09958924353122711)","('NON-ESG', 0.06213102489709854)"
Line 138,"Diagnosis can be especially complicated due to the  prevalence of co-infections.
","('Employee_Health_And_Safety', 0.29922914505004883)","('Access_And_Affordability', 0.11945628374814987)","('Product_Quality_And_Safety', 0.0939108282327652)","('NON-ESG', 0.29922914505004883)","('NON-ESG', 0.11945628374814987)","('NON-ESG', 0.0939108282327652)"
Line 139,"For example, one in five patients with symptoms of vaginitis have two causes of vaginitis.
","('Employee_Health_And_Safety', 0.5807693600654602)","('Product_Quality_And_Safety', 0.07722974568605423)","('Employee_Engagement_Inclusion_And_Diversity', 0.038921572268009186)","(['Operational Eco-Efficiency'], 0.5807693600654602)","('NON-ESG', 0.07722974568605423)","('NON-ESG', 0.038921572268009186)"
Line 140,"Accurate diagnosis is complicated by the subjective nature of traditional methods, which often leads to misdiagnosis and ineffective treatment.
","('Employee_Health_And_Safety', 0.19041447341442108)","('Access_And_Affordability', 0.1620793342590332)","('Product_Quality_And_Safety', 0.15472517907619476)","('NON-ESG', 0.19041447341442108)","('NON-ESG', 0.1620793342590332)","('NON-ESG', 0.15472517907619476)"
Line 141,"The inclination for many women to self-diagnose and self-treat before seeking treatment from their healthcare provider further exacerbates the problem.
","('Access_And_Affordability', 0.5500105023384094)","('Employee_Health_And_Safety', 0.22044940292835236)","('Product_Quality_And_Safety', 0.025951163843274117)","(['Health Outcome Contribution'], 0.5500105023384094)","('NON-ESG', 0.22044940292835236)","('NON-ESG', 0.025951163843274117)"
Line 142,"When left untreated, these infections can put women  at increased risk for sexually transmitted infections, pelvic inflammatory disease or other fertility-related complications.
","('Employee_Health_And_Safety', 0.8265130519866943)","('Product_Quality_And_Safety', 0.020477132871747017)","('Business_Ethics', 0.020124252885580063)","(['Operational Eco-Efficiency'], 0.8265130519866943)","('NON-ESG', 0.020477132871747017)","('NON-ESG', 0.020124252885580063)"
Line 143,"Therefore, it is particularly important for providers to accurately identify and treat the underlying cause of vaginitis symptoms.
","('Employee_Health_And_Safety', 0.6159148812294006)","('Product_Quality_And_Safety', 0.061227113008499146)","('Employee_Engagement_Inclusion_And_Diversity', 0.046312689781188965)","(['Operational Eco-Efficiency'], 0.6159148812294006)","('NON-ESG', 0.061227113008499146)","('NON-ESG', 0.046312689781188965)"
Line 144,"Nucleic acid amplification tests (NAATs) offer a more objective, comprehensive and accurate method for diagnosing the cause of vaginitis compared to traditional methods.What does the future look like for BV and   CV/TV testing?
","('Employee_Health_And_Safety', 0.866358757019043)","('Employee_Engagement_Inclusion_And_Diversity', 0.021238738670945168)","('Product_Quality_And_Safety', 0.015826361253857613)","(['Operational Eco-Efficiency'], 0.866358757019043)","('NON-ESG', 0.021238738670945168)","('NON-ESG', 0.015826361253857613)"
Line 145,"In 2021, the CDC updated its STI Treatment Guidelines .
","('Access_And_Affordability', 0.3058747947216034)","('Product_Quality_And_Safety', 0.22829249501228333)","('Employee_Health_And_Safety', 0.09183420985937119)","('NON-ESG', 0.3058747947216034)","('NON-ESG', 0.22829249501228333)","('NON-ESG', 0.09183420985937119)"
Line 146,"The guidelines now note that vaginitis can be diagnosed by NAATs to detect the underlying cause of infection of vaginitis in symptomatic women.
","('Employee_Health_And_Safety', 0.7198492884635925)","('Product_Quality_And_Safety', 0.04001189395785332)","('Employee_Engagement_Inclusion_And_Diversity', 0.03298893943428993)","(['Operational Eco-Efficiency'], 0.7198492884635925)","('NON-ESG', 0.04001189395785332)","('NON-ESG', 0.03298893943428993)"
Line 147,"We are encouraged that the CDC is reinforcing the value of these molecular assays and hope it will foster faster adoption among clinicians.
","('Customer_Welfare', 0.28569382429122925)","('Competitive_Behavior', 0.11567319184541702)","('Access_And_Affordability', 0.10111445933580399)","('NON-ESG', 0.28569382429122925)","('NON-ESG', 0.11567319184541702)","('NON-ESG', 0.10111445933580399)"
Line 148,"We look forward to more healthcare providers and  laboratories using these CDC-recommended assays to   offer better clinical management for their patients.
","('Customer_Welfare', 0.22270344197750092)","('Competitive_Behavior', 0.15170028805732727)","('Access_And_Affordability', 0.115639328956604)","('NON-ESG', 0.22270344197750092)","('NON-ESG', 0.15170028805732727)","('NON-ESG', 0.115639328956604)"
Line 149,"Acessa® launches ProVu® ,  a laparoscopic system  for eﬀective and safe treatment of uterine ﬁbroids.FDA approves the Fluent® Fluid Management System, used to streamline hysteroscopic procedures.
","('Employee_Health_And_Safety', 0.5147964358329773)","('Employee_Engagement_Inclusion_And_Diversity', 0.06372872740030289)","('Access_And_Affordability', 0.05945347994565964)","(['Operational Eco-Efficiency'], 0.5147964358329773)","('NON-ESG', 0.06372872740030289)","('NON-ESG', 0.05945347994565964)"
Line 150,"19871985 2014FDA clears Clarity HD high- resolution 3D™ imaging and the SmartCurve™ breast stabilization system, providing superior image quality and a clinically proven solution for a more comfortable mammogram.2019 FDA grants Emergency Use Authorization (EUA) for the Panther Fusion® SARS-CoV-2 Assay and Aptima® SARS-CoV-2 Assay, molecular diagnostic tests  detecting the novel coronavirus.Introduction of CE-marked Genius™ Digital Diagnostics System.Biotheranostics launches Breast Cancer Index™ , a test  that helps breast cancer survivorsmake clearer decisions aboutextended endocrine therapy.
","('Access_And_Affordability', 0.20672409236431122)","('Employee_Health_And_Safety', 0.11668778210878372)","('Product_Quality_And_Safety', 0.10085386782884598)","('NON-ESG', 0.20672409236431122)","('NON-ESG', 0.11668778210878372)","('NON-ESG', 0.10085386782884598)"
Line 151,"19871985 2014FDA clears Clarity HD high- resolution 3D™ imaging and the SmartCurve™ breast stabilization system, providing superior image quality and a clinically proven solution for a more comfortable mammogram.2019 FDA grants Emergency Use Authorization (EUA) for the Panther Fusion® SARS-CoV-2 Assay and Aptima® SARS-CoV-2 Assay, molecular diagnostic tests  detecting the novel coronavirus.Introduction of CE-marked Genius™ Digital Diagnostics System.Biotheranostics launches Breast Cancer Index™ , a test  that helps breast cancer survivorsmake clearer decisions aboutextended endocrine therapy.
","('Access_And_Affordability', 0.3914768695831299)","('Customer_Welfare', 0.071190744638443)","('Product_Quality_And_Safety', 0.07024125009775162)","('NON-ESG', 0.3914768695831299)","('NON-ESG', 0.071190744638443)","('NON-ESG', 0.07024125009775162)"
Line 152,"FDA approves the break-through Selenia Dimensions®digital tomosynthesis systemwith the Genius® 3D Mammography™ exam.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5343804359436035)","('GHG_Emissions', 0.06086320802569389)","('Product_Quality_And_Safety', 0.05287894606590271)","(['Corporate Governance'], 0.5343804359436035)","('NON-ESG', 0.06086320802569389)","('NON-ESG', 0.05287894606590271)"
Line 153,"FDA clears the Panther®system, an automated,integrated molecularplatform for use with theAptima® Combo 2® Assay.
","('Competitive_Behavior', 0.2936243414878845)","('Management_Of_Legal_And_Regulatory_Framework', 0.22807441651821136)","('Customer_Welfare', 0.09726407378911972)","('NON-ESG', 0.2936243414878845)","('NON-ESG', 0.22807441651821136)","('NON-ESG', 0.09726407378911972)"
Line 154,"2021 20212017FDA a pproves the Rapid fFN® test.Hologic introduces the ﬁrst d ual-energy X-ray absorpti ometry system for evaluating osteoporosis.
","('Access_And_Affordability', 0.1854911595582962)","('Employee_Health_And_Safety', 0.11374145746231079)","('Customer_Welfare', 0.08712323009967804)","('NON-ESG', 0.1854911595582962)","('NON-ESG', 0.11374145746231079)","('NON-ESG', 0.08712323009967804)"
Line 155,"FDA clears the ﬁrstnucleic acid test.
","('Management_Of_Legal_And_Regulatory_Framework', 0.19785811007022858)","('Product_Quality_And_Safety', 0.13118189573287964)","('Customer_Welfare', 0.12091197818517685)","('NON-ESG', 0.19785811007022858)","('NON-ESG', 0.13118189573287964)","('NON-ESG', 0.12091197818517685)"
Line 156,"FDA clears the ﬁrstmolecular diagnostictest kit for a sexuallytransmitted infection.
","('Employee_Health_And_Safety', 0.21304358541965485)","('Product_Quality_And_Safety', 0.18170219659805298)","('Access_And_Affordability', 0.09511006623506546)","('NON-ESG', 0.21304358541965485)","('NON-ESG', 0.18170219659805298)","('NON-ESG', 0.09511006623506546)"
Line 157,"FDA approves the Selenia ® mammography system—thebeginning of a new era inbreast cancer screening.
","('Access_And_Affordability', 0.16687864065170288)","('Product_Quality_And_Safety', 0.149738609790802)","('Customer_Welfare', 0.08583957701921463)","('NON-ESG', 0.16687864065170288)","('NON-ESG', 0.149738609790802)","('NON-ESG', 0.08583957701921463)"
Line 158,"FDA approves the NovaSure ® endometrial  ablation treatment for abnormal uterine bleeding (AUB).
","('Employee_Health_And_Safety', 0.5672385096549988)","('Employee_Engagement_Inclusion_And_Diversity', 0.05750974267721176)","('Access_And_Affordability', 0.04148173704743385)","(['Operational Eco-Efficiency'], 0.5672385096549988)","('NON-ESG', 0.05750974267721176)","('NON-ESG', 0.04148173704743385)"
Line 159,"FDA a pproves the ThinPrep ® Pap test,  a liquid-based cytology for cervical cancer scree ning.
","('Employee_Health_And_Safety', 0.28713688254356384)","('Access_And_Affordability', 0.13260023295879364)","('Product_Quality_And_Safety', 0.11798641830682755)","('NON-ESG', 0.28713688254356384)","('NON-ESG', 0.13260023295879364)","('NON-ESG', 0.11798641830682755)"
Line 160,"FDA approves the ﬁrstnucleic acid test forscreening donated blood prior to transfusion.
","('Customer_Welfare', 0.17461293935775757)","('Access_And_Affordability', 0.15123331546783447)","('Water_And_Wastewater_Management', 0.07623454928398132)","('NON-ESG', 0.17461293935775757)","('NON-ESG', 0.15123331546783447)","('NON-ESG', 0.07623454928398132)"
Line 161,"Release of the Tigris®  DTS® system forautomated screening of sexually transmittedinfections.
","('Water_And_Wastewater_Management', 0.11923481523990631)","('Systemic_Risk_Management', 0.0985446572303772)","('Ecological_Impacts', 0.09491679817438126)","('NON-ESG', 0.11923481523990631)","('NON-ESG', 0.0985446572303772)","('NON-ESG', 0.09491679817438126)"
Line 162,"FDA approves theProcleix® Ultrio®* triplexblood screening assay forHIV-1, hepatitis B and C.
","('Customer_Welfare', 0.22339163720607758)","('Selling_Practices_And_Product_Labeling', 0.1275281459093094)","('Management_Of_Legal_And_Regulatory_Framework', 0.09770382940769196)","('NON-ESG', 0.22339163720607758)","('NON-ESG', 0.1275281459093094)","('NON-ESG', 0.09770382940769196)"
Line 163,"FDA approves the MyoSure®tissue removal procedure forthe hysteroscopic treatmentof uterine tissue, includingﬁbroids and polyps.
","('Employee_Health_And_Safety', 0.15877693891525269)","('Customer_Welfare', 0.09426843374967575)","('Access_And_Affordability', 0.09108033776283264)","('NON-ESG', 0.15877693891525269)","('NON-ESG', 0.09426843374967575)","('NON-ESG', 0.09108033776283264)"
Line 164,"2021FDA clears the use of the bone densitometer for assessing critical health problems, including/uni00A0osteoporosis.
","('Employee_Health_And_Safety', 0.9151745438575745)","('Product_Quality_And_Safety', 0.011943111196160316)","('Employee_Engagement_Inclusion_And_Diversity', 0.009855454787611961)","(['Operational Eco-Efficiency'], 0.9151745438575745)","('NON-ESG', 0.011943111196160316)","('NON-ESG', 0.009855454787611961)"
Line 165,"Introduction of CE-marked virology portfolio, including Aptima® HIV, HCV and HBV assays, along with the Aptima® M.
","('Customer_Welfare', 0.2532748878002167)","('Competitive_Behavior', 0.17354092001914978)","('GHG_Emissions', 0.09424383193254471)","('NON-ESG', 0.2532748878002167)","('NON-ESG', 0.17354092001914978)","('NON-ESG', 0.09424383193254471)"
Line 166,"genitalium/uni00A0Assay.Mobidiag develops and markets new near-to-patient molecular testing system.
","('Customer_Welfare', 0.18872395157814026)","('Access_And_Affordability', 0.15764790773391724)","('Competitive_Behavior', 0.09992723166942596)","('NON-ESG', 0.18872395157814026)","('NON-ESG', 0.15764790773391724)","('NON-ESG', 0.09992723166942596)"
Line 167,"Introduction of CE-marked Aptima® CMV Quant Assay in Europe, Hologic’s ﬁrst assay for organ transplant patients.
","('Customer_Welfare', 0.35762932896614075)","('Access_And_Affordability', 0.07981783896684647)","('Competitive_Behavior', 0.06805996596813202)","('NON-ESG', 0.35762932896614075)","('NON-ESG', 0.07981783896684647)","('NON-ESG', 0.06805996596813202)"
Line 168,"2022Introduction of CE-mark approval of Panther Fusion® EBV Quant Assay, Panther Fusion® BKV Quant Assay, Panther Fusion® SARS-CoV-2/FluA/B/RSV Assay and Novodiag® RESP-4 Assay.
","('Competitive_Behavior', 0.49467653036117554)","('Customer_Welfare', 0.1339576691389084)","('GHG_Emissions', 0.040159083902835846)","('NON-ESG', 0.49467653036117554)","('NON-ESG', 0.1339576691389084)","('NON-ESG', 0.040159083902835846)"
Line 169,"Bolder Surgical launches CoolSeal® platform, including tools used for vessel sealing, dividing and dissecting.FDA approval of Aptima® BV and CV/TV assays, which provide an accurate and objective method for diagnosing vaginitis.2016FDA clears the new Aﬃrm®/uni00A0prone breast biopsy system.
","('Employee_Health_And_Safety', 0.7812049984931946)","('Employee_Engagement_Inclusion_And_Diversity', 0.03427106514573097)","('Product_Quality_And_Safety', 0.029178624972701073)","(['Operational Eco-Efficiency'], 0.7812049984931946)","('NON-ESG', 0.03427106514573097)","('NON-ESG', 0.029178624972701073)"
Line 170,"2022 Hologic Sustainability Report 9From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  History of Innovation2022 Hologic Sustainability Report 10From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic Costa Rica has more than 1,000 employees.Hologic Costa Rica earned the  prestigious Shingo Prize , an  assessment of how a company's culture drives world-class results   and the guiding principles of the Shingo Model™:  • Respect every individual.
","('Human_Rights_And_Community_Relations', 0.7921528816223145)","('Employee_Engagement_Inclusion_And_Diversity', 0.03290526196360588)","('Business_Model_Resilience', 0.02608328126370907)","(['Community Relations'], 0.7921528816223145)","('NON-ESG', 0.03290526196360588)","('NON-ESG', 0.02608328126370907)"
Line 171,"2022 Hologic Sustainability Report 9From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  History of Innovation2022 Hologic Sustainability Report 10From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic Costa Rica has more than 1,000 employees.Hologic Costa Rica earned the  prestigious Shingo Prize , an  assessment of how a company's culture drives world-class results   and the guiding principles of the Shingo Model™:  • Respect every individual.
","('Human_Rights_And_Community_Relations', 0.5507817268371582)","('Business_Ethics', 0.08017394691705704)","('Competitive_Behavior', 0.04885895550251007)","(['Community Relations'], 0.5507817268371582)","('NON-ESG', 0.08017394691705704)","('NON-ESG', 0.04885895550251007)"
Line 172,"• Lead with humility.• Seek perfection.• Embrace scientific thinking.• Focus on process.• Assure quality at the source.• Think systematically.• Create consistency of purpose.
","('Competitive_Behavior', 0.1905503273010254)","('Business_Ethics', 0.14933758974075317)","('Business_Model_Resilience', 0.10567432641983032)","('NON-ESG', 0.1905503273010254)","('NON-ESG', 0.14933758974075317)","('NON-ESG', 0.10567432641983032)"
Line 173,"• Create value for the customer.Shingo Prize: A World-Class Culture of Excellence The Shingo Prize “affirms the purpose-driven ethos of  Hologic Costa Rica.
","('Business_Model_Resilience', 0.1941821128129959)","('Product_Design_And_Lifecycle_Management', 0.16684556007385254)","('Competitive_Behavior', 0.08435158431529999)","('NON-ESG', 0.1941821128129959)","('NON-ESG', 0.16684556007385254)","('NON-ESG', 0.08435158431529999)"
Line 174,"It reflects what is at the heart of our mission: pursuing continuous improvement that allows us to deliver services and products of the highest quality with the goal of enabling healthier lives everywhere, every day,” said Nilo Caravaca, Vice President of Supply Chain and Manufacturing Operations, Costa Rica “ S hingo Prize recipients are in a   class of the best organizations in   the world, regardless of industry   or country,”   K en Snyder, executive  director of the Shingo Institute, said  in announcing this year’s award    for Hologic .The Shingo Prize represents   the culmination of Hologic   Costa Rica’s employee-centered   culture, which emphasizes   empowerment and commitment   in every job function and   at every job level.
","('Product_Design_And_Lifecycle_Management', 0.7577394843101501)","('Supply_Chain_Management', 0.11516666412353516)","('Product_Quality_And_Safety', 0.016535302624106407)","(['Product Stewardship'], 0.7577394843101501)","('NON-ESG', 0.11516666412353516)","('NON-ESG', 0.016535302624106407)"
Line 175,"It reflects what is at the heart of our mission: pursuing continuous improvement that allows us to deliver services and products of the highest quality with the goal of enabling healthier lives everywhere, every day,” said Nilo Caravaca, Vice President of Supply Chain and Manufacturing Operations, Costa Rica “ S hingo Prize recipients are in a   class of the best organizations in   the world, regardless of industry   or country,”   K en Snyder, executive  director of the Shingo Institute, said  in announcing this year’s award    for Hologic .The Shingo Prize represents   the culmination of Hologic   Costa Rica’s employee-centered   culture, which emphasizes   empowerment and commitment   in every job function and   at every job level.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6927819848060608)","('Employee_Health_And_Safety', 0.07495222985744476)","('Human_Rights_And_Community_Relations', 0.07201462239027023)","(['Human Capital Development'], 0.6927819848060608)","('NON-ESG', 0.07495222985744476)","('NON-ESG', 0.07201462239027023)"
Line 176,"Continuous Stewardship: Multiple projects (page 27)   help the environment   and reduce expenses.Continuous Development:  More than 75% of openings are   filled with internal promotions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.447311133146286)","('Ecological_Impacts', 0.1402561366558075)","('Human_Rights_And_Community_Relations', 0.09619288891553879)","('NON-ESG', 0.447311133146286)","('NON-ESG', 0.1402561366558075)","('NON-ESG', 0.09619288891553879)"
Line 177,"Continuous Community: Provide on-site health services, host science, technology, engineering and math ( STEM ) education programs for  children and distribute care packages for workers’ families during the year-end holiday season.Continuous Improvement: An estimated 6,385 ideas have been implemented in the past  four years.
","('Access_And_Affordability', 0.8824597001075745)","('Employee_Health_And_Safety', 0.024073176085948944)","('Employee_Engagement_Inclusion_And_Diversity', 0.00998065248131752)","(['Health Outcome Contribution'], 0.8824597001075745)","('NON-ESG', 0.024073176085948944)","('NON-ESG', 0.00998065248131752)"
Line 178,"2022 Hologic Sustainability Report 11From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  A key component of developing our 2022 Sustainability Report included the evaluation of our materiality  assessment to confirm the key environmental, social and governance issues that are most important to   our stakeholders.
","('Human_Rights_And_Community_Relations', 0.914038360118866)","('Management_Of_Legal_And_Regulatory_Framework', 0.011472620069980621)","('Ecological_Impacts', 0.010021997615695)","(['Community Relations'], 0.914038360118866)","('NON-ESG', 0.011472620069980621)","('NON-ESG', 0.010021997615695)"
Line 179,"Our disclosures are managed by a cross-functional internal  steering committee consisting of senior leaders from Operations, Finance, Legal, Human Resources, Global Communications and Investor Relations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5991163849830627)","('Business_Model_Resilience', 0.058130115270614624)","('Director_Removal', 0.05670302361249924)","(['Corporate Governance'], 0.5991163849830627)","('NON-ESG', 0.058130115270614624)","('NON-ESG', 0.05670302361249924)"
Line 180,"The ongoing goal of this committee is to identify material sustainability topics and establish a corresponding sustainability reporting framework.
","('Product_Design_And_Lifecycle_Management', 0.18318532407283783)","('Business_Model_Resilience', 0.15761782228946686)","('Management_Of_Legal_And_Regulatory_Framework', 0.08633130043745041)","('NON-ESG', 0.18318532407283783)","('NON-ESG', 0.15761782228946686)","('NON-ESG', 0.08633130043745041)"
Line 181,"The committee relies on shareholders’ feedback, sustainability  frameworks and guidelines such as those published by the Sustainability Accounting Standards Board (SASB), Global Reporting Initiative (GRI) and Task Force on Climate-Related Financial Disclosures and the U.N.’s Global Compact and Sustainable Development Goals.
","('Physical_Impacts_Of_Climate_Change', 0.6882622838020325)","('Business_Model_Resilience', 0.07373929023742676)","('GHG_Emissions', 0.04019153118133545)","(['Climate Change'], 0.6882622838020325)","('NON-ESG', 0.07373929023742676)","('NON-ESG', 0.04019153118133545)"
Line 182,"In addition, we use external benchmarking and data providers’ scoring methodologies to identify new areas of focus and opportunities.
","('Systemic_Risk_Management', 0.2718506455421448)","('Competitive_Behavior', 0.12205962091684341)","('Employee_Engagement_Inclusion_And_Diversity', 0.1218288317322731)","('NON-ESG', 0.2718506455421448)","('NON-ESG', 0.12205962091684341)","('NON-ESG', 0.1218288317322731)"
Line 183,"These insights, along with our management team’s contributions, inform our materiality framework and help us identify relevant topics  for disclosure.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8205740451812744)","('Business_Model_Resilience', 0.02007395774126053)","('Business_Ethics', 0.016275722533464432)","(['Corporate Governance'], 0.8205740451812744)","('NON-ESG', 0.02007395774126053)","('NON-ESG', 0.016275722533464432)"
Line 184,"We are committed to incorporating these topics into our  business operations, to focusing on the topics that matter  most to our business and stakeholders as well as evaluating  our sustainability topics for the future.Materiality Assessment Stakeholder  Groups Championing Women,   Our Communities and   the Environment • Access to healthcare   • Product innovation   • The environment   • Philanthropic impact   Our People • Talent   • Engagement   • Diversity  Good Governance • Board role, composition and structure   • Compensation   • Risk management   • Policies and ethics   • Sustainable supply chain   • Product quality and complianceCustomers Employees  Healthcare  Organizations Distributors Investors Regulatory  Agencies and  Governments Patients Industry  Leaders Suppliers  The Local  Communities   Where We  Operate Sustainability Topics2022 Hologic Sustainability Report 12From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic’s Commitment to   U.N. Sustainable Development Goals When performing our materiality assessment,   we considered Hologic’s unique opportunity   to make a positive impact on the world.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9454420804977417)","('Business_Model_Resilience', 0.006424797233194113)","('Human_Rights_And_Community_Relations', 0.005949930287897587)","(['Human Capital Development'], 0.9454420804977417)","('NON-ESG', 0.006424797233194113)","('NON-ESG', 0.005949930287897587)"
Line 185,"We are committed to incorporating these topics into our  business operations, to focusing on the topics that matter  most to our business and stakeholders as well as evaluating  our sustainability topics for the future.Materiality Assessment Stakeholder  Groups Championing Women,   Our Communities and   the Environment • Access to healthcare   • Product innovation   • The environment   • Philanthropic impact   Our People • Talent   • Engagement   • Diversity  Good Governance • Board role, composition and structure   • Compensation   • Risk management   • Policies and ethics   • Sustainable supply chain   • Product quality and complianceCustomers Employees  Healthcare  Organizations Distributors Investors Regulatory  Agencies and  Governments Patients Industry  Leaders Suppliers  The Local  Communities   Where We  Operate Sustainability Topics2022 Hologic Sustainability Report 12From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic’s Commitment to   U.N. Sustainable Development Goals When performing our materiality assessment,   we considered Hologic’s unique opportunity   to make a positive impact on the world.
","('Supply_Chain_Management', 0.8966602087020874)","('Product_Design_And_Lifecycle_Management', 0.013208613730967045)","('Product_Quality_And_Safety', 0.0075602298602461815)","(['Supply Chain Management'], 0.8966602087020874)","('NON-ESG', 0.013208613730967045)","('NON-ESG', 0.0075602298602461815)"
Line 186,"We are committed to incorporating these topics into our  business operations, to focusing on the topics that matter  most to our business and stakeholders as well as evaluating  our sustainability topics for the future.Materiality Assessment Stakeholder  Groups Championing Women,   Our Communities and   the Environment • Access to healthcare   • Product innovation   • The environment   • Philanthropic impact   Our People • Talent   • Engagement   • Diversity  Good Governance • Board role, composition and structure   • Compensation   • Risk management   • Policies and ethics   • Sustainable supply chain   • Product quality and complianceCustomers Employees  Healthcare  Organizations Distributors Investors Regulatory  Agencies and  Governments Patients Industry  Leaders Suppliers  The Local  Communities   Where We  Operate Sustainability Topics2022 Hologic Sustainability Report 12From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  Hologic’s Commitment to   U.N. Sustainable Development Goals When performing our materiality assessment,   we considered Hologic’s unique opportunity   to make a positive impact on the world.
","('Business_Model_Resilience', 0.3427407443523407)","('Human_Rights_And_Community_Relations', 0.26501625776290894)","('Ecological_Impacts', 0.06282269209623337)","('NON-ESG', 0.3427407443523407)","('NON-ESG', 0.26501625776290894)","('NON-ESG', 0.06282269209623337)"
Line 187,"We identified the following areas most relevant   to our business:    G ood Health and Well-Being (SDG 3)    Q uality Education (SDG 4)    G ender Equality (SDG 5)    A ffordable and Clean Energy (SDG 7)    D ecent Work and Economic Growth (SDG 8)    I ndustry, Innovation and Infrastructure (SDG 9)    R educed Inequalities (SDG 10)      R esponsible Consumption and   P roduction (SDG 12)The Sustainable Development Goals  (SDGs) were adopted by all United Nations Member States in 2015 with an aim  to end poverty, protect the environment and ensure that all people enjoy peace and prosperity.
","('Human_Rights_And_Community_Relations', 0.33089426159858704)","('Access_And_Affordability', 0.17397503554821014)","('Business_Model_Resilience', 0.12452293187379837)","('NON-ESG', 0.33089426159858704)","('NON-ESG', 0.17397503554821014)","('NON-ESG', 0.12452293187379837)"
Line 188,"We identified the following areas most relevant   to our business:    G ood Health and Well-Being (SDG 3)    Q uality Education (SDG 4)    G ender Equality (SDG 5)    A ffordable and Clean Energy (SDG 7)    D ecent Work and Economic Growth (SDG 8)    I ndustry, Innovation and Infrastructure (SDG 9)    R educed Inequalities (SDG 10)      R esponsible Consumption and   P roduction (SDG 12)The Sustainable Development Goals  (SDGs) were adopted by all United Nations Member States in 2015 with an aim  to end poverty, protect the environment and ensure that all people enjoy peace and prosperity.
","('Human_Rights_And_Community_Relations', 0.807707667350769)","('Ecological_Impacts', 0.03157500550150871)","('Physical_Impacts_Of_Climate_Change', 0.02248036302626133)","(['Community Relations'], 0.807707667350769)","('NON-ESG', 0.03157500550150871)","('NON-ESG', 0.02248036302626133)"
Line 189,"We believe we have a key role measuring the  state of women’s health globally.
","('Employee_Health_And_Safety', 0.6921294927597046)","('Access_And_Affordability', 0.10114328563213348)","('Human_Rights_And_Community_Relations', 0.03629957139492035)","(['Operational Eco-Efficiency'], 0.6921294927597046)","('NON-ESG', 0.10114328563213348)","('NON-ESG', 0.03629957139492035)"
Line 190,"The Hologic Global Women’s Health Index highlights the importance of women’s health represented in SDG 3, Good Health and Well-Being.
","('Employee_Health_And_Safety', 0.34109777212142944)","('Human_Rights_And_Community_Relations', 0.25778958201408386)","('Access_And_Affordability', 0.17959363758563995)","('NON-ESG', 0.34109777212142944)","('NON-ESG', 0.25778958201408386)","('NON-ESG', 0.17959363758563995)"
Line 191,"The results from Hologic’s Global Women’s  Health Index, as detailed on page 15,  are sadly consistent with recent gender findings from the U.N.’s Progress on the Sustainable Development Goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38875603675842285)","('Human_Rights_And_Community_Relations', 0.20654402673244476)","('Employee_Health_And_Safety', 0.10343905538320541)","('NON-ESG', 0.38875603675842285)","('NON-ESG', 0.20654402673244476)","('NON-ESG', 0.10343905538320541)"
Line 192,"Throughout the pandemic, women globally have experienced setbacks across a variety of crucial measures such as disruptions to essential health services, acute employment losses, and declining availability to mental health services.
","('Access_And_Affordability', 0.44413965940475464)","('Employee_Health_And_Safety', 0.15950404107570648)","('Critical_Incident_Risk_Management', 0.14427343010902405)","('NON-ESG', 0.44413965940475464)","('NON-ESG', 0.15950404107570648)","('NON-ESG', 0.14427343010902405)"
Line 193,"In fact, only one of the U.N.’s 18 indicators  that track the state of women’s health is defined as being “close to target.”  We are committed to addressing inequities  relevant to the global state of women’s  health.
","('Employee_Health_And_Safety', 0.6671203374862671)","('Access_And_Affordability', 0.08601880818605423)","('Human_Rights_And_Community_Relations', 0.0588335357606411)","(['Operational Eco-Efficiency'], 0.6671203374862671)","('NON-ESG', 0.08601880818605423)","('NON-ESG', 0.0588335357606411)"
Line 194,"We intend to use data from Hologic’s Global Women’s Health Index, in conjunction with gender findings from the U.N. Sustainable Development Goals, to influence decision-makers and improve access to essential healthcare for women.2022 Hologic Sustainability Report 13From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  A Sustainability Discussion With  Our CFO, Karleen Oberton The key aspects of Hologic’s sustainability efforts and impact:“I would like to share Hologic’s sustainability strategy, goals and journey of growing leadership.
","('Human_Rights_And_Community_Relations', 0.7175964117050171)","('Access_And_Affordability', 0.10145769268274307)","('Employee_Engagement_Inclusion_And_Diversity', 0.044823113828897476)","(['Community Relations'], 0.7175964117050171)","('NON-ESG', 0.10145769268274307)","('NON-ESG', 0.044823113828897476)"
Line 195,"We intend to use data from Hologic’s Global Women’s Health Index, in conjunction with gender findings from the U.N. Sustainable Development Goals, to influence decision-makers and improve access to essential healthcare for women.2022 Hologic Sustainability Report 13From Our CEO      Our Purpose       Championing Women      Our Communities      The Environment     Our People      Good Governance  A Sustainability Discussion With  Our CFO, Karleen Oberton The key aspects of Hologic’s sustainability efforts and impact:“I would like to share Hologic’s sustainability strategy, goals and journey of growing leadership.
","('Business_Model_Resilience', 0.7209328413009644)","('Product_Design_And_Lifecycle_Management', 0.048912934958934784)","('Director_Removal', 0.02690676599740982)","(['Codes of Business Conduct'], 0.7209328413009644)","('NON-ESG', 0.048912934958934784)","('NON-ESG', 0.02690676599740982)"
Line 196,"This is an increasingly important area of focus for our leadership team.
","('Employee_Engagement_Inclusion_And_Diversity', 0.30746811628341675)","('Business_Model_Resilience', 0.1979062855243683)","('Human_Rights_And_Community_Relations', 0.10718981176614761)","('NON-ESG', 0.30746811628341675)","('NON-ESG', 0.1979062855243683)","('NON-ESG', 0.10718981176614761)"
Line 197,"I am incredibly proud to be part of an organization whose purpose-driven mission authentically informs our business strategies and initiatives.
","('Business_Model_Resilience', 0.7824516892433167)","('Human_Rights_And_Community_Relations', 0.0328698568046093)","('Product_Design_And_Lifecycle_Management', 0.020470445975661278)","(['Codes of Business Conduct'], 0.7824516892433167)","('NON-ESG', 0.0328698568046093)","('NON-ESG', 0.020470445975661278)"
Line 198,"” Karleen Oberton   Chief Financial Officer Our Approach to Sustainability We focus on areas where we know we  can make a unique difference, such as providing access to our best-in-class products for underserved communities, funding STEM  education and driving   global policy change to improve early detection and treatment of disease.
","('Access_And_Affordability', 0.9438043832778931)","('Product_Quality_And_Safety', 0.005518355406820774)","('Human_Rights_And_Community_Relations', 0.0048690238036215305)","(['Health Outcome Contribution'], 0.9438043832778931)","('NON-ESG', 0.005518355406820774)","('NON-ESG', 0.0048690238036215305)"
Line 199,"Our sustainability strategy is directly  linked to our business strategy.
","('Business_Model_Resilience', 0.8199304938316345)","('Product_Design_And_Lifecycle_Management', 0.026736188679933548)","('Supply_Chain_Management', 0.025233427062630653)","(['Codes of Business Conduct'], 0.8199304938316345)","('NON-ESG', 0.026736188679933548)","('NON-ESG', 0.025233427062630653)"
Line 200,"By driving innovation, we deliver strong financial results, enabling us to invest in key initiatives such as the Hologic Global Women’s Health Index  and Project Health   Equality .
","('Human_Rights_And_Community_Relations', 0.21971113979816437)","('Access_And_Affordability', 0.18896113336086273)","('Employee_Health_And_Safety', 0.15065546333789825)","('NON-ESG', 0.21971113979816437)","('NON-ESG', 0.18896113336086273)","('NON-ESG', 0.15065546333789825)"
Line 201,"By helping more women, we are  driving meaningful societal benefits.Development of the  Sustainability Industry It is clear this expanding investment  thesis will only strengthen over the next few years.
","('Human_Rights_And_Community_Relations', 0.3490673899650574)","('Employee_Engagement_Inclusion_And_Diversity', 0.1883794516324997)","('Access_And_Affordability', 0.1821281909942627)","('NON-ESG', 0.3490673899650574)","('NON-ESG', 0.1883794516324997)","('NON-ESG', 0.1821281909942627)"
Line 202,"Hologic finds this encouraging, and we are excited to share our story and grow our investor base with shareholders who share our vision of helping more women.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5466452240943909)","('Human_Rights_And_Community_Relations', 0.17437472939491272)","('Access_And_Affordability', 0.07797997444868088)","(['Human Capital Development'], 0.5466452240943909)","('NON-ESG', 0.17437472939491272)","('NON-ESG', 0.07797997444868088)"
Line 203,"We also see sustainability becoming  more formalized, with more disclosure expectations and reporting.
","('Business_Model_Resilience', 0.2021368443965912)","('Management_Of_Legal_And_Regulatory_Framework', 0.15950971841812134)","('Systemic_Risk_Management', 0.14026109874248505)","('NON-ESG', 0.2021368443965912)","('NON-ESG', 0.15950971841812134)","('NON-ESG', 0.14026109874248505)"
Line 204,"Our teams are working to understand how newly proposed rules may impact Hologic and how to best prepare as an organization.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9452831149101257)","('Director_Removal', 0.005066949874162674)","('Physical_Impacts_Of_Climate_Change', 0.004652214236557484)","(['Corporate Governance'], 0.9452831149101257)","('NON-ESG', 0.005066949874162674)","('NON-ESG', 0.004652214236557484)"
Line 205,"Finally, we believe as the movement  towards sustainability gains further traction, this will create more opportunities to attract and retain key talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9030950665473938)","('Business_Model_Resilience', 0.009354324080049992)","('Systemic_Risk_Management', 0.006337590981274843)","(['Human Capital Development'], 0.9030950665473938)","('NON-ESG', 0.009354324080049992)","('NON-ESG', 0.006337590981274843)"
Line 206,"We have confidence that connecting Hologic’s purpose, passion and promise with our business strategy will resonate strongly with the next generation of leaders.CFO’s Role in Sustainability  Oversight Traditionally, a CFO’s job is to ensure  financial returns.
","('Business_Model_Resilience', 0.7001639008522034)","('Director_Removal', 0.05504082143306732)","('Systemic_Risk_Management', 0.044152673333883286)","(['Codes of Business Conduct'], 0.7001639008522034)","('NON-ESG', 0.05504082143306732)","('NON-ESG', 0.044152673333883286)"
Line 207,"In today’s world, the role has evolved.
","('Competitive_Behavior', 0.20063237845897675)","('Business_Model_Resilience', 0.1454818695783615)","('Employee_Engagement_Inclusion_And_Diversity', 0.11264189332723618)","('NON-ESG', 0.20063237845897675)","('NON-ESG', 0.1454818695783615)","('NON-ESG', 0.11264189332723618)"
Line 208,"It’s “and” instead of “or.” In other words, how do I ensure financial return AND make a difference?
","('Competitive_Behavior', 0.35795480012893677)","('Systemic_Risk_Management', 0.225600466132164)","('Business_Model_Resilience', 0.14105989038944244)","('NON-ESG', 0.35795480012893677)","('NON-ESG', 0.225600466132164)","('NON-ESG', 0.14105989038944244)"
Line 209,"The difference between a good CFO and  a great one is the ability to deliver financial success while also making the world a better place for stakeholders — and for society more broadly.
","('Business_Model_Resilience', 0.33374932408332825)","('Human_Rights_And_Community_Relations', 0.19608275592327118)","('Systemic_Risk_Management', 0.05728888139128685)","('NON-ESG', 0.33374932408332825)","('NON-ESG', 0.19608275592327118)","('NON-ESG', 0.05728888139128685)"
Line 210,"Connecting Hologic’s sustainability  strategy with our business strategy helps me lead in a purpose-driven way, deliver financial returns to our shareholders   and drive meaningful initiatives to improve t he lives of our customers and patients  around the world.Our Sustainability Momentum  and Impact We formalized our sustainability journey in  2019.
","('Business_Model_Resilience', 0.6466679573059082)","('Product_Design_And_Lifecycle_Management', 0.0639834776520729)","('Supply_Chain_Management', 0.048003386706113815)","(['Codes of Business Conduct'], 0.6466679573059082)","('NON-ESG', 0.0639834776520729)","('NON-ESG', 0.048003386706113815)"
Line 211,"It was the same year we launched our first annual sustainability report.
","('Business_Model_Resilience', 0.2339673936367035)","('Physical_Impacts_Of_Climate_Change', 0.1215980276465416)","('Product_Design_And_Lifecycle_Management', 0.08023838698863983)","('NON-ESG', 0.2339673936367035)","('NON-ESG', 0.1215980276465416)","('NON-ESG', 0.08023838698863983)"
Line 212,"Since that time, we’ve come a long way.
","('Business_Model_Resilience', 0.189147487282753)","('Employee_Engagement_Inclusion_And_Diversity', 0.1179867833852768)","('Product_Design_And_Lifecycle_Management', 0.09938397258520126)","('NON-ESG', 0.189147487282753)","('NON-ESG', 0.1179867833852768)","('NON-ESG', 0.09938397258520126)"
Line 213,"We describe this sustainability journey as   one of continuous improvement.
","('Business_Model_Resilience', 0.34896495938301086)","('Product_Design_And_Lifecycle_Management', 0.11494603008031845)","('Supply_Chain_Management', 0.0778115764260292)","('NON-ESG', 0.34896495938301086)","('NON-ESG', 0.11494603008031845)","('NON-ESG', 0.0778115764260292)"
Line 214,"At the   start, we set out to define what was central   to our mission with Hologic’s purpose,  passion and promise.
","('Business_Model_Resilience', 0.24444609880447388)","('Human_Rights_And_Community_Relations', 0.22270256280899048)","('Employee_Engagement_Inclusion_And_Diversity', 0.11202672123908997)","('NON-ESG', 0.24444609880447388)","('NON-ESG', 0.22270256280899048)","('NON-ESG', 0.11202672123908997)"
Line 215,"By expanding our societal footprint, launching important initiatives such as the Hologic Global Women’s Health Index, Project Health Equality and the Global Access Initiative ,  we help more patients globally, where we know we can make a difference based on our unique capabilities as an organization.
","('Access_And_Affordability', 0.6886546611785889)","('Human_Rights_And_Community_Relations', 0.06388672441244125)","('Employee_Engagement_Inclusion_And_Diversity', 0.03953002765774727)","(['Health Outcome Contribution'], 0.6886546611785889)","('NON-ESG', 0.06388672441244125)","('NON-ESG', 0.03953002765774727)"
Line 216,"As we move forward on our sustainability  journey for 2023 and beyond, we are excited to build on our progress and unwavering commitment to help more women.
","('Human_Rights_And_Community_Relations', 0.6870660185813904)","('Employee_Engagement_Inclusion_And_Diversity', 0.05624033510684967)","('Access_And_Affordability', 0.033600833266973495)","(['Community Relations'], 0.6870660185813904)","('NON-ESG', 0.05624033510684967)","('NON-ESG', 0.033600833266973495)"
Line 217,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Championing   Women We see so often that women put themselves last,   often to their detriment.
","('Human_Rights_And_Community_Relations', 0.9001956582069397)","('Employee_Engagement_Inclusion_And_Diversity', 0.014325922355055809)","('Labor_Practices', 0.011693084612488747)","(['Community Relations'], 0.9001956582069397)","('NON-ESG', 0.014325922355055809)","('NON-ESG', 0.011693084612488747)"
Line 218,"Despite advances in healthcare,  women’s health is not a priority in much of the world.
","('Employee_Health_And_Safety', 0.5727767944335938)","('Access_And_Affordability', 0.114592045545578)","('Human_Rights_And_Community_Relations', 0.06203363835811615)","(['Operational Eco-Efficiency'], 0.5727767944335938)","('NON-ESG', 0.114592045545578)","('NON-ESG', 0.06203363835811615)"
Line 219,"In 2022, health situations for women and girls did   not get better.
","('Access_And_Affordability', 0.5304190516471863)","('Employee_Health_And_Safety', 0.24874143302440643)","('Human_Rights_And_Community_Relations', 0.03719416260719299)","(['Health Outcome Contribution'], 0.5304190516471863)","('NON-ESG', 0.24874143302440643)","('NON-ESG', 0.03719416260719299)"
Line 220,"The divide between women in high-income and low-income economies grew even larger than the year before.
","('Employee_Engagement_Inclusion_And_Diversity', 0.20419220626354218)","('Systemic_Risk_Management', 0.13775359094142914)","('Supply_Chain_Management', 0.12212182581424713)","('NON-ESG', 0.20419220626354218)","('NON-ESG', 0.13775359094142914)","('NON-ESG', 0.12212182581424713)"
Line 221,"Hologic works tirelessly to   ensure that women’s health is prioritized and that   more women can access world-class technologies   that have the potential to improve and save lives.Hologic Global Women’s Health Index  .
","('Employee_Health_And_Safety', 0.47337606549263)","('Access_And_Affordability', 0.22961099445819855)","('Human_Rights_And_Community_Relations', 0.0479259230196476)","('NON-ESG', 0.47337606549263)","('NON-ESG', 0.22961099445819855)","('NON-ESG', 0.0479259230196476)"
Line 222,"S erving the Greater Good   With the WTA    .
","('Competitive_Behavior', 0.15270383656024933)","('Access_And_Affordability', 0.14961056411266327)","('Management_Of_Legal_And_Regulatory_Framework', 0.06503515690565109)","('NON-ESG', 0.15270383656024933)","('NON-ESG', 0.14961056411266327)","('NON-ESG', 0.06503515690565109)"
Line 223,"Global Access Initiative    .
","('Access_And_Affordability', 0.3171587884426117)","('Human_Rights_And_Community_Relations', 0.23243270814418793)","('Management_Of_Legal_And_Regulatory_Framework', 0.1535843312740326)","('NON-ESG', 0.3171587884426117)","('NON-ESG', 0.23243270814418793)","('NON-ESG', 0.1535843312740326)"
Line 224,"Project Health Equality    .
","('Human_Rights_And_Community_Relations', 0.7255350947380066)","('Employee_Engagement_Inclusion_And_Diversity', 0.04093559831380844)","('Access_And_Affordability', 0.03448456525802612)","(['Community Relations'], 0.7255350947380066)","('NON-ESG', 0.04093559831380844)","('NON-ESG', 0.03448456525802612)"
Line 225,"Helping Underserved Women Globally .
","('Access_And_Affordability', 0.93672776222229)","('Critical_Incident_Risk_Management', 0.0072798519395291805)","('Human_Rights_And_Community_Relations', 0.005857971962541342)","(['Health Outcome Contribution'], 0.93672776222229)","('NON-ESG', 0.0072798519395291805)","('NON-ESG', 0.005857971962541342)"
Line 226,"23From Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance 2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Hologic Global Women’s Health Index A Powerful Framework for Understanding the State of Women’s Health This breakthrough survey, conducted annually in partnership with Gallup®, measures the experiences of women and girls across 122 countries  and territories, accounting for 94% of the female global population aged 15 and older.
","('Human_Rights_And_Community_Relations', 0.9003933072090149)","('Employee_Engagement_Inclusion_And_Diversity', 0.016316737979650497)","('Access_And_Affordability', 0.01267329417169094)","(['Community Relations'], 0.9003933072090149)","('NON-ESG', 0.016316737979650497)","('NON-ESG', 0.01267329417169094)"
Line 227,"23From Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance 2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Hologic Global Women’s Health Index A Powerful Framework for Understanding the State of Women’s Health This breakthrough survey, conducted annually in partnership with Gallup®, measures the experiences of women and girls across 122 countries  and territories, accounting for 94% of the female global population aged 15 and older.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6515343189239502)","('Access_And_Affordability', 0.13053569197654724)","('Labor_Practices', 0.03966877609491348)","(['Human Capital Development'], 0.6515343189239502)","('NON-ESG', 0.13053569197654724)","('NON-ESG', 0.03966877609491348)"
Line 228,"The latest findings underscore that the disparities in women’s health continue to grow, making the need for prioritizing women’s health policies more important than ever.
","('Employee_Health_And_Safety', 0.3654934763908386)","('Access_And_Affordability', 0.29128003120422363)","('Human_Rights_And_Community_Relations', 0.09082339704036713)","('NON-ESG', 0.3654934763908386)","('NON-ESG', 0.29128003120422363)","('NON-ESG', 0.09082339704036713)"
Line 229,"These key results reflect the five dimensions of health (Preventive Care, Emotional Health, Opinions of Health and Safety, Basic Needs and Individual Health) that together account for more than 80% of variances contributing to women’s life expectancy.
","('Employee_Health_And_Safety', 0.9255431890487671)","('Access_And_Affordability', 0.015048851259052753)","('Product_Quality_And_Safety', 0.008961685001850128)","(['Operational Eco-Efficiency'], 0.9255431890487671)","('NON-ESG', 0.015048851259052753)","('NON-ESG', 0.008961685001850128)"
Line 230,"Increased Longevity  |  Routine visits with healthcare professionals correspond with up to two more years of life expectancy for women,   even after accounting for differences in per-capita GDP across countries and territories.Preventive Care Worldwide, 40% of women said they   had not gone to a healthcare   professional in the last year.
","('Access_And_Affordability', 0.5072987079620361)","('Employee_Health_And_Safety', 0.1479412019252777)","('Employee_Engagement_Inclusion_And_Diversity', 0.07201053202152252)","(['Health Outcome Contribution'], 0.5072987079620361)","('NON-ESG', 0.1479412019252777)","('NON-ESG', 0.07201053202152252)"
Line 231,"Similarly, only 60% of women  said they  were tested for any type of cancer,  diabetes, blood pressure or STDs/STIs.  Opinions of Health and Safety More than 37%  of women worldwide  said they did not feel safe walking  alone at night, up from 32% in 2020, the first year of the Hologic Global Women’s Health Index.
","('Employee_Health_And_Safety', 0.8022044897079468)","('Product_Quality_And_Safety', 0.043580152094364166)","('Access_And_Affordability', 0.02011926658451557)","(['Operational Eco-Efficiency'], 0.8022044897079468)","('NON-ESG', 0.043580152094364166)","('NON-ESG', 0.02011926658451557)"
Line 232,"Individual Health 1 in 4 women said they experienced health problems that prevent them from doing  things people their age normally could do.
","('Employee_Health_And_Safety', 0.9585570693016052)","('Access_And_Affordability', 0.004460604395717382)","('Product_Quality_And_Safety', 0.004233187064528465)","(['Operational Eco-Efficiency'], 0.9585570693016052)","('NON-ESG', 0.004460604395717382)","('NON-ESG', 0.004233187064528465)"
Line 233,"Basic Needs About 1 in 3 women said they  struggled to afford adequate food or  shelter for themselves or their families during the previous 12 months.Emotional Health More than 4 in 10 women worldwide  said they experienced worry during the previous day, a record high since the Gallup World Poll began polling on this topic a decade ago.
","('Access_And_Affordability', 0.717759370803833)","('Employee_Health_And_Safety', 0.07696490734815598)","('Critical_Incident_Risk_Management', 0.035879600793123245)","(['Health Outcome Contribution'], 0.717759370803833)","('NON-ESG', 0.07696490734815598)","('NON-ESG', 0.035879600793123245)"
Line 234,"Record percentages of women also experienced stress (41%), sadness (32%)  and anger (26%) .
","('Employee_Health_And_Safety', 0.35055607557296753)","('Business_Ethics', 0.13549861311912537)","('Labor_Practices', 0.06607922911643982)","('NON-ESG', 0.35055607557296753)","('NON-ESG', 0.13549861311912537)","('NON-ESG', 0.06607922911643982)"
Line 235,"From Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 16* Countries in gray do not participate in the Gallup World Poll and are not included in the Hologic Global Women’s Health Index.
","('Human_Rights_And_Community_Relations', 0.9463919401168823)","('Access_And_Affordability', 0.0056034899316728115)","('Management_Of_Legal_And_Regulatory_Framework', 0.004343296401202679)","(['Community Relations'], 0.9463919401168823)","('NON-ESG', 0.0056034899316728115)","('NON-ESG', 0.004343296401202679)"
Line 236,"Women’s Health Around the World 0 700 The World Has Much Work To Do To Improve Women’s Health With the overall score of just 53 out of 100 on the Hologic Global Women’s Health Index — one point lower than the previous year’s   score — the health of the world’s women and girls did not improve last year.
","('Employee_Health_And_Safety', 0.7519038915634155)","('Access_And_Affordability', 0.05450964719057083)","('Human_Rights_And_Community_Relations', 0.0465460903942585)","(['Operational Eco-Efficiency'], 0.7519038915634155)","('NON-ESG', 0.05450964719057083)","('NON-ESG', 0.0465460903942585)"
Line 237,"Scores ranged from a high of 70 in Taiwan to a low of  22 in Afghanistan.
","('Systemic_Risk_Management', 0.1449483186006546)","('Human_Rights_And_Community_Relations', 0.1363353133201599)","('Management_Of_Legal_And_Regulatory_Framework', 0.11162208020687103)","('NON-ESG', 0.1449483186006546)","('NON-ESG', 0.1363353133201599)","('NON-ESG', 0.11162208020687103)"
Line 238,"See how your country ranks at womenshealthindex.com.
","('Employee_Engagement_Inclusion_And_Diversity', 0.332897424697876)","('Competitive_Behavior', 0.08791533857584)","('Systemic_Risk_Management', 0.0833858996629715)","('NON-ESG', 0.332897424697876)","('NON-ESG', 0.08791533857584)","('NON-ESG', 0.0833858996629715)"
Line 239,"Index Score2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  17A Worldwide Call to Action     Hologic continues to meet with policymakers and other stakeholders at events around the world, including the prestigious   World Economic Forum  (WEF) and Concordia Annual Summit , to discuss how women’s health can be improved using data   from the study and other resources.
","('Human_Rights_And_Community_Relations', 0.41455313563346863)","('Employee_Health_And_Safety', 0.2906563878059387)","('Access_And_Affordability', 0.08825261890888214)","('NON-ESG', 0.41455313563346863)","('NON-ESG', 0.2906563878059387)","('NON-ESG', 0.08825261890888214)"
Line 240,"CONCORDIA ANNUAL SUMMIT Timed to the United Nations General Assembly in New  York City, Hologic released data from the second year of the Hologic Global Women’s Health Index during the Concordia Annual Summit.
","('Access_And_Affordability', 0.2609936594963074)","('Employee_Health_And_Safety', 0.23090490698814392)","('Product_Quality_And_Safety', 0.08710312843322754)","('NON-ESG', 0.2609936594963074)","('NON-ESG', 0.23090490698814392)","('NON-ESG', 0.08710312843322754)"
Line 241,"Dr. Susan Harvey, Hologic’s Vice President of Global Medical Affairs, joined Kolinda Grabar-Kitarović, former president of the Republic of Croatia, and Dr. Lia Tadesse, health minister for the Federal Democratic Republic of Ethiopia, at the summit for a discussion about women’s health.
","('Employee_Health_And_Safety', 0.5275038480758667)","('Access_And_Affordability', 0.1382686197757721)","('Employee_Engagement_Inclusion_And_Diversity', 0.06354481726884842)","(['Operational Eco-Efficiency'], 0.5275038480758667)","('NON-ESG', 0.1382686197757721)","('NON-ESG', 0.06354481726884842)"
Line 242,"An Innovative Partnership With  the World Economic Forum Hologic’s global leadership in women’s health anchors our work with WEF, an important convener of the public and private sectors to address the world’s most pressing issues.
","('Employee_Health_And_Safety', 0.5239202380180359)","('Access_And_Affordability', 0.15203671157360077)","('Employee_Engagement_Inclusion_And_Diversity', 0.07438343018293381)","(['Operational Eco-Efficiency'], 0.5239202380180359)","('NON-ESG', 0.15203671157360077)","('NON-ESG', 0.07438343018293381)"
Line 243,"This collaboration includes Hologic’s key role in the Women’s Health Initiative at WEF.
","('Access_And_Affordability', 0.5944882035255432)","('Employee_Engagement_Inclusion_And_Diversity', 0.07733204215765)","('Employee_Health_And_Safety', 0.07058092951774597)","(['Health Outcome Contribution'], 0.5944882035255432)","('NON-ESG', 0.07733204215765)","('NON-ESG', 0.07058092951774597)"
Line 244,"For all the progress we have made in the  last few decades, women’s health around the world is still lagging despite the clear evidence that improving women’s health results in stronger families, higher income  and more effective, thriving societies.
","('Employee_Health_And_Safety', 0.555639922618866)","('Access_And_Affordability', 0.1992068737745285)","('Human_Rights_And_Community_Relations', 0.07094957679510117)","(['Operational Eco-Efficiency'], 0.555639922618866)","('NON-ESG', 0.1992068737745285)","('NON-ESG', 0.07094957679510117)"
Line 245,"The Women’s Health Initiative draws global focus to the need for investment in women’s and girls’ health.
","('Access_And_Affordability', 0.562990128993988)","('Employee_Health_And_Safety', 0.18587540090084076)","('Human_Rights_And_Community_Relations', 0.07653678208589554)","(['Health Outcome Contribution'], 0.562990128993988)","('NON-ESG', 0.18587540090084076)","('NON-ESG', 0.07653678208589554)"
Line 246,"It supports and amplifies leading efforts; connects ecosystems across sectors; and engages global leaders and communities through sustained, impactful dialogue and the enablement of action plans.
","('Human_Rights_And_Community_Relations', 0.9492227435112)","('Access_And_Affordability', 0.007912218570709229)","('Management_Of_Legal_And_Regulatory_Framework', 0.0034773098304867744)","(['Community Relations'], 0.9492227435112)","('NON-ESG', 0.007912218570709229)","('NON-ESG', 0.0034773098304867744)"
Line 247,"There are three active projects in the  Women’s Health Initiative:  •    P rotecting women’s and girls’ reproductive  and maternal health.
","('Access_And_Affordability', 0.3989478647708893)","('Employee_Health_And_Safety', 0.3594619035720825)","('Human_Rights_And_Community_Relations', 0.04896574839949608)","('NON-ESG', 0.3989478647708893)","('NON-ESG', 0.3594619035720825)","('NON-ESG', 0.04896574839949608)"
Line 248,"•   C apturing women’s and girls’ perspectives  on cancer care.
","('Access_And_Affordability', 0.7483242750167847)","('Employee_Engagement_Inclusion_And_Diversity', 0.060825787484645844)","('Employee_Health_And_Safety', 0.0414314791560173)","(['Health Outcome Contribution'], 0.7483242750167847)","('NON-ESG', 0.060825787484645844)","('NON-ESG', 0.0414314791560173)"
Line 249,"•   O ffering family planning programming   to protect the health of vulnerable women   and girls.
","('Access_And_Affordability', 0.782181441783905)","('Human_Rights_And_Community_Relations', 0.07207079231739044)","('Employee_Health_And_Safety', 0.027775872498750687)","(['Health Outcome Contribution'], 0.782181441783905)","('NON-ESG', 0.07207079231739044)","('NON-ESG', 0.027775872498750687)"
Line 250,"Hologic contributes to each of these projects through the provision of data and other insights from the Hologic Global Women’s Health Index — findings that provide important perspective at the global, regional and country levels.
","('Access_And_Affordability', 0.2159237265586853)","('Employee_Health_And_Safety', 0.14538618922233582)","('Systemic_Risk_Management', 0.11597858369350433)","('NON-ESG', 0.2159237265586853)","('NON-ESG', 0.14538618922233582)","('NON-ESG', 0.11597858369350433)"
Line 251,"Left: Jan Verstreken, Tanja Brycker, Laura Gillespie  and Steve MacMillan at the World Economic Forum in Davos, Switzerland.
","('Competitive_Behavior', 0.16917003691196442)","('Management_Of_Legal_And_Regulatory_Framework', 0.1576109677553177)","('Systemic_Risk_Management', 0.1508893370628357)","('NON-ESG', 0.16917003691196442)","('NON-ESG', 0.1576109677553177)","('NON-ESG', 0.1508893370628357)"
Line 252,"Dr. Harvey and other Concordia Summit panelists discuss the state of women’s health.
","('Employee_Health_And_Safety', 0.7271726727485657)","('Access_And_Affordability', 0.06379979103803635)","('Employee_Engagement_Inclusion_And_Diversity', 0.05066360533237457)","(['Operational Eco-Efficiency'], 0.7271726727485657)","('NON-ESG', 0.06379979103803635)","('NON-ESG', 0.05066360533237457)"
Line 253,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  18Serving the Greater Good   With the WTA Two Champions for Women Join Forces On and Off the Court “We couldn’t ask for a better partner  to champion women’s health.
","('Human_Rights_And_Community_Relations', 0.9381971955299377)","('Access_And_Affordability', 0.009275547228753567)","('Employee_Engagement_Inclusion_And_Diversity', 0.006005051080137491)","(['Community Relations'], 0.9381971955299377)","('NON-ESG', 0.009275547228753567)","('NON-ESG', 0.006005051080137491)"
Line 254,"We are  grateful for Hologic’s support of ACEing  Cancer and because of it, we will  be able to expand our ability to help  women around the world.”  Ann Austin, WTA   Vice President of Community Development   and Charitable ProgramsACEing Cancer Program Hologic proudly supports ACEing Cancer, the  WTA Charities’ first global philanthropic program supporting women’s health and wellness with a focus on women’s cancers.
","('Access_And_Affordability', 0.4664871096611023)","('Employee_Health_And_Safety', 0.15639975666999817)","('Product_Quality_And_Safety', 0.04643016681075096)","('NON-ESG', 0.4664871096611023)","('NON-ESG', 0.15639975666999817)","('NON-ESG', 0.04643016681075096)"
Line 255,"The program has three main objectives: •   R aising awareness through public service  announcements and player ambassadors.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24612706899642944)","('Access_And_Affordability', 0.22354327142238617)","('Business_Ethics', 0.0714549645781517)","('NON-ESG', 0.24612706899642944)","('NON-ESG', 0.22354327142238617)","('NON-ESG', 0.0714549645781517)"
Line 256,"• S torytelling to share firsthand experiences.
","('Product_Design_And_Lifecycle_Management', 0.1461109220981598)","('Customer_Privacy', 0.12295113503932953)","('Employee_Health_And_Safety', 0.11578592658042908)","('NON-ESG', 0.1461109220981598)","('NON-ESG', 0.12295113503932953)","('NON-ESG', 0.11578592658042908)"
Line 257,"•  F undraising to support the fight against  women’s cancers.
","('Access_And_Affordability', 0.5544965267181396)","('Employee_Engagement_Inclusion_And_Diversity', 0.08338172733783722)","('Employee_Health_And_Safety', 0.06826748698949814)","(['Health Outcome Contribution'], 0.5544965267181396)","('NON-ESG', 0.08338172733783722)","('NON-ESG', 0.06826748698949814)"
Line 258,"For every ace that players hit at 500- and  1000-level tournaments worldwide, Hologic makes a monetary donation to ACEing Cancer.
","('Competitive_Behavior', 0.36282777786254883)","('Business_Ethics', 0.22681234776973724)","('Management_Of_Legal_And_Regulatory_Framework', 0.08958806097507477)","('NON-ESG', 0.36282777786254883)","('NON-ESG', 0.22681234776973724)","('NON-ESG', 0.08958806097507477)"
Line 259,"Each year, these funds then support a new researcher and various nonprofit groups.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7764047384262085)","('Ecological_Impacts', 0.025086168199777603)","('Business_Ethics', 0.018961893394589424)","(['Corporate Governance'], 0.7764047384262085)","('NON-ESG', 0.025086168199777603)","('NON-ESG', 0.018961893394589424)"
Line 260,"Hologic is the WTA’s  official health partner and equality champion.
","('Access_And_Affordability', 0.24107159674167633)","('Employee_Health_And_Safety', 0.1583070456981659)","('Product_Quality_And_Safety', 0.10260431468486786)","('NON-ESG', 0.24107159674167633)","('NON-ESG', 0.1583070456981659)","('NON-ESG', 0.10260431468486786)"
Line 261,"Our organizations jointly amplify the  message that women’s health is foundational to the well-being of families, communities and societies.
","('Human_Rights_And_Community_Relations', 0.7621365785598755)","('Access_And_Affordability', 0.10273455083370209)","('Employee_Health_And_Safety', 0.03409566357731819)","(['Community Relations'], 0.7621365785598755)","('NON-ESG', 0.10273455083370209)","('NON-ESG', 0.03409566357731819)"
Line 262,"In collaboration with current WTA legends and players, we inspire women to make their health a greater  priority through preventive care.
","('Access_And_Affordability', 0.39677953720092773)","('Employee_Health_And_Safety', 0.3748038709163666)","('Critical_Incident_Risk_Management', 0.030865110456943512)","('NON-ESG', 0.39677953720092773)","('NON-ESG', 0.3748038709163666)","('NON-ESG', 0.030865110456943512)"
Line 263,"The launch of the Hologic-WTA partnership included a media panel at the BNP Paribas Open in Indian Wells, California in March 2022.
","('Business_Model_Resilience', 0.4051279127597809)","('Systemic_Risk_Management', 0.10476040095090866)","('Physical_Impacts_Of_Climate_Change', 0.06941580772399902)","('NON-ESG', 0.4051279127597809)","('NON-ESG', 0.10476040095090866)","('NON-ESG', 0.06941580772399902)"
Line 264,"From left to  right: Tennis Channel reporter Blair Henley, WTA athlete Jessica Pegula, WTA President Micky Lawler, Hologic Senior Vice President Lisa Hellmann, WTA legend Pam Shriver and WTA athlete Christina McHale.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  A Smashing Partnership With the  Women’s Tennis Association Game, Set, Match for Preventive Care Awareness: Special Event Highlights from Tournament Showcases Hologic has provided special, onsite  engagements at WTA tournaments in: • I ndian Wells, California.
","('Human_Rights_And_Community_Relations', 0.40134119987487793)","('Access_And_Affordability', 0.2802492678165436)","('Employee_Health_And_Safety', 0.11114629358053207)","('NON-ESG', 0.40134119987487793)","('NON-ESG', 0.2802492678165436)","('NON-ESG', 0.11114629358053207)"
Line 265,"From left to  right: Tennis Channel reporter Blair Henley, WTA athlete Jessica Pegula, WTA President Micky Lawler, Hologic Senior Vice President Lisa Hellmann, WTA legend Pam Shriver and WTA athlete Christina McHale.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  A Smashing Partnership With the  Women’s Tennis Association Game, Set, Match for Preventive Care Awareness: Special Event Highlights from Tournament Showcases Hologic has provided special, onsite  engagements at WTA tournaments in: • I ndian Wells, California.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2343379557132721)","('Competitive_Behavior', 0.17124982178211212)","('Business_Model_Resilience', 0.11172845959663391)","('NON-ESG', 0.2343379557132721)","('NON-ESG', 0.17124982178211212)","('NON-ESG', 0.11172845959663391)"
Line 266,"•  S an Diego, California.
","('Ecological_Impacts', 0.13729839026927948)","('Management_Of_Legal_And_Regulatory_Framework', 0.1318783015012741)","('Business_Model_Resilience', 0.08274571597576141)","('NON-ESG', 0.13729839026927948)","('NON-ESG', 0.1318783015012741)","('NON-ESG', 0.08274571597576141)"
Line 267,"•  F ort Worth, Texas.
","('Competitive_Behavior', 0.16491730511188507)","('Management_Of_Legal_And_Regulatory_Framework', 0.11442209035158157)","('GHG_Emissions', 0.10358229279518127)","('NON-ESG', 0.16491730511188507)","('NON-ESG', 0.11442209035158157)","('NON-ESG', 0.10358229279518127)"
Line 268,"•  M adrid, Spain.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4761229157447815)","('Competitive_Behavior', 0.10742928832769394)","('GHG_Emissions', 0.07606527209281921)","('NON-ESG', 0.4761229157447815)","('NON-ESG', 0.10742928832769394)","('NON-ESG', 0.07606527209281921)"
Line 269,"• B erlin, Germany.
","('Management_Of_Legal_And_Regulatory_Framework', 0.28660017251968384)","('Competitive_Behavior', 0.09798372536897659)","('GHG_Emissions', 0.06865940243005753)","('NON-ESG', 0.28660017251968384)","('NON-ESG', 0.09798372536897659)","('NON-ESG', 0.06865940243005753)"
Line 270,"• T okyo, Japan.Powerful Voices WTA legends and athletes contributed their  high-profile voices to the Hologic WTA Tour’s efforts to elevate women’s health, raising awareness and normalizing conversations about preventive care.
","('Employee_Health_And_Safety', 0.8243291974067688)","('Access_And_Affordability', 0.05083183944225311)","('Employee_Engagement_Inclusion_And_Diversity', 0.01746281050145626)","(['Operational Eco-Efficiency'], 0.8243291974067688)","('NON-ESG', 0.05083183944225311)","('NON-ESG', 0.01746281050145626)"
Line 271,"They include: •  M artina Navratilova.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16196615993976593)","('Competitive_Behavior', 0.13994750380516052)","('Employee_Engagement_Inclusion_And_Diversity', 0.08205893635749817)","('NON-ESG', 0.16196615993976593)","('NON-ESG', 0.13994750380516052)","('NON-ESG', 0.08205893635749817)"
Line 272,"• C hris Evert.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6206995844841003)","('Business_Ethics', 0.08068118244409561)","('Director_Removal', 0.04104382172226906)","(['Corporate Governance'], 0.6206995844841003)","('NON-ESG', 0.08068118244409561)","('NON-ESG', 0.04104382172226906)"
Line 273,"• C arla Suárez Navarro.
","('Competitive_Behavior', 0.14628155529499054)","('Management_Of_Legal_And_Regulatory_Framework', 0.12267138808965683)","('Director_Removal', 0.12222503125667572)","('NON-ESG', 0.14628155529499054)","('NON-ESG', 0.12267138808965683)","('NON-ESG', 0.12222503125667572)"
Line 274,"•  I ga Świątek.
","('Competitive_Behavior', 0.3145294487476349)","('Management_Of_Legal_And_Regulatory_Framework', 0.16608041524887085)","('Business_Ethics', 0.09655166417360306)","('NON-ESG', 0.3145294487476349)","('NON-ESG', 0.16608041524887085)","('NON-ESG', 0.09655166417360306)"
Line 275,"• S loane Stephens.
","('Systemic_Risk_Management', 0.1900109201669693)","('Business_Model_Resilience', 0.14197666943073273)","('Management_Of_Legal_And_Regulatory_Framework', 0.0712832435965538)","('NON-ESG', 0.1900109201669693)","('NON-ESG', 0.14197666943073273)","('NON-ESG', 0.0712832435965538)"
Line 276,"• Sim ona Halep.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17324338853359222)","('Human_Rights_And_Community_Relations', 0.09478554874658585)","('Business_Ethics', 0.08276820927858353)","('NON-ESG', 0.17324338853359222)","('NON-ESG', 0.09478554874658585)","('NON-ESG', 0.08276820927858353)"
Line 277,"•  B ianca Andreescu.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2575700879096985)","('Ecological_Impacts', 0.07195518910884857)","('Director_Removal', 0.07068026065826416)","('NON-ESG', 0.2575700879096985)","('NON-ESG', 0.07195518910884857)","('NON-ESG', 0.07068026065826416)"
Line 278,"•  P etra Kvitová.
","('Management_Of_Legal_And_Regulatory_Framework', 0.37446942925453186)","('Competitive_Behavior', 0.1946495622396469)","('GHG_Emissions', 0.06387782841920853)","('NON-ESG', 0.37446942925453186)","('NON-ESG', 0.1946495622396469)","('NON-ESG', 0.06387782841920853)"
Line 279,"•  O ns Jabeur.
","('Business_Ethics', 0.3237846791744232)","('Competitive_Behavior', 0.11779128760099411)","('Management_Of_Legal_And_Regulatory_Framework', 0.07430792599916458)","('NON-ESG', 0.3237846791744232)","('NON-ESG', 0.11779128760099411)","('NON-ESG', 0.07430792599916458)"
Line 280,"•  A nett Kontaveit.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4038870632648468)","('Competitive_Behavior', 0.2446274608373642)","('Business_Ethics', 0.04627574607729912)","('NON-ESG', 0.4038870632648468)","('NON-ESG', 0.2446274608373642)","('NON-ESG', 0.04627574607729912)"
Line 281,"•  J essica Pegula.
","('Customer_Welfare', 0.26676782965660095)","('Systemic_Risk_Management', 0.09935222566127777)","('Competitive_Behavior', 0.09054987877607346)","('NON-ESG', 0.26676782965660095)","('NON-ESG', 0.09935222566127777)","('NON-ESG', 0.09054987877607346)"
Line 282,"•  M adison Keys.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2623899579048157)","('Competitive_Behavior', 0.20212069153785706)","('Systemic_Risk_Management', 0.0903327688574791)","('NON-ESG', 0.2623899579048157)","('NON-ESG', 0.20212069153785706)","('NON-ESG', 0.0903327688574791)"
Line 283,"•  C oco Gauff.
","('Management_Of_Legal_And_Regulatory_Framework', 0.1525181084871292)","('Customer_Welfare', 0.14652734994888306)","('GHG_Emissions', 0.13270796835422516)","('NON-ESG', 0.1525181084871292)","('NON-ESG', 0.14652734994888306)","('NON-ESG', 0.13270796835422516)"
Line 284,"• M aria Sakkari.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24457016587257385)","('Employee_Engagement_Inclusion_And_Diversity', 0.10888025164604187)","('Human_Rights_And_Community_Relations', 0.0773589015007019)","('NON-ESG', 0.24457016587257385)","('NON-ESG', 0.10888025164604187)","('NON-ESG', 0.0773589015007019)"
Line 285,"•  P aula Badosa.
","('Ecological_Impacts', 0.489603728055954)","('Supply_Chain_Management', 0.042340394109487534)","('Product_Design_And_Lifecycle_Management', 0.04178519546985626)","('NON-ESG', 0.489603728055954)","('NON-ESG', 0.042340394109487534)","('NON-ESG', 0.04178519546985626)"
Line 286,"• G arbiñe Muguruza.
","('Energy_Management', 0.2513819634914398)","('Product_Design_And_Lifecycle_Management', 0.11139882355928421)","('GHG_Emissions', 0.08277935534715652)","('NON-ESG', 0.2513819634914398)","('NON-ESG', 0.11139882355928421)","('NON-ESG', 0.08277935534715652)"
Line 287,"• Sh elby Rogers.Performance and Preventive Care  With support from Hologic, the WTA now provides player physicals on an annual basis.
","('Access_And_Affordability', 0.5800720453262329)","('Employee_Health_And_Safety', 0.21125482022762299)","('Product_Quality_And_Safety', 0.030513189733028412)","(['Health Outcome Contribution'], 0.5800720453262329)","('NON-ESG', 0.21125482022762299)","('NON-ESG', 0.030513189733028412)"
Line 288,"Those physicals include body composition analysis with Hologic’s Horizon® DXA system, an addition the WTA sought for years.
","('Employee_Health_And_Safety', 0.3911028206348419)","('Employee_Engagement_Inclusion_And_Diversity', 0.22824762761592865)","('Waste_And_Hazardous_Materials_Management', 0.04819987341761589)","('NON-ESG', 0.3911028206348419)","('NON-ESG', 0.22824762761592865)","('NON-ESG', 0.04819987341761589)"
Line 289,"Clockwise from top left: 1.
","('Competitive_Behavior', 0.35494235157966614)","('Employee_Engagement_Inclusion_And_Diversity', 0.09249595552682877)","('Customer_Welfare', 0.047051914036273956)","('NON-ESG', 0.35494235157966614)","('NON-ESG', 0.09249595552682877)","('NON-ESG', 0.047051914036273956)"
Line 290,"Dr. Susan Harvey at “Her Health Advantage” with WTA legend Martina Navratilova and WTA athletes Sloane Stephens and Madison Keys in New  York, New York.
","('Employee_Health_And_Safety', 0.497985303401947)","('Employee_Engagement_Inclusion_And_Diversity', 0.05207451060414314)","('Customer_Welfare', 0.04905015975236893)","('NON-ESG', 0.497985303401947)","('NON-ESG', 0.05207451060414314)","('NON-ESG', 0.04905015975236893)"
Line 291,"2.
","('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 292,"CEO Steve MacMillan, WTA legend Martina Navratilova and WTA President Micky Lawler at NASDAQ headquarters in New York City to kick off Breast Cancer Awareness Month.
","('Employee_Health_And_Safety', 0.3218962550163269)","('Employee_Engagement_Inclusion_And_Diversity', 0.18378973007202148)","('Access_And_Affordability', 0.1343868374824524)","('NON-ESG', 0.3218962550163269)","('NON-ESG', 0.18378973007202148)","('NON-ESG', 0.1343868374824524)"
Line 293,"3.
","('Competitive_Behavior', 0.1465800553560257)","('Customer_Welfare', 0.10041514039039612)","('Product_Design_And_Lifecycle_Management', 0.07025990635156631)","('NON-ESG', 0.1465800553560257)","('NON-ESG', 0.10041514039039612)","('NON-ESG', 0.07025990635156631)"
Line 294,"Béatrice Lemberg (far left), Hologic’s Senior Director of Surgical Marketing for EMEA and Canada, joins other female leaders at Bett1 Open in Berlin, Germany.
","('Employee_Engagement_Inclusion_And_Diversity', 0.34044143557548523)","('Business_Model_Resilience', 0.28612658381462097)","('Director_Removal', 0.058369170874357224)","('NON-ESG', 0.34044143557548523)","('NON-ESG', 0.28612658381462097)","('NON-ESG', 0.058369170874357224)"
Line 295,"4.
","('Competitive_Behavior', 0.1400022953748703)","('GHG_Emissions', 0.0895392969250679)","('Customer_Welfare', 0.0845675989985466)","('NON-ESG', 0.1400022953748703)","('NON-ESG', 0.0895392969250679)","('NON-ESG', 0.0845675989985466)"
Line 296,"WTA tennis pro Shelby Rogers talks with Hologic’s Joan Spoden about the Horizon DXA body composition system.
","('Employee_Engagement_Inclusion_And_Diversity', 0.361142098903656)","('Employee_Health_And_Safety', 0.10041792690753937)","('Customer_Welfare', 0.07951626926660538)","('NON-ESG', 0.361142098903656)","('NON-ESG', 0.10041792690753937)","('NON-ESG', 0.07951626926660538)"
Line 297,"5.
","('Competitive_Behavior', 0.15210691094398499)","('Energy_Management', 0.09276141971349716)","('Customer_Welfare', 0.08200553804636002)","('NON-ESG', 0.15210691094398499)","('NON-ESG', 0.09276141971349716)","('NON-ESG', 0.08200553804636002)"
Line 298,"WTA athlete Ons Jabeur (left) connects with a competitor after their tennis match.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Global Access  Initiative The Global Access Initiative (GAI) — Innovation With a Humanitarian  Purpose — Transforms HIV and Cervical Cancer Screening for   Many Countries The GAI is a partnership with the Clinton Health Access Initiative and MedAccess.
","('Access_And_Affordability', 0.6894389986991882)","('Product_Quality_And_Safety', 0.04227294772863388)","('Employee_Engagement_Inclusion_And_Diversity', 0.04150457680225372)","(['Health Outcome Contribution'], 0.6894389986991882)","('NON-ESG', 0.04227294772863388)","('NON-ESG', 0.04150457680225372)"
Line 299,"It provides access to testing for HIV, HCV, HBV, HPV and COVID-19 using our  Panther® system.
","('Access_And_Affordability', 0.4618435800075531)","('Product_Quality_And_Safety', 0.06628675013780594)","('Customer_Welfare', 0.04906797781586647)","('NON-ESG', 0.4618435800075531)","('NON-ESG', 0.06628675013780594)","('NON-ESG', 0.04906797781586647)"
Line 300,"This testing is delivered with a cost-effective pricing structure and no requirement for capital expenditure.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4441617727279663)","('Competitive_Behavior', 0.2236398458480835)","('Energy_Management', 0.06927048414945602)","('NON-ESG', 0.4441617727279663)","('NON-ESG', 0.2236398458480835)","('NON-ESG', 0.06927048414945602)"
Line 301,"The GAI brings a holistic model of pricing, training and service to a region in dire need of  innovative solutions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16251106560230255)","('Product_Quality_And_Safety', 0.09356919676065445)","('Business_Model_Resilience', 0.09023653715848923)","('NON-ESG', 0.16251106560230255)","('NON-ESG', 0.09356919676065445)","('NON-ESG', 0.09023653715848923)"
Line 302,"Thanks to our ability to adapt and meet market needs, more people  can be helped through advanced diagnostics screening and co-testing for cervical cancer,  greatly improving the quality of life for those throughout Africa.
","('Employee_Health_And_Safety', 0.4297678768634796)","('Access_And_Affordability', 0.13441163301467896)","('Product_Quality_And_Safety', 0.0784396231174469)","('NON-ESG', 0.4297678768634796)","('NON-ESG', 0.13441163301467896)","('NON-ESG', 0.0784396231174469)"
Line 303,"The Global Access Initiative began   with two countries and has grown to a  dozen participants.
","('Access_And_Affordability', 0.774989902973175)","('Product_Quality_And_Safety', 0.026319283992052078)","('Human_Rights_And_Community_Relations', 0.025670256465673447)","(['Health Outcome Contribution'], 0.774989902973175)","('NON-ESG', 0.026319283992052078)","('NON-ESG', 0.025670256465673447)"
Line 304,"To date, it has saved $27 million in direct procurement for governments, donors and public entities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9128367304801941)","('Energy_Management', 0.011958781629800797)","('GHG_Emissions', 0.011447113007307053)","(['Corporate Governance'], 0.9128367304801941)","('NON-ESG', 0.011958781629800797)","('NON-ESG', 0.011447113007307053)"
Line 305,"Hologic’s Global Access Initiative team, shown here at an international AIDS conference, has provided millions of  diagnostic tests across sub-Saharan Africa.Supported :  Botswana, Eswatini,  Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Tanzania, Uganda, Zambia and Zimbabwe Planned Additions:  Cameroon, Cote d’Ivoire and Democratic Republic of Congo Eligible:  Angola, Benin, Burkina Faso, Burundi, Cape Verde, Central African Republic, Comoros, Egypt, Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Rwanda,   Timor-Leste and Togo Timor-Leste2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  21Project Health Equality Helping Provide Greater Awareness and Access for Underserved Women Since our founding in 1985, Hologic has dedicated itself to advancing greater well-being for all women.
","('Access_And_Affordability', 0.49178776144981384)","('Customer_Welfare', 0.05595221742987633)","('Product_Quality_And_Safety', 0.05196923762559891)","('NON-ESG', 0.49178776144981384)","('NON-ESG', 0.05595221742987633)","('NON-ESG', 0.05196923762559891)"
Line 306,"Hologic’s Global Access Initiative team, shown here at an international AIDS conference, has provided millions of  diagnostic tests across sub-Saharan Africa.Supported :  Botswana, Eswatini,  Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Tanzania, Uganda, Zambia and Zimbabwe Planned Additions:  Cameroon, Cote d’Ivoire and Democratic Republic of Congo Eligible:  Angola, Benin, Burkina Faso, Burundi, Cape Verde, Central African Republic, Comoros, Egypt, Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Rwanda,   Timor-Leste and Togo Timor-Leste2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  21Project Health Equality Helping Provide Greater Awareness and Access for Underserved Women Since our founding in 1985, Hologic has dedicated itself to advancing greater well-being for all women.
","('Access_And_Affordability', 0.9170087575912476)","('Human_Rights_And_Community_Relations', 0.014582720585167408)","('Product_Quality_And_Safety', 0.0079228226095438)","(['Health Outcome Contribution'], 0.9170087575912476)","('NON-ESG', 0.014582720585167408)","('NON-ESG', 0.0079228226095438)"
Line 307,"Through Project  Health Equality , Hologic and our partners champion underserved women through greater awareness about the importance  of preventive care, access to care at strategic locations and culturally informed research.
","('Access_And_Affordability', 0.9467278718948364)","('Product_Quality_And_Safety', 0.005013346206396818)","('Critical_Incident_Risk_Management', 0.004975887946784496)","(['Health Outcome Contribution'], 0.9467278718948364)","('NON-ESG', 0.005013346206396818)","('NON-ESG', 0.004975887946784496)"
Line 308,"Systemic racism, bias and a well-documented history of mistrust between people of color and the medical establishment continue to drive disparities in access to healthcare.
","('Business_Ethics', 0.3981899917125702)","('Employee_Engagement_Inclusion_And_Diversity', 0.3727025091648102)","('Labor_Practices', 0.03925483301281929)","('NON-ESG', 0.3981899917125702)","('NON-ESG', 0.3727025091648102)","('NON-ESG', 0.03925483301281929)"
Line 309,"We created Project Health Equality  to fund initiatives that help overcome these disparities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3848778307437897)","('Labor_Practices', 0.08248045295476913)","('Business_Ethics', 0.0679159164428711)","('NON-ESG', 0.3848778307437897)","('NON-ESG', 0.08248045295476913)","('NON-ESG', 0.0679159164428711)"
Line 310,"Some of  Project Health Equality’s 2022 featured highlights include: College of American  Pathologists (CAP) Foundation   “See, Test, Treat” Hologic joined the CAP Foundation in Jackson, Mississippi on August 20, 2022,   for its “See, Test, Treat” day.
","('Customer_Welfare', 0.1865791231393814)","('Competitive_Behavior', 0.16131234169006348)","('Access_And_Affordability', 0.0901944637298584)","('NON-ESG', 0.1865791231393814)","('NON-ESG', 0.16131234169006348)","('NON-ESG', 0.0901944637298584)"
Line 311,"The event provided a wide range of preventive-care services to underserved residents, from screening for cervical and breast cancers   to gynecologic health checks.Promise Fund of Florida Hologic’s financial support helps the Promise Fund of Florida employ 20 patient navigators to guide patients through the care process across a dozen health facilities in Palm Beach County and Broward County, Florida.
","('Access_And_Affordability', 0.9388988018035889)","('Product_Quality_And_Safety', 0.0058582983911037445)","('Critical_Incident_Risk_Management', 0.005073930136859417)","(['Health Outcome Contribution'], 0.9388988018035889)","('NON-ESG', 0.0058582983911037445)","('NON-ESG', 0.005073930136859417)"
Line 312,"These specialists conduct outreach, book appointments, arrange transportation, provide translation services, explain medical procedures and coordinate follow-up care.
","('Access_And_Affordability', 0.4451972544193268)","('Employee_Health_And_Safety', 0.20083120465278625)","('Product_Quality_And_Safety', 0.053618174046278)","('NON-ESG', 0.4451972544193268)","('NON-ESG', 0.20083120465278625)","('NON-ESG', 0.053618174046278)"
Line 313,"National Alliance for Hispanic Health (NAHH) Hologic supports the NAHH program “Mi Hermana, Latina Health Champions,” which has developed a seminar series for community health workers on wellness, partnered with community groups to train health workers, funded 10 university teams’ research on health disparities and provided messaging about how race, ethnicity and gender matter in healthcare.Breast Cancer Support Fund  In Ontario, Canada, Hologic and the Breast Cancer Support Fund (BCSF) joined forces to promote the importance of routine screenings — and to highlight practical resources that help more women access those screenings.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9399451017379761)","('Employee_Health_And_Safety', 0.014708297327160835)","('Human_Rights_And_Community_Relations', 0.004928039386868477)","(['Human Capital Development'], 0.9399451017379761)","('NON-ESG', 0.014708297327160835)","('NON-ESG', 0.004928039386868477)"
Line 314,"National Alliance for Hispanic Health (NAHH) Hologic supports the NAHH program “Mi Hermana, Latina Health Champions,” which has developed a seminar series for community health workers on wellness, partnered with community groups to train health workers, funded 10 university teams’ research on health disparities and provided messaging about how race, ethnicity and gender matter in healthcare.Breast Cancer Support Fund  In Ontario, Canada, Hologic and the Breast Cancer Support Fund (BCSF) joined forces to promote the importance of routine screenings — and to highlight practical resources that help more women access those screenings.
","('Access_And_Affordability', 0.7839375138282776)","('Employee_Engagement_Inclusion_And_Diversity', 0.02878464385867119)","('Human_Rights_And_Community_Relations', 0.02083498425781727)","(['Health Outcome Contribution'], 0.7839375138282776)","('NON-ESG', 0.02878464385867119)","('NON-ESG', 0.02083498425781727)"
Line 315,"These health professionals provided “See,  Test, Treat” services.
","('Access_And_Affordability', 0.2946288287639618)","('Customer_Welfare', 0.13736489415168762)","('Product_Quality_And_Safety', 0.09248095750808716)","('NON-ESG', 0.2946288287639618)","('NON-ESG', 0.13736489415168762)","('NON-ESG', 0.09248095750808716)"
Line 316,"Promise Fund co-founder Nancy Brinker  and First Lady Dr. Jill Biden tour a women’s imaging center.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5293224453926086)","('Access_And_Affordability', 0.10659676045179367)","('Human_Rights_And_Community_Relations', 0.07489356398582458)","(['Human Capital Development'], 0.5293224453926086)","('NON-ESG', 0.10659676045179367)","('NON-ESG', 0.07489356398582458)"
Line 317,"Community health workers during “Mi Hermana” training in the U.S. city of Chicago, Illinois.BCSF takes breast cancer screenings to the community.
","('Employee_Health_And_Safety', 0.5464854836463928)","('Access_And_Affordability', 0.1294831931591034)","('Employee_Engagement_Inclusion_And_Diversity', 0.10825739055871964)","(['Operational Eco-Efficiency'], 0.5464854836463928)","('NON-ESG', 0.1294831931591034)","('NON-ESG', 0.10825739055871964)"
Line 318,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Breast Care for Washington Hologic’s leadership in championing healthcare for underserved women —  raising awareness, increasing access and promoting equitable access while inspiring early screening and disease detection — reached another milestone   on October 24, 2022.
","('Access_And_Affordability', 0.9388043284416199)","('Product_Quality_And_Safety', 0.006364316213876009)","('Human_Rights_And_Community_Relations', 0.005994150415062904)","(['Health Outcome Contribution'], 0.9388043284416199)","('NON-ESG', 0.006364316213876009)","('NON-ESG', 0.005994150415062904)"
Line 319,"Hologic leaders and legendary entertainer Mary J.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3435411751270294)","('Competitive_Behavior', 0.08423006534576416)","('Business_Ethics', 0.06253059208393097)","('NON-ESG', 0.3435411751270294)","('NON-ESG', 0.08423006534576416)","('NON-ESG', 0.06253059208393097)"
Line 320,"Blige, a partner of our   Project Health Equality initiative, came together in Washington, D.C. to elevate  the profile of women’s health.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4481472671031952)","('Labor_Practices', 0.24248558282852173)","('Human_Rights_And_Community_Relations', 0.11389041692018509)","('NON-ESG', 0.4481472671031952)","('NON-ESG', 0.24248558282852173)","('NON-ESG', 0.11389041692018509)"
Line 321,"Blige delivered remarks at The White House   about preventive care for breast and cervical cancers alongside First Lady   Dr. Jill Biden, then witnessed firsthand how Hologic’s collaboration with the nonprofit organization Breast Care for Washington makes a lifesaving   difference for patients.
","('Access_And_Affordability', 0.3083469271659851)","('Employee_Health_And_Safety', 0.27489206194877625)","('Employee_Engagement_Inclusion_And_Diversity', 0.10383760184049606)","('NON-ESG', 0.3083469271659851)","('NON-ESG', 0.27489206194877625)","('NON-ESG', 0.10383760184049606)"
Line 322,"“I’m here today as a Black woman who  is passionate about using my platform  to encourage other women to prioritize  their health — namely, their annual   Well Woman visits, mammograms and  Pap + HPV tests.
","('Employee_Health_And_Safety', 0.6339667439460754)","('Access_And_Affordability', 0.1058589369058609)","('Employee_Engagement_Inclusion_And_Diversity', 0.056668512523174286)","(['Operational Eco-Efficiency'], 0.6339667439460754)","('NON-ESG', 0.1058589369058609)","('NON-ESG', 0.056668512523174286)"
Line 323,"I’ve dedicated a great  deal of time to increasing awareness   of the importance of preventive care —   reminding people that their health is  their wealth and urging them to make   it a priority.” Mary J.
","('Employee_Health_And_Safety', 0.3795474171638489)","('Access_And_Affordability', 0.3559539318084717)","('Human_Rights_And_Community_Relations', 0.038496099412441254)","('NON-ESG', 0.3795474171638489)","('NON-ESG', 0.3559539318084717)","('NON-ESG', 0.038496099412441254)"
Line 324,"Blige Clockwise from top: 1.
","('Competitive_Behavior', 0.3748217523097992)","('Management_Of_Legal_And_Regulatory_Framework', 0.06137741729617119)","('Employee_Engagement_Inclusion_And_Diversity', 0.0573614276945591)","('NON-ESG', 0.3748217523097992)","('NON-ESG', 0.06137741729617119)","('NON-ESG', 0.0573614276945591)"
Line 325,"Mary J.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23909588158130646)","('Business_Ethics', 0.10879714041948318)","('Management_Of_Legal_And_Regulatory_Framework', 0.06003892794251442)","('NON-ESG', 0.23909588158130646)","('NON-ESG', 0.10879714041948318)","('NON-ESG', 0.06003892794251442)"
Line 326,"Blige and First Lady Dr. Jill Biden meet at The White House.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2101915180683136)","('Management_Of_Legal_And_Regulatory_Framework', 0.11641043424606323)","('Director_Removal', 0.08125444501638412)","('NON-ESG', 0.2101915180683136)","('NON-ESG', 0.11641043424606323)","('NON-ESG', 0.08125444501638412)"
Line 327,"2.
","('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 328,"Erik Anderson,  president of Hologic’s Breast and Skeletal Health Solutions Division, meets with Grammy Award-winning  and Academy Award-nominated artist, actress, producer and preventive care advocate Mary J.
","('Employee_Health_And_Safety', 0.4596046209335327)","('Access_And_Affordability', 0.13488757610321045)","('Employee_Engagement_Inclusion_And_Diversity', 0.06230826675891876)","('NON-ESG', 0.4596046209335327)","('NON-ESG', 0.13488757610321045)","('NON-ESG', 0.06230826675891876)"
Line 329,"Blige and   Dr. Regina Hampton, co-founder, medical officer and interim CEO of Breast Care for Washington.
","('Access_And_Affordability', 0.3047025799751282)","('Employee_Engagement_Inclusion_And_Diversity', 0.17937952280044556)","('Employee_Health_And_Safety', 0.15080268681049347)","('NON-ESG', 0.3047025799751282)","('NON-ESG', 0.17937952280044556)","('NON-ESG', 0.15080268681049347)"
Line 330,"3.
","('Competitive_Behavior', 0.1465800553560257)","('Customer_Welfare', 0.10041514039039612)","('Product_Design_And_Lifecycle_Management', 0.07025990635156631)","('NON-ESG', 0.1465800553560257)","('NON-ESG', 0.10041514039039612)","('NON-ESG', 0.07025990635156631)"
Line 331,"Mary J.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23909588158130646)","('Business_Ethics', 0.10879714041948318)","('Management_Of_Legal_And_Regulatory_Framework', 0.06003892794251442)","('NON-ESG', 0.23909588158130646)","('NON-ESG', 0.10879714041948318)","('NON-ESG', 0.06003892794251442)"
Line 332,"Blige speaking at The White House.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women       Our Communities      The Environment     Our People      Good Governance  Helping Underserved Women Worldwide  In addition to Project Health  Equality, Hologic partners with organizations in other ways to deliver care and improve access to underserved women around the world.
","('Access_And_Affordability', 0.9398545622825623)","('Human_Rights_And_Community_Relations', 0.00669552106410265)","('Product_Quality_And_Safety', 0.005874014925211668)","(['Health Outcome Contribution'], 0.9398545622825623)","('NON-ESG', 0.00669552106410265)","('NON-ESG', 0.005874014925211668)"
Line 333,"These partners connect women with culturally competent care through awareness, education, clinical resources and research.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3637653589248657)","('Access_And_Affordability', 0.29202255606651306)","('Human_Rights_And_Community_Relations', 0.15778259932994843)","('NON-ESG', 0.3637653589248657)","('NON-ESG', 0.29202255606651306)","('NON-ESG', 0.15778259932994843)"
Line 334,"Fundeso   Costa Rica Hologic provides grants, food and other  resources to this nonprofit hostel that   offers free lodging, food and basic health services to women across Costa Rica who come to the capital, San Jose, for breast cancer treatment.Kanjanabaramee Foundation   Thailand Hologic’s Genius® 3Dimensions® mammography systems are installed on this foundation’s fleet of buses, which travel the country to provide free mammograms as part of a comprehensive health check-up.
","('Access_And_Affordability', 0.5200197696685791)","('Employee_Health_And_Safety', 0.11840374022722244)","('Product_Quality_And_Safety', 0.06008473038673401)","(['Health Outcome Contribution'], 0.5200197696685791)","('NON-ESG', 0.11840374022722244)","('NON-ESG', 0.06008473038673401)"
Line 335,"Breast Cancer Initiative   East Africa   Rwanda Hologic’s support enables this nonprofit, which started with 27 breast-cancer survivors, to increase outreach activities to low-income communities across East Africa.
","('Access_And_Affordability', 0.3226964473724365)","('Employee_Health_And_Safety', 0.2649587094783783)","('Employee_Engagement_Inclusion_And_Diversity', 0.10289829224348068)","('NON-ESG', 0.3226964473724365)","('NON-ESG', 0.2649587094783783)","('NON-ESG', 0.10289829224348068)"
Line 336,"The organization educates women about optimal breast health, which includes learning about risk factors and gaining access to regular screenings.Mobile Mammography   Taiwan Hologic’s mammography systems are part of a mobile program that visits remote areas of Taiwan to provide easy access to breast health screenings, free of charge.
","('Access_And_Affordability', 0.41824281215667725)","('Employee_Health_And_Safety', 0.21140412986278534)","('Employee_Engagement_Inclusion_And_Diversity', 0.06985749304294586)","('NON-ESG', 0.41824281215667725)","('NON-ESG', 0.21140412986278534)","('NON-ESG', 0.06985749304294586)"
Line 337,"Ewang’an Nadede   Advocacy Initiative   Kenya With a grant from Hologic, this organization is increasing its screening program for breast cancer, cervical cancer and sexually transmitted infections among women in Kajiado County.
","('Employee_Health_And_Safety', 0.5268069505691528)","('Access_And_Affordability', 0.17529511451721191)","('Employee_Engagement_Inclusion_And_Diversity', 0.0527409166097641)","(['Operational Eco-Efficiency'], 0.5268069505691528)","('NON-ESG', 0.17529511451721191)","('NON-ESG', 0.0527409166097641)"
Line 338,"It’s also expanding   education efforts to lower the region’s rate   of teenage pregnancies.Community Clinics   San Diego County (U.S.) Funded with grants from Hologic, these   San Diego County community clinics   provide preventive care for a diverse   range of women: • L a Maestra Family Clinic.
","('Access_And_Affordability', 0.7542454600334167)","('Employee_Health_And_Safety', 0.0404554046690464)","('Employee_Engagement_Inclusion_And_Diversity', 0.028871018439531326)","(['Health Outcome Contribution'], 0.7542454600334167)","('NON-ESG', 0.0404554046690464)","('NON-ESG', 0.028871018439531326)"
Line 339,"• N eighborhood Healthcare.
","('Access_And_Affordability', 0.31572797894477844)","('Customer_Welfare', 0.08227699995040894)","('Supply_Chain_Management', 0.07355883717536926)","('NON-ESG', 0.31572797894477844)","('NON-ESG', 0.08227699995040894)","('NON-ESG', 0.07355883717536926)"
Line 340,"•  V ista Community Clinic.
","('Access_And_Affordability', 0.5265247821807861)","('Human_Rights_And_Community_Relations', 0.06443673372268677)","('Critical_Incident_Risk_Management', 0.051930103451013565)","(['Health Outcome Contribution'], 0.5265247821807861)","('NON-ESG', 0.06443673372268677)","('NON-ESG', 0.051930103451013565)"
Line 341,"• S outhern California Care Community.
","('Access_And_Affordability', 0.7838669419288635)","('Customer_Welfare', 0.018651144579052925)","('Employee_Health_And_Safety', 0.018377449363470078)","(['Health Outcome Contribution'], 0.7838669419288635)","('NON-ESG', 0.018651144579052925)","('NON-ESG', 0.018377449363470078)"
Line 342,"From Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance  2022 Hologic Sustainability Report Our  Communities A global company has a responsibility to help wherever  it can — not only where it conducts   business.
","('Human_Rights_And_Community_Relations', 0.9585701823234558)","('Access_And_Affordability', 0.004472494591027498)","('Ecological_Impacts', 0.003879460971802473)","(['Community Relations'], 0.9585701823234558)","('NON-ESG', 0.004472494591027498)","('NON-ESG', 0.003879460971802473)"
Line 343,"That means serving unique populations   with different needs.
","('Human_Rights_And_Community_Relations', 0.2818526029586792)","('Employee_Engagement_Inclusion_And_Diversity', 0.21022666990756989)","('Access_And_Affordability', 0.10354641079902649)","('NON-ESG', 0.2818526029586792)","('NON-ESG', 0.21022666990756989)","('NON-ESG', 0.10354641079902649)"
Line 344,"Hologic listens to the specific needs of many local audiences to deliver support   that resonates within the community.Strengthening Communities   Through Philanthropy    .
","('Human_Rights_And_Community_Relations', 0.8582937121391296)","('Access_And_Affordability', 0.0374547615647316)","('Employee_Engagement_Inclusion_And_Diversity', 0.009502800181508064)","(['Community Relations'], 0.8582937121391296)","('NON-ESG', 0.0374547615647316)","('NON-ESG', 0.009502800181508064)"
Line 345,"Supporting a Diverse Range  of Causes    .
","('Human_Rights_And_Community_Relations', 0.656360924243927)","('Access_And_Affordability', 0.10252001881599426)","('Management_Of_Legal_And_Regulatory_Framework', 0.03813844174146652)","(['Community Relations'], 0.656360924243927)","('NON-ESG', 0.10252001881599426)","('NON-ESG', 0.03813844174146652)"
Line 346,"26From Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance 2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance  25Strengthening Communities   Through Philanthropy Supporting the communities where our employees live and work is central to our mission.
","('Human_Rights_And_Community_Relations', 0.9560120701789856)","('Access_And_Affordability', 0.004711484536528587)","('Ecological_Impacts', 0.004364370368421078)","(['Community Relations'], 0.9560120701789856)","('NON-ESG', 0.004711484536528587)","('NON-ESG', 0.004364370368421078)"
Line 347,"We are proud of the positive impact our philanthropy is making on   cancer patients, underserved women, innovation-minded students and many others.
","('Access_And_Affordability', 0.9377814531326294)","('Human_Rights_And_Community_Relations', 0.006182490848004818)","('Critical_Incident_Risk_Management', 0.006079515907913446)","(['Health Outcome Contribution'], 0.9377814531326294)","('NON-ESG', 0.006182490848004818)","('NON-ESG', 0.006079515907913446)"
Line 348,"To maximize our impact in ways that align with our business, we concentrate our giving efforts locally, and in three areas: •  W omen’s health and other healthcare fields in which we operate.
","('Access_And_Affordability', 0.25054848194122314)","('Customer_Welfare', 0.09783382713794708)","('Employee_Health_And_Safety', 0.08960690349340439)","('NON-ESG', 0.25054848194122314)","('NON-ESG', 0.09783382713794708)","('NON-ESG', 0.08960690349340439)"
Line 349,"•  S TEM  education, especially for underprivileged students.
","('Access_And_Affordability', 0.918942928314209)","('Product_Quality_And_Safety', 0.008723585866391659)","('Human_Rights_And_Community_Relations', 0.007737381849437952)","(['Health Outcome Contribution'], 0.918942928314209)","('NON-ESG', 0.008723585866391659)","('NON-ESG', 0.007737381849437952)"
Line 350,"• S ocial and racial equality, especially in healthcare.
","('Employee_Engagement_Inclusion_And_Diversity', 0.929598331451416)","('Human_Rights_And_Community_Relations', 0.015541362576186657)","('Employee_Health_And_Safety', 0.0060816495679318905)","(['Human Capital Development'], 0.929598331451416)","('NON-ESG', 0.015541362576186657)","('NON-ESG', 0.0060816495679318905)"
Line 351,"organizations   worldwidereceived philanthropic assistance   from Hologic.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8556089401245117)","('Human_Rights_And_Community_Relations', 0.020542742684483528)","('Access_And_Affordability', 0.01933889277279377)","(['Corporate Governance'], 0.8556089401245117)","('NON-ESG', 0.020542742684483528)","('NON-ESG', 0.01933889277279377)"
Line 352,"We have donated   millions of dollars to these non-profit  organizations, directly and through  Partners in Giving, a program in which  Hologic matches employees’   donations to charitable groups.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5474847555160522)","('Access_And_Affordability', 0.09580770879983902)","('Human_Rights_And_Community_Relations', 0.06481938809156418)","(['Corporate Governance'], 0.5474847555160522)","('NON-ESG', 0.09580770879983902)","('NON-ESG', 0.06481938809156418)"
Line 353,"Ann Arbor, Michigan, U.S. Boston, Massachusetts, U.S.Cartago, Costa RicaCleveland, Ohio, U.S.Dallas, Texas, U.S.Danbury, Connecticut, U.S.Hartford, Connecticut, U.S.Holmes, Pennsylvania, U.S.Indianapolis, Indiana, U.S.Kajiado, KenyaKigali, RwandaLondon, United KingdomLos Angeles, California, U.S.Manchester, United KingdomNeedham, Massachusetts, U.S.Newark, Delaware, U.S.Phoenix, Arizona, U.S.Pocatello, Idaho, U.S.Quebec, CanadaRaleigh, North Carolina, U.S.Rochester Hills, Michigan, U.S.San Diego, California, U.S.San Jose, Costa RicaSan Marcos, California, U.S.Syracuse, New York, U.S.West Palm Beach, Florida, U.S.Wilmington, Delaware, U.S.Worcester, Massachusetts, U.S. Dozens of Communities Supported,  Including:Corporate Philanthropy   Grant Breakdown ● Women’s Health (53%)    ●  STEM (30%)   ●  Other (17%)Women’s  HealthOther STEM2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance  26Supporting a Diverse Range of Causes Ellie Fund® Massachusetts The Ellie Fund provides essential services such as grocery gift  cards, meal deliveries and transportation to treatment sites for breast cancer patients residing or receiving treatment in Massachusetts, regardless of economic circumstances.
","('Competitive_Behavior', 0.10998842865228653)","('Business_Model_Resilience', 0.10838886350393295)","('Management_Of_Legal_And_Regulatory_Framework', 0.10463622212409973)","('NON-ESG', 0.10998842865228653)","('NON-ESG', 0.10838886350393295)","('NON-ESG', 0.10463622212409973)"
Line 354,"Ann Arbor, Michigan, U.S. Boston, Massachusetts, U.S.Cartago, Costa RicaCleveland, Ohio, U.S.Dallas, Texas, U.S.Danbury, Connecticut, U.S.Hartford, Connecticut, U.S.Holmes, Pennsylvania, U.S.Indianapolis, Indiana, U.S.Kajiado, KenyaKigali, RwandaLondon, United KingdomLos Angeles, California, U.S.Manchester, United KingdomNeedham, Massachusetts, U.S.Newark, Delaware, U.S.Phoenix, Arizona, U.S.Pocatello, Idaho, U.S.Quebec, CanadaRaleigh, North Carolina, U.S.Rochester Hills, Michigan, U.S.San Diego, California, U.S.San Jose, Costa RicaSan Marcos, California, U.S.Syracuse, New York, U.S.West Palm Beach, Florida, U.S.Wilmington, Delaware, U.S.Worcester, Massachusetts, U.S. Dozens of Communities Supported,  Including:Corporate Philanthropy   Grant Breakdown ● Women’s Health (53%)    ●  STEM (30%)   ●  Other (17%)Women’s  HealthOther STEM2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance  26Supporting a Diverse Range of Causes Ellie Fund® Massachusetts The Ellie Fund provides essential services such as grocery gift  cards, meal deliveries and transportation to treatment sites for breast cancer patients residing or receiving treatment in Massachusetts, regardless of economic circumstances.
","('Human_Rights_And_Community_Relations', 0.7694544792175293)","('Employee_Engagement_Inclusion_And_Diversity', 0.059255439788103104)","('Access_And_Affordability', 0.02031395584344864)","(['Community Relations'], 0.7694544792175293)","('NON-ESG', 0.059255439788103104)","('NON-ESG', 0.02031395584344864)"
Line 355,"Ann Arbor, Michigan, U.S. Boston, Massachusetts, U.S.Cartago, Costa RicaCleveland, Ohio, U.S.Dallas, Texas, U.S.Danbury, Connecticut, U.S.Hartford, Connecticut, U.S.Holmes, Pennsylvania, U.S.Indianapolis, Indiana, U.S.Kajiado, KenyaKigali, RwandaLondon, United KingdomLos Angeles, California, U.S.Manchester, United KingdomNeedham, Massachusetts, U.S.Newark, Delaware, U.S.Phoenix, Arizona, U.S.Pocatello, Idaho, U.S.Quebec, CanadaRaleigh, North Carolina, U.S.Rochester Hills, Michigan, U.S.San Diego, California, U.S.San Jose, Costa RicaSan Marcos, California, U.S.Syracuse, New York, U.S.West Palm Beach, Florida, U.S.Wilmington, Delaware, U.S.Worcester, Massachusetts, U.S. Dozens of Communities Supported,  Including:Corporate Philanthropy   Grant Breakdown ● Women’s Health (53%)    ●  STEM (30%)   ●  Other (17%)Women’s  HealthOther STEM2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities       The Environment     Our People      Good Governance  26Supporting a Diverse Range of Causes Ellie Fund® Massachusetts The Ellie Fund provides essential services such as grocery gift  cards, meal deliveries and transportation to treatment sites for breast cancer patients residing or receiving treatment in Massachusetts, regardless of economic circumstances.
","('Access_And_Affordability', 0.7926021814346313)","('Product_Quality_And_Safety', 0.030281592160463333)","('Employee_Health_And_Safety', 0.028566159307956696)","(['Health Outcome Contribution'], 0.7926021814346313)","('NON-ESG', 0.030281592160463333)","('NON-ESG', 0.028566159307956696)"
Line 356,"Fundación Ayúdenos Para Ayudar Costa Rica Fundación Ayúdenos Para Ayudar (Museo de los Niños) operates a science, technology, engineering, arts and mathematics (STEAM) learning project through a public-private partnership.
","('Access_And_Affordability', 0.26800432801246643)","('Ecological_Impacts', 0.22616732120513916)","('Management_Of_Legal_And_Regulatory_Framework', 0.0937168151140213)","('NON-ESG', 0.26800432801246643)","('NON-ESG', 0.22616732120513916)","('NON-ESG', 0.0937168151140213)"
Line 357,"This program raises awareness among young people in Costa Rica about their opportunities to pursue STEAM education and careers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.673267126083374)","('Access_And_Affordability', 0.11921869218349457)","('Human_Rights_And_Community_Relations', 0.03299279883503914)","(['Human Capital Development'], 0.673267126083374)","('NON-ESG', 0.11921869218349457)","('NON-ESG', 0.03299279883503914)"
Line 358,"The museum’s STEAM Room is where young people from diverse backgrounds learn together.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9152411818504333)","('Access_And_Affordability', 0.012075348757207394)","('Human_Rights_And_Community_Relations', 0.010576821863651276)","(['Human Capital Development'], 0.9152411818504333)","('NON-ESG', 0.012075348757207394)","('NON-ESG', 0.010576821863651276)"
Line 359,"Room to Read®  International This global literacy program strives to create a world free  from illiteracy and gender inequality, helping more children  in low-income communities develop reading skills while also supporting girls’ efforts to succeed in secondary school.
","('Access_And_Affordability', 0.3236538767814636)","('Employee_Engagement_Inclusion_And_Diversity', 0.3139188289642334)","('Labor_Practices', 0.10610461235046387)","('NON-ESG', 0.3236538767814636)","('NON-ESG', 0.3139188289642334)","('NON-ESG', 0.10610461235046387)"
Line 360,"To date, Room to Read has benefited more than 32 million children across 21 countries.
","('Access_And_Affordability', 0.8691859245300293)","('Energy_Management', 0.012101436033844948)","('Human_Rights_And_Community_Relations', 0.011172452010214329)","(['Health Outcome Contribution'], 0.8691859245300293)","('NON-ESG', 0.012101436033844948)","('NON-ESG', 0.011172452010214329)"
Line 361,"Hologic strives to make a difference in the communities in which we operate.
","('Human_Rights_And_Community_Relations', 0.8347960710525513)","('Employee_Engagement_Inclusion_And_Diversity', 0.02514377050101757)","('Business_Model_Resilience', 0.01719769835472107)","(['Community Relations'], 0.8347960710525513)","('NON-ESG', 0.02514377050101757)","('NON-ESG', 0.01719769835472107)"
Line 362,"As such, we continue to expand  our relationship with OneUnited Bank, a Massachusetts-based institution that provides financial services to  support economic development in urban communities.
","('Human_Rights_And_Community_Relations', 0.42771607637405396)","('Access_And_Affordability', 0.2555077075958252)","('Business_Model_Resilience', 0.04430069774389267)","('NON-ESG', 0.42771607637405396)","('NON-ESG', 0.2555077075958252)","('NON-ESG', 0.04430069774389267)"
Line 363,"OneUnited has recently purchased a building in Roxbury, Massachusetts to build its national headquarters.
","('Business_Model_Resilience', 0.5323901772499084)","('Employee_Engagement_Inclusion_And_Diversity', 0.0712004154920578)","('Product_Design_And_Lifecycle_Management', 0.04482405260205269)","(['Codes of Business Conduct'], 0.5323901772499084)","('NON-ESG', 0.0712004154920578)","('NON-ESG', 0.04482405260205269)"
Line 364,"The bank also sponsors the Mass Black Expo, which provides financial literacy and financial opportunities for  small businesses throughout the state.Banking with a Purpose OneUnited is a leader in providing innovative products and services that increase access to critically needed financial services for underserved communities, including its CashPlease program, which offers short-term small dollar loans to consumers who would ordinarily only have predatory lenders as an option.
","('Access_And_Affordability', 0.9442301988601685)","('Critical_Incident_Risk_Management', 0.005064888391643763)","('Product_Quality_And_Safety', 0.0049524796195328236)","(['Health Outcome Contribution'], 0.9442301988601685)","('NON-ESG', 0.005064888391643763)","('NON-ESG', 0.0049524796195328236)"
Line 365,"In the past few years, the bank has financed nearly $1 billion in loans mostly in U.S. communities such as:  •  S outh Central Los Angeles, California.
","('Systemic_Risk_Management', 0.41815319657325745)","('Management_Of_Legal_And_Regulatory_Framework', 0.2516677677631378)","('Business_Model_Resilience', 0.05005836486816406)","('NON-ESG', 0.41815319657325745)","('NON-ESG', 0.2516677677631378)","('NON-ESG', 0.05005836486816406)"
Line 366,"• C ompton, California.
","('Management_Of_Legal_And_Regulatory_Framework', 0.45379403233528137)","('GHG_Emissions', 0.09475743025541306)","('Competitive_Behavior', 0.07025744020938873)","('NON-ESG', 0.45379403233528137)","('NON-ESG', 0.09475743025541306)","('NON-ESG', 0.07025744020938873)"
Line 367,"•  L iberty City, Florida.
","('Business_Model_Resilience', 0.1005663126707077)","('Management_Of_Legal_And_Regulatory_Framework', 0.0840068906545639)","('Competitive_Behavior', 0.08246014267206192)","('NON-ESG', 0.1005663126707077)","('NON-ESG', 0.0840068906545639)","('NON-ESG', 0.08246014267206192)"
Line 368,"•  R oxbury, Massachusetts.OneUnited Bank® and Hologic: Investing in Urban CommunitiesFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment      Our People      Good Governance  2022 Hologic Sustainability Report The Environment Hologic contributes to the greater good for both  the communities of today and those of future generations.
","('Human_Rights_And_Community_Relations', 0.9377059936523438)","('Access_And_Affordability', 0.006699507590383291)","('Business_Model_Resilience', 0.00533749395981431)","(['Community Relations'], 0.9377059936523438)","('NON-ESG', 0.006699507590383291)","('NON-ESG', 0.00533749395981431)"
Line 369,"While we specialize in healthcare innovation, we recognize that basic human needs affect health issues at a much higher level.
","('Access_And_Affordability', 0.21212232112884521)","('Human_Rights_And_Community_Relations', 0.11377616971731186)","('Employee_Health_And_Safety', 0.10798431932926178)","('NON-ESG', 0.21212232112884521)","('NON-ESG', 0.11377616971731186)","('NON-ESG', 0.10798431932926178)"
Line 370,"At Hologic, growing while being mindful of our environmental impact is key.
","('Business_Model_Resilience', 0.39091771841049194)","('Supply_Chain_Management', 0.09105352312326431)","('Physical_Impacts_Of_Climate_Change', 0.08858973532915115)","('NON-ESG', 0.39091771841049194)","('NON-ESG', 0.09105352312326431)","('NON-ESG', 0.08858973532915115)"
Line 371,"We are working to ensure that our progress is also measured by a diminished carbon footprint.Environmental Goals  .
","('GHG_Emissions', 0.20467473566532135)","('Ecological_Impacts', 0.1826891452074051)","('Physical_Impacts_Of_Climate_Change', 0.14090955257415771)","('NON-ESG', 0.20467473566532135)","('NON-ESG', 0.1826891452074051)","('NON-ESG', 0.14090955257415771)"
Line 372,"Hologic Costa Rica’s   Climate Leadership   .
","('Physical_Impacts_Of_Climate_Change', 0.9174896478652954)","('Business_Model_Resilience', 0.01640193536877632)","('GHG_Emissions', 0.010664910078048706)","(['Climate Change'], 0.9174896478652954)","('NON-ESG', 0.01640193536877632)","('NON-ESG', 0.010664910078048706)"
Line 373,"Environmental Initiatives in  Our Diagnostics Division   .
","('Human_Rights_And_Community_Relations', 0.1182086393237114)","('Management_Of_Legal_And_Regulatory_Framework', 0.10981602221727371)","('Access_And_Affordability', 0.10860225558280945)","('NON-ESG', 0.1182086393237114)","('NON-ESG', 0.10981602221727371)","('NON-ESG', 0.10860225558280945)"
Line 374,"Climate Risks and Opportunities  .
","('Physical_Impacts_Of_Climate_Change', 0.9217859506607056)","('Business_Model_Resilience', 0.014471305534243584)","('GHG_Emissions', 0.011922153644263744)","(['Climate Change'], 0.9217859506607056)","('NON-ESG', 0.014471305534243584)","('NON-ESG', 0.011922153644263744)"
Line 375,"32From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 28Environmental Goals Achieve a 15% reduction in non-hazardous/non-recyclable   waste by 2025*   Hologic is currently operating or launching several initiatives globally in support of our goal to  achieve a 15% reduction in non-hazardous/non-recyclable waste by 2025.
","('Waste_And_Hazardous_Materials_Management', 0.9611808657646179)","('Product_Design_And_Lifecycle_Management', 0.005842097569257021)","('Water_And_Wastewater_Management', 0.003997681196779013)","(['Operational Eco-Efficiency'], 0.9611808657646179)","('NON-ESG', 0.005842097569257021)","('NON-ESG', 0.003997681196779013)"
Line 376,"32From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 28Environmental Goals Achieve a 15% reduction in non-hazardous/non-recyclable   waste by 2025*   Hologic is currently operating or launching several initiatives globally in support of our goal to  achieve a 15% reduction in non-hazardous/non-recyclable waste by 2025.
","('Waste_And_Hazardous_Materials_Management', 0.9837605953216553)","('Water_And_Wastewater_Management', 0.0013997491914778948)","('Data_Security', 0.0011353285517543554)","(['Operational Eco-Efficiency'], 0.9837605953216553)","('NON-ESG', 0.0013997491914778948)","('NON-ESG', 0.0011353285517543554)"
Line 377,"Many of our U.S. sites are utilizing a dedicated single stream methodology for waste usage, ensuring zero hazardous waste is going to landfills.
","('Waste_And_Hazardous_Materials_Management', 0.9849056601524353)","('Data_Security', 0.0012456270633265376)","('Air_Quality', 0.001091200509108603)","(['Operational Eco-Efficiency'], 0.9849056601524353)","('NON-ESG', 0.0012456270633265376)","('NON-ESG', 0.001091200509108603)"
Line 378,"In addition, we are piloting an initiative at our Londonderry, New Hampshire facility to reduce plastic waste via recycling by 25% and are studying the feasibility of rolling this program out at other U.S. locations.
","('Waste_And_Hazardous_Materials_Management', 0.9817461967468262)","('Product_Design_And_Lifecycle_Management', 0.0016664918512105942)","('Water_And_Wastewater_Management', 0.001627342076972127)","(['Operational Eco-Efficiency'], 0.9817461967468262)","('NON-ESG', 0.0016664918512105942)","('NON-ESG', 0.001627342076972127)"
Line 379,"We remain on target in other countries, pursuing zero-waste certification by 2025 at our Costa Rica location while sharing these best practice efforts with our European sites, ensuring all our global enterprise pursues best-in-class sustainability practices.Hologic aims to make business decisions that have a positive impact on the environment and we manage our environmental strategy as an integral  part of our business.
","('Waste_And_Hazardous_Materials_Management', 0.256144642829895)","('Product_Design_And_Lifecycle_Management', 0.12910018861293793)","('Ecological_Impacts', 0.1097085028886795)","('NON-ESG', 0.256144642829895)","('NON-ESG', 0.12910018861293793)","('NON-ESG', 0.1097085028886795)"
Line 380,"In our quest to responsibly limit our carbon footprint, our initiatives focus on expanding the use of renewable energy sources and incorporating more sustainable practices into our operations.
","('Energy_Management', 0.9285237193107605)","('Product_Design_And_Lifecycle_Management', 0.023085499182343483)","('Supply_Chain_Management', 0.006025619339197874)","(['Operational Eco-Efficiency'], 0.9285237193107605)","('NON-ESG', 0.023085499182343483)","('NON-ESG', 0.006025619339197874)"
Line 381,"Contributing to the greater good only matters if we preserve our world for future generations.Given this philosophy, we are pleased to reaffirm our long-term environmental targets† from last year.
","('Human_Rights_And_Community_Relations', 0.31693729758262634)","('Business_Model_Resilience', 0.21779531240463257)","('Ecological_Impacts', 0.07191105931997299)","('NON-ESG', 0.31693729758262634)","('NON-ESG', 0.21779531240463257)","('NON-ESG', 0.07191105931997299)"
Line 382,"Achieve a 30% reduction of Scope 1 & 2 GHG emissions   by 2030*   Although our emissions as a percentage of sales increased modestly in FY22, this was   driven by higher COVID revenue in 2021.
","('GHG_Emissions', 0.9681842923164368)","('Air_Quality', 0.004793746396899223)","('Ecological_Impacts', 0.00285900104790926)","(['Climate Change'], 0.9681842923164368)","('NON-ESG', 0.004793746396899223)","('NON-ESG', 0.00285900104790926)"
Line 383,"Hologic continues to achieve material reductions  in its greenhouse gas (GHG) emissions since 2013, while also growing sales globally.
","('GHG_Emissions', 0.969235360622406)","('Ecological_Impacts', 0.00402337871491909)","('Air_Quality', 0.002747633494436741)","(['Climate Change'], 0.969235360622406)","('NON-ESG', 0.00402337871491909)","('NON-ESG', 0.002747633494436741)"
Line 384,"Relative to our 2020 baseline, emissions as a percentage of revenue have declined approximately 20%.
","('GHG_Emissions', 0.7636523246765137)","('Energy_Management', 0.06244216114282608)","('Air_Quality', 0.05731372535228729)","(['Climate Change'], 0.7636523246765137)","('NON-ESG', 0.06244216114282608)","('NON-ESG', 0.05731372535228729)"
Line 385,"To achieve our future emissions target, we will focus on supply-side initiatives, while also working to incorporate future initiatives that are aligned with the  Science Based Targets Initiative.
","('Supply_Chain_Management', 0.9296150207519531)","('Energy_Management', 0.00825967825949192)","('Product_Design_And_Lifecycle_Management', 0.0073344833217561245)","(['Supply Chain Management'], 0.9296150207519531)","('NON-ESG', 0.00825967825949192)","('NON-ESG', 0.0073344833217561245)"
Line 386,"Hologic Emissions Summary 2013-35,30,00025,00020,000Metric Ton COMetric Ton CO2e / MM $ Sales 15,00010,0005,2013 2014 2015 2016 2017 2018 2019 2020 2021 202214.12.10.6.08.4.0.02.012.3.54.15.26.66.98.49.610.411.631,29,28,27,25,22,289 22,6,982 7,5127 ,42712,11,98312,51219,684 19,49619,Note: Above emissions summary chart breaks out Scope 1 and 2 GHG emissions starting in Hologic’s fiscal 2020, as this is the  base year for the emissions reduction goal.● Metric Ton CO2      ●  Metric Ton CO2 Scope 1      ●  Metric Ton CO2 Scope 2      ●  Metric Ton CO2e / MM $ Sales † Environmental goals are expressed as a percentage of revenue.* Reduction compared to fiscal 2020.From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 291.
","('GHG_Emissions', 0.9607836604118347)","('Air_Quality', 0.009196636267006397)","('Ecological_Impacts', 0.003509066766127944)","(['Climate Change'], 0.9607836604118347)","('NON-ESG', 0.009196636267006397)","('NON-ESG', 0.003509066766127944)"
Line 387,"Hologic Emissions Summary 2013-35,30,00025,00020,000Metric Ton COMetric Ton CO2e / MM $ Sales 15,00010,0005,2013 2014 2015 2016 2017 2018 2019 2020 2021 202214.12.10.6.08.4.0.02.012.3.54.15.26.66.98.49.610.411.631,29,28,27,25,22,289 22,6,982 7,5127 ,42712,11,98312,51219,684 19,49619,Note: Above emissions summary chart breaks out Scope 1 and 2 GHG emissions starting in Hologic’s fiscal 2020, as this is the  base year for the emissions reduction goal.● Metric Ton CO2      ●  Metric Ton CO2 Scope 1      ●  Metric Ton CO2 Scope 2      ●  Metric Ton CO2e / MM $ Sales † Environmental goals are expressed as a percentage of revenue.* Reduction compared to fiscal 2020.From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 291.
","('Human_Rights_And_Community_Relations', 0.5106540322303772)","('GHG_Emissions', 0.10922357439994812)","('Ecological_Impacts', 0.08668206632137299)","(['Community Relations'], 0.5106540322303772)","('NON-ESG', 0.10922357439994812)","('NON-ESG', 0.08668206632137299)"
Line 388,"Solid waste is defined as the quantity of waste disposed as landfill, recycled, composted, and other (ex.
","('Waste_And_Hazardous_Materials_Management', 0.9842848777770996)","('Water_And_Wastewater_Management', 0.0014260828029364347)","('Data_Security', 0.0012759773526340723)","(['Operational Eco-Efficiency'], 0.9842848777770996)","('NON-ESG', 0.0014260828029364347)","('NON-ESG', 0.0012759773526340723)"
Line 389,"reclaimed for energy).
","('Energy_Management', 0.9355598092079163)","('Management_Of_Legal_And_Regulatory_Framework', 0.010725058615207672)","('Air_Quality', 0.0074834395200014114)","(['Operational Eco-Efficiency'], 0.9355598092079163)","('NON-ESG', 0.010725058615207672)","('NON-ESG', 0.0074834395200014114)"
Line 390,"2.
","('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 391,"Regulated waste is defined as the quantity of waste disposed as hazardous waste, biohazardous or medical waste,  universal waste, or radioactive waste.
","('Waste_And_Hazardous_Materials_Management', 0.9836486577987671)","('Data_Security', 0.001388011733070016)","('Water_And_Wastewater_Management', 0.001163942739367485)","(['Operational Eco-Efficiency'], 0.9836486577987671)","('NON-ESG', 0.001388011733070016)","('NON-ESG', 0.001163942739367485)"
Line 392,"Note: Historical data may differ from Hologic’s 2021 Sustainability Report.
","('Business_Model_Resilience', 0.28244489431381226)","('Supply_Chain_Management', 0.09565170854330063)","('Systemic_Risk_Management', 0.07820431888103485)","('NON-ESG', 0.28244489431381226)","('NON-ESG', 0.09565170854330063)","('NON-ESG', 0.07820431888103485)"
Line 393,"In fiscal 2022, Hologic conducted an internal audit of environmental data and this year’s report has adjusted figures as necessary based on this exercise.Achieve a 40% reliance on self-generated renewable energy   at owned sites by 2030    Hologic has procured proposals to construct several types of solar generation systems at   our owned sites.
","('Energy_Management', 0.9783130884170532)","('Management_Of_Legal_And_Regulatory_Framework', 0.00336993089877069)","('Product_Design_And_Lifecycle_Management', 0.0017755543813109398)","(['Operational Eco-Efficiency'], 0.9783130884170532)","('NON-ESG', 0.00336993089877069)","('NON-ESG', 0.0017755543813109398)"
Line 394,"In addition to the energy generation component, we forecast a reduction  in our annual energy consumption by continuing to invest in more energy efficient properties, plants and equipment over the next eight years.
","('Energy_Management', 0.981084406375885)","('Air_Quality', 0.0016477780882269144)","('Critical_Incident_Risk_Management', 0.001622397219762206)","(['Operational Eco-Efficiency'], 0.981084406375885)","('NON-ESG', 0.0016477780882269144)","('NON-ESG', 0.001622397219762206)"
Line 395,"We will continue to explore other renewable energy opportunities, giving us confidence that the necessary means are in place to achieve  the 2030 goal.
","('Energy_Management', 0.9676870107650757)","('Management_Of_Legal_And_Regulatory_Framework', 0.007128127850592136)","('Product_Design_And_Lifecycle_Management', 0.002399960532784462)","(['Operational Eco-Efficiency'], 0.9676870107650757)","('NON-ESG', 0.007128127850592136)","('NON-ESG', 0.002399960532784462)"
Line 396,"Convert to 50% renewable electricity by 2030 and 75%   renewable electricity by 2035   Hologic will procure energy in accordance with the renewable energy targets stipulated in our long-term goals.
","('Energy_Management', 0.9742234945297241)","('Management_Of_Legal_And_Regulatory_Framework', 0.005805177614092827)","('GHG_Emissions', 0.0017038194928318262)","(['Operational Eco-Efficiency'], 0.9742234945297241)","('NON-ESG', 0.005805177614092827)","('NON-ESG', 0.0017038194928318262)"
Line 397,"In addition, Hologic partnered with an external consultant, Sustainability Roundtable and their Net Zero Consortium for Buyers.
","('Management_Of_Legal_And_Regulatory_Framework', 0.28265994787216187)","('Business_Model_Resilience', 0.12875154614448547)","('GHG_Emissions', 0.0904119610786438)","('NON-ESG', 0.28265994787216187)","('NON-ESG', 0.12875154614448547)","('NON-ESG', 0.0904119610786438)"
Line 398,"This consortium is a confidential  buyers’ community and a leading transaction platform committed to facilitating renewable  energy transactions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5542246699333191)","('Competitive_Behavior', 0.2046080380678177)","('Energy_Management', 0.03318985924124718)","(['Corporate Governance'], 0.5542246699333191)","('NON-ESG', 0.2046080380678177)","('NON-ESG', 0.03318985924124718)"
Line 399,"Environmental Goals and Data Presented Are for   Operational Sites The Environmental Goals, Emissions Summary Chart and Environmental Data table presented above are for Operational Sites.
","('GHG_Emissions', 0.34449806809425354)","('Energy_Management', 0.126434788107872)","('Management_Of_Legal_And_Regulatory_Framework', 0.11375635117292404)","('NON-ESG', 0.34449806809425354)","('NON-ESG', 0.126434788107872)","('NON-ESG', 0.11375635117292404)"
Line 400,"Operational Sites are defined as those where Hologic has  a manufacturing presence and/or the ability to manage utilities.
","('Energy_Management', 0.23308777809143066)","('Business_Model_Resilience', 0.17172986268997192)","('Supply_Chain_Management', 0.0778234526515007)","('NON-ESG', 0.23308777809143066)","('NON-ESG', 0.17172986268997192)","('NON-ESG', 0.0778234526515007)"
Line 401,"Data includes estimates  where necessary.2019 2020 2021 Electricity (MwH) 50,470 47,542 47,841 48,Solid Waste1 (MT) 1,511 1,351 1,925 1,Regulated Waste2 (MT) 242 245 255 Water Consumption (Cubic Meters) 136,741 137,856 156,169 156,596Further, we are again pleased to disclose data pertaining to electricity, waste and water consumption — metrics that we track internally to measure our environmental footprint.
","('Waste_And_Hazardous_Materials_Management', 0.6387269496917725)","('Water_And_Wastewater_Management', 0.1629006415605545)","('Energy_Management', 0.07335677742958069)","(['Operational Eco-Efficiency'], 0.6387269496917725)","('NON-ESG', 0.1629006415605545)","('NON-ESG', 0.07335677742958069)"
Line 402,"The table below is based on data available and quantifiable through the end of our fiscal  2022.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5430474877357483)","('Systemic_Risk_Management', 0.07410197705030441)","('Business_Model_Resilience', 0.06234096735715866)","(['Corporate Governance'], 0.5430474877357483)","('NON-ESG', 0.07410197705030441)","('NON-ESG', 0.06234096735715866)"
Line 403,"This data has been normalized to exclude sites that have been closed.Environmental Goals (continued)From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 30Hologic Costa Rica Climate Initiatives Solar Panels and Battery System Our Costa Rica team continues to lead Hologic forward with innovative solutions to help address  climate change.
","('Physical_Impacts_Of_Climate_Change', 0.9373916387557983)","('Business_Model_Resilience', 0.012328303419053555)","('GHG_Emissions', 0.008205977268517017)","(['Climate Change'], 0.9373916387557983)","('NON-ESG', 0.012328303419053555)","('NON-ESG', 0.008205977268517017)"
Line 404,"Since 2018, when the Costa Rica site initially installed solar panels, the team has harnessed the power of solar electricity to deliver environmental benefits and financial savings.
","('Energy_Management', 0.9615228176116943)","('Product_Design_And_Lifecycle_Management', 0.0063951276242733)","('Management_Of_Legal_And_Regulatory_Framework', 0.0060981400310993195)","(['Operational Eco-Efficiency'], 0.9615228176116943)","('NON-ESG', 0.0063951276242733)","('NON-ESG', 0.0060981400310993195)"
Line 405,"For example, these solar panels have reduced the facility’s carbon footprint by 25.5 tons of CO 2  per year; saving the equivalent of 8,000 trees, while also saving approximately $71,000 per year in electricity costs.
","('Energy_Management', 0.9600658416748047)","('Management_Of_Legal_And_Regulatory_Framework', 0.0074114869348704815)","('GHG_Emissions', 0.0058193514123559)","(['Operational Eco-Efficiency'], 0.9600658416748047)","('NON-ESG', 0.0074114869348704815)","('NON-ESG', 0.0058193514123559)"
Line 406,"Given these outstanding benefits, in June of 2022, the Costa Rica team chose to expand its   solar panel capacity.
","('Energy_Management', 0.9322701692581177)","('Management_Of_Legal_And_Regulatory_Framework', 0.012204582802951336)","('GHG_Emissions', 0.006491613108664751)","(['Operational Eco-Efficiency'], 0.9322701692581177)","('NON-ESG', 0.012204582802951336)","('NON-ESG', 0.006491613108664751)"
Line 407,"We expect the new panels to generate 220 kilowatts (kW) of power at maximum capacity, which represents more than 456 thousand kilowatt-hours (kWh) of power  per year, equivalent to the average annual consumption of more than 200 houses in Costa Rica.
","('Energy_Management', 0.9765729308128357)","('Management_Of_Legal_And_Regulatory_Framework', 0.002644832246005535)","('Water_And_Wastewater_Management', 0.001977215986698866)","(['Operational Eco-Efficiency'], 0.9765729308128357)","('NON-ESG', 0.002644832246005535)","('NON-ESG', 0.001977215986698866)"
Line 408,"The facility is also implementing a battery system to save and store electricity generated   during periods of low energy usage, with a goal to offset activity during periods of peak  energy consumption.
","('Energy_Management', 0.9808035492897034)","('Management_Of_Legal_And_Regulatory_Framework', 0.0020159713458269835)","('Critical_Incident_Risk_Management', 0.0016118382336571813)","(['Operational Eco-Efficiency'], 0.9808035492897034)","('NON-ESG', 0.0020159713458269835)","('NON-ESG', 0.0016118382336571813)"
Line 409,"These initiatives are part our global strategy to achieve a 40% reliance on self-generated   renewable energy at Hologic-owned sites by 2030.
","('Energy_Management', 0.9793146848678589)","('Management_Of_Legal_And_Regulatory_Framework', 0.002746648620814085)","('Product_Design_And_Lifecycle_Management', 0.0016753451200202107)","(['Operational Eco-Efficiency'], 0.9793146848678589)","('NON-ESG', 0.002746648620814085)","('NON-ESG', 0.0016753451200202107)"
Line 410,"Water Reclamation                                                                                    In addition to expanding solar panel capacity and introducing an efficient battery system, Hologic Costa Rica’s tremendous commitment to sustainability is evidenced by the team’s water reclamation project.
","('Water_And_Wastewater_Management', 0.9734357595443726)","('Energy_Management', 0.002523702336475253)","('Waste_And_Hazardous_Materials_Management', 0.002298979554325342)","(['Operational Eco-Efficiency'], 0.9734357595443726)","('NON-ESG', 0.002523702336475253)","('NON-ESG', 0.002298979554325342)"
Line 411,"The team has created an ingenious solution to collect rainwater from the facility’s roof and reuse it in the site’s air conditioning system.
","('Water_And_Wastewater_Management', 0.5993221402168274)","('Air_Quality', 0.2485647350549698)","('Waste_And_Hazardous_Materials_Management', 0.03213265538215637)","(['Operational Eco-Efficiency'], 0.5993221402168274)","('NON-ESG', 0.2485647350549698)","('NON-ESG', 0.03213265538215637)"
Line 412,"With the project, Hologic Costa Rica expects to save more than 1,500 cubic meters of rainwater annually and save $4,700.00 USD in annual air conditioning costs.
","('Water_And_Wastewater_Management', 0.35013866424560547)","('Energy_Management', 0.2755415439605713)","('Air_Quality', 0.2316892147064209)","('NON-ESG', 0.35013866424560547)","('NON-ESG', 0.2755415439605713)","('NON-ESG', 0.2316892147064209)"
Line 413,"Zero Waste By fiscal 2025, Hologic Costa Rica aims to achieve “zero waste” status as defined by the Zero Waste International Alliance.
","('Waste_And_Hazardous_Materials_Management', 0.9840312004089355)","('Water_And_Wastewater_Management', 0.001220050035044551)","('Data_Security', 0.0012009859783574939)","(['Operational Eco-Efficiency'], 0.9840312004089355)","('NON-ESG', 0.001220050035044551)","('NON-ESG', 0.0012009859783574939)"
Line 414,"This initiative has led to multiple process improvements since the program was launched, including more sustainable packaging, more efficient material segregation and site meal preparation that is more data oriented.
","('Product_Design_And_Lifecycle_Management', 0.9195973873138428)","('Customer_Welfare', 0.012283195741474628)","('Selling_Practices_And_Product_Labeling', 0.012036814354360104)","(['Product Stewardship'], 0.9195973873138428)","('NON-ESG', 0.012283195741474628)","('NON-ESG', 0.012036814354360104)"
Line 415,"This is yet another example  of the site’s exceptional commitment to environmental stewardship.
","('Ecological_Impacts', 0.9426496624946594)","('Human_Rights_And_Community_Relations', 0.008032984100282192)","('GHG_Emissions', 0.006682114209979773)","(['Natural Capital'], 0.9426496624946594)","('NON-ESG', 0.008032984100282192)","('NON-ESG', 0.006682114209979773)"
Line 416,"Hologic’s Costa Rica site achieved  zero waste to landfill as part of a  pilot project.
","('Waste_And_Hazardous_Materials_Management', 0.9827331304550171)","('Air_Quality', 0.0016196449287235737)","('Water_And_Wastewater_Management', 0.001556753064505756)","(['Operational Eco-Efficiency'], 0.9827331304550171)","('NON-ESG', 0.0016196449287235737)","('NON-ESG', 0.001556753064505756)"
Line 417,"In addition, the team’s efforts support  Hologic’s strategy to contribute to the United Nations Sustainable Development Goals (SDGs 7 and 12).
","('Human_Rights_And_Community_Relations', 0.3801879584789276)","('Business_Model_Resilience', 0.15165531635284424)","('Ecological_Impacts', 0.1141163632273674)","('NON-ESG', 0.3801879584789276)","('NON-ESG', 0.15165531635284424)","('NON-ESG', 0.1141163632273674)"
Line 418,"Hologic Costa Rica celebrates its commitment to solar power.From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 31Environmental Initiatives in Our Diagnostics Division A Hologic operations team member inspects an order prior to shipment.Packaging Hologic’s Diagnostics team set out to reduce paper use associated with our collection devices.
","('Human_Rights_And_Community_Relations', 0.36972224712371826)","('Product_Design_And_Lifecycle_Management', 0.15815074741840363)","('Access_And_Affordability', 0.060594264417886734)","('NON-ESG', 0.36972224712371826)","('NON-ESG', 0.15815074741840363)","('NON-ESG', 0.060594264417886734)"
Line 419,"Our collection devices originally included package insert pamphlets that clinicians could give to patients, detailing how to use the product.
","('Product_Design_And_Lifecycle_Management', 0.7727887034416199)","('Selling_Practices_And_Product_Labeling', 0.07232963293790817)","('Waste_And_Hazardous_Materials_Management', 0.02986523136496544)","(['Product Stewardship'], 0.7727887034416199)","('NON-ESG', 0.07232963293790817)","('NON-ESG', 0.02986523136496544)"
Line 420,"Hologic’s Operations and Commercial teams collaborated to remove these inserts from our Aptima® Multitest Swab Specimen Collection Kits and replaced them with a simple business card instructing clinicians where to find, and if needed, print the package insert information online.
","('Selling_Practices_And_Product_Labeling', 0.24566428363323212)","('Customer_Welfare', 0.12533941864967346)","('Waste_And_Hazardous_Materials_Management', 0.12120217084884644)","('NON-ESG', 0.24566428363323212)","('NON-ESG', 0.12533941864967346)","('NON-ESG', 0.12120217084884644)"
Line 421,"Approximately 500kg of paper is saved each year  as a result of this initiative.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3836449086666107)","('Energy_Management', 0.2027752697467804)","('Access_And_Affordability', 0.08536820858716965)","('NON-ESG', 0.3836449086666107)","('NON-ESG', 0.2027752697467804)","('NON-ESG', 0.08536820858716965)"
Line 422,"Shipping To reduce carbon emissions and the use of environmentally unfriendly plastics, our Diagnostics team redesigned several insulated shipping containers.
","('Waste_And_Hazardous_Materials_Management', 0.6185778379440308)","('Product_Design_And_Lifecycle_Management', 0.201856330037117)","('Energy_Management', 0.02197951450943947)","(['Operational Eco-Efficiency'], 0.6185778379440308)","('NON-ESG', 0.201856330037117)","('NON-ESG', 0.02197951450943947)"
Line 423,"These temperature-controlled containers were reconfigured with better insulation while also using less material.
","('Energy_Management', 0.8736433982849121)","('Product_Design_And_Lifecycle_Management', 0.03324064984917641)","('Waste_And_Hazardous_Materials_Management', 0.010680200532078743)","(['Operational Eco-Efficiency'], 0.8736433982849121)","('NON-ESG', 0.03324064984917641)","('NON-ESG', 0.010680200532078743)"
Line 424,"Manufacturing Our Diagnostics team designed, developed and implemented new “flow wrapper” production lines for our collection devices.
","('Product_Design_And_Lifecycle_Management', 0.3715464472770691)","('Waste_And_Hazardous_Materials_Management', 0.09392040222883224)","('Supply_Chain_Management', 0.08458507806062698)","('NON-ESG', 0.3715464472770691)","('NON-ESG', 0.09392040222883224)","('NON-ESG', 0.08458507806062698)"
Line 425,"These lines use significantly less material and energy to manufacture each collection device.
","('Energy_Management', 0.8901516199111938)","('Product_Design_And_Lifecycle_Management', 0.03446021303534508)","('Waste_And_Hazardous_Materials_Management', 0.009848772548139095)","(['Operational Eco-Efficiency'], 0.8901516199111938)","('NON-ESG', 0.03446021303534508)","('NON-ESG', 0.009848772548139095)"
Line 426,"The new production process successfully helps to reduce the carbon footprint of our facilities in San Diego, California, and Manchester, United Kingdom.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  32An employee at Hologic’s Newark, Delaware facility processes a critical component of our mammography systems.Climate Risks and Opportunities Opportunities We view climate-related opportunities through the lens of TCFD and specifically   look to areas in resource efficiency, energy sources as well as products and services  to add value.
","('Physical_Impacts_Of_Climate_Change', 0.9365902543067932)","('Business_Model_Resilience', 0.011065944097936153)","('GHG_Emissions', 0.01046853605657816)","(['Climate Change'], 0.9365902543067932)","('NON-ESG', 0.011065944097936153)","('NON-ESG', 0.01046853605657816)"
Line 427,"The new production process successfully helps to reduce the carbon footprint of our facilities in San Diego, California, and Manchester, United Kingdom.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  32An employee at Hologic’s Newark, Delaware facility processes a critical component of our mammography systems.Climate Risks and Opportunities Opportunities We view climate-related opportunities through the lens of TCFD and specifically   look to areas in resource efficiency, energy sources as well as products and services  to add value.
","('Energy_Management', 0.626068651676178)","('Product_Design_And_Lifecycle_Management', 0.293105810880661)","('Product_Quality_And_Safety', 0.006268452852964401)","(['Operational Eco-Efficiency'], 0.626068651676178)","('NON-ESG', 0.293105810880661)","('NON-ESG', 0.006268452852964401)"
Line 428,"As with the current renovation of our facility in Newark, New Jersey,  we continue to look to improve efficiency and sustainability across our production,  distribution and facilities management.
","('Product_Design_And_Lifecycle_Management', 0.470447838306427)","('Energy_Management', 0.38562116026878357)","('Supply_Chain_Management', 0.027308044955134392)","('NON-ESG', 0.470447838306427)","('NON-ESG', 0.38562116026878357)","('NON-ESG', 0.027308044955134392)"
Line 429,"We pursue opportunities to lower our emissions with alternative energy sources like   adding capacity to our solar panel system in Costa Rica.
","('Energy_Management', 0.9501035809516907)","('Air_Quality', 0.010870487429201603)","('GHG_Emissions', 0.008195138536393642)","(['Operational Eco-Efficiency'], 0.9501035809516907)","('NON-ESG', 0.010870487429201603)","('NON-ESG', 0.008195138536393642)"
Line 430,"Finally, we continue to look at ways to lower our carbon footprint with our products   and services.Risks Hologic is committed to identifying and mitigating climate-related risks in accordance with  the Task Force on Climate-Related Financial Disclosures (TCFD).
","('Physical_Impacts_Of_Climate_Change', 0.9180251359939575)","('Business_Model_Resilience', 0.018131198361516)","('GHG_Emissions', 0.008332929573953152)","(['Climate Change'], 0.9180251359939575)","('NON-ESG', 0.018131198361516)","('NON-ESG', 0.008332929573953152)"
Line 431,"We assess and manage these risks through our enterprise risk management process (ERM), which identifies environmental, social and governance issues having the potential to cause disruption to our business.
","('Human_Rights_And_Community_Relations', 0.22313345968723297)","('Systemic_Risk_Management', 0.1730290800333023)","('Physical_Impacts_Of_Climate_Change', 0.1669560819864273)","('NON-ESG', 0.22313345968723297)","('NON-ESG', 0.1730290800333023)","('NON-ESG', 0.1669560819864273)"
Line 432,"Our  ERM process guides our Board of Directors and management team in mitigating the most  critical climate-related risks facing Hologic.
","('Physical_Impacts_Of_Climate_Change', 0.938940703868866)","('Business_Model_Resilience', 0.015550828538835049)","('Supply_Chain_Management', 0.0059356652200222015)","(['Climate Change'], 0.938940703868866)","('NON-ESG', 0.015550828538835049)","('NON-ESG', 0.0059356652200222015)"
Line 433,"2022 Hologic Sustainability Report 33From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Our People Passion for the work Hologic does every day can be  felt in our offices around the globe.
","('Human_Rights_And_Community_Relations', 0.924527108669281)","('Business_Model_Resilience', 0.008031300269067287)","('Ecological_Impacts', 0.007594105787575245)","(['Community Relations'], 0.924527108669281)","('NON-ESG', 0.008031300269067287)","('NON-ESG', 0.007594105787575245)"
Line 434,"We were founded by passionate innovators and thousands of equally inspired employees continue to carry that flame to this day.
","('Business_Model_Resilience', 0.38320818543434143)","('Employee_Engagement_Inclusion_And_Diversity', 0.1272655427455902)","('Product_Design_And_Lifecycle_Management', 0.10168225318193436)","('NON-ESG', 0.38320818543434143)","('NON-ESG', 0.1272655427455902)","('NON-ESG', 0.10168225318193436)"
Line 435,"After all, who hasn’t been impacted by the health crisis of a loved one?
","('Critical_Incident_Risk_Management', 0.274730384349823)","('Employee_Health_And_Safety', 0.2689789831638336)","('Access_And_Affordability', 0.24005308747291565)","('NON-ESG', 0.274730384349823)","('NON-ESG', 0.2689789831638336)","('NON-ESG', 0.24005308747291565)"
Line 436,"The motivation that so many Hologic employees bring to work every day creates   a culture of progress and change.People First  .
","('Human_Rights_And_Community_Relations', 0.5119807124137878)","('Employee_Engagement_Inclusion_And_Diversity', 0.17053954303264618)","('Employee_Health_And_Safety', 0.05917292460799217)","(['Community Relations'], 0.5119807124137878)","('NON-ESG', 0.17053954303264618)","('NON-ESG', 0.05917292460799217)"
Line 437,"K ey Indicators of Engagement    .
","('Business_Model_Resilience', 0.3522787392139435)","('Human_Rights_And_Community_Relations', 0.25551119446754456)","('Systemic_Risk_Management', 0.055223915725946426)","('NON-ESG', 0.3522787392139435)","('NON-ESG', 0.25551119446754456)","('NON-ESG', 0.055223915725946426)"
Line 438,"Our People Drive Our Passion    .
","('Employee_Engagement_Inclusion_And_Diversity', 0.22082504630088806)","('Human_Rights_And_Community_Relations', 0.21965357661247253)","('Business_Model_Resilience', 0.13893316686153412)","('NON-ESG', 0.22082504630088806)","('NON-ESG', 0.21965357661247253)","('NON-ESG', 0.13893316686153412)"
Line 439,"Our People Deliver Our Promise    .
","('Human_Rights_And_Community_Relations', 0.3213636577129364)","('Employee_Engagement_Inclusion_And_Diversity', 0.18537552654743195)","('Business_Model_Resilience', 0.10227951407432556)","('NON-ESG', 0.3213636577129364)","('NON-ESG', 0.18537552654743195)","('NON-ESG', 0.10227951407432556)"
Line 440,"Raising the Bar: Championing   World-Class Managers    .
","('Competitive_Behavior', 0.5526652336120605)","('Business_Ethics', 0.07190944254398346)","('Systemic_Risk_Management', 0.04167407751083374)","(['Business Ethics'], 0.5526652336120605)","('NON-ESG', 0.07190944254398346)","('NON-ESG', 0.04167407751083374)"
Line 441,"Employee Workforce Composition    .
","('Employee_Engagement_Inclusion_And_Diversity', 0.9320091605186462)","('Labor_Practices', 0.014642306603491306)","('Employee_Health_And_Safety', 0.006965104956179857)","(['Human Capital Development'], 0.9320091605186462)","('NON-ESG', 0.014642306603491306)","('NON-ESG', 0.006965104956179857)"
Line 442,"39From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  2022 Hologic Sustainability Report2022 Hologic Sustainability Report 34From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  People First World-Class Employee Engagement  Engagement on the Rise It isn’t enough to garner high scores in a single year.
","('Human_Rights_And_Community_Relations', 0.9178939461708069)","('Ecological_Impacts', 0.008910883218050003)","('Business_Model_Resilience', 0.007867472246289253)","(['Community Relations'], 0.9178939461708069)","('NON-ESG', 0.008910883218050003)","('NON-ESG', 0.007867472246289253)"
Line 443,"Our track record is a result of our concerted,  consistent effort to dynamically engage our employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.49578067660331726)","('Labor_Practices', 0.1657141149044037)","('Employee_Health_And_Safety', 0.04970359429717064)","('NON-ESG', 0.49578067660331726)","('NON-ESG', 0.1657141149044037)","('NON-ESG', 0.04970359429717064)"
Line 444,"While scores from 2021 were already impressive, we managed to continue making progress in key areas in 2022.More Engaged than Ever The percentage of Hologic employees who say they are engaged with the company  continues to increase.
","('Labor_Practices', 0.3671325147151947)","('Employee_Engagement_Inclusion_And_Diversity', 0.10918998718261719)","('Employee_Health_And_Safety', 0.09855430573225021)","('NON-ESG', 0.3671325147151947)","('NON-ESG', 0.10918998718261719)","('NON-ESG', 0.09855430573225021)"
Line 445,"The grand mean is scored out of 5 and represents overall feedback to all questions asked by Gallup   in its employee survey.“Our world-class engagement results in 2022 reflect the commitment of each employee to Hologic’s  purpose, our colleagues and our global work culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5762974619865417)","('Human_Rights_And_Community_Relations', 0.12073951214551926)","('Employee_Health_And_Safety', 0.07100125402212143)","(['Human Capital Development'], 0.5762974619865417)","('NON-ESG', 0.12073951214551926)","('NON-ESG', 0.07100125402212143)"
Line 446,"We know that when employees are engaged, they perform at their best.
","('Employee_Engagement_Inclusion_And_Diversity', 0.30041542649269104)","('Employee_Health_And_Safety', 0.13763894140720367)","('Labor_Practices', 0.0860881432890892)","('NON-ESG', 0.30041542649269104)","('NON-ESG', 0.13763894140720367)","('NON-ESG', 0.0860881432890892)"
Line 447,"Hologic’s teams across three  dozen countries are driven by our singular purpose – to enable healthier lives everywhere, every day.
","('Employee_Health_And_Safety', 0.8083891272544861)","('Critical_Incident_Risk_Management', 0.028042377904057503)","('Access_And_Affordability', 0.025168076157569885)","(['Operational Eco-Efficiency'], 0.8083891272544861)","('NON-ESG', 0.028042377904057503)","('NON-ESG', 0.025168076157569885)"
Line 448,"We maintained a high level of engagement amid a great deal of uncertainty and complexity, including  record-setting business growth, organizational changes, a stream of acquisitions and supply chain  challenges driven by COVID.
","('Supply_Chain_Management', 0.9502000212669373)","('Systemic_Risk_Management', 0.006524951197206974)","('Business_Model_Resilience', 0.005780345294624567)","(['Supply Chain Management'], 0.9502000212669373)","('NON-ESG', 0.006524951197206974)","('NON-ESG', 0.005780345294624567)"
Line 449,"Our progress results from people truly committing and working together.” Lisa Hellmann   Senior Vice President, Global Human Resources and Corporate Communications Hologic Engagement Ratio Hologic Grand Mean 2022 2021 2020 2019 2018 2017 201623% 24% 25%33%40% 42% 43%52%73% 72% 70%60%52% 50% 49%37% 201511%4% 4% 5% 7% 8% 8% 8% 202296th 202196th 202096th 201983rd 201873rd 201764th 201663rd 36th 4.444.+0.04+0.024.4.4.094.064.3.● Engaged      ●  Not Engaged      ●  Actively Disengaged2022 Hologic Sustainability Report 35From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Key Indicators of Engagement Gallup’s global employee engagement survey asks 12 questions.
","('Business_Model_Resilience', 0.4987628161907196)","('Product_Design_And_Lifecycle_Management', 0.056090619415044785)","('Systemic_Risk_Management', 0.04695749282836914)","('NON-ESG', 0.4987628161907196)","('NON-ESG', 0.056090619415044785)","('NON-ESG', 0.04695749282836914)"
Line 450,"Our progress results from people truly committing and working together.” Lisa Hellmann   Senior Vice President, Global Human Resources and Corporate Communications Hologic Engagement Ratio Hologic Grand Mean 2022 2021 2020 2019 2018 2017 201623% 24% 25%33%40% 42% 43%52%73% 72% 70%60%52% 50% 49%37% 201511%4% 4% 5% 7% 8% 8% 8% 202296th 202196th 202096th 201983rd 201873rd 201764th 201663rd 36th 4.444.+0.04+0.024.4.4.094.064.3.● Engaged      ●  Not Engaged      ●  Actively Disengaged2022 Hologic Sustainability Report 35From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Key Indicators of Engagement Gallup’s global employee engagement survey asks 12 questions.
","('Human_Rights_And_Community_Relations', 0.9582267999649048)","('Access_And_Affordability', 0.0041934046894311905)","('Management_Of_Legal_And_Regulatory_Framework', 0.0035025966353714466)","(['Community Relations'], 0.9582267999649048)","('NON-ESG', 0.0041934046894311905)","('NON-ESG', 0.0035025966353714466)"
Line 451,"We proudly share these highlights from Hologic employees’ responses.
","('Employee_Health_And_Safety', 0.2719135284423828)","('Employee_Engagement_Inclusion_And_Diversity', 0.17182111740112305)","('Business_Ethics', 0.08236038684844971)","('NON-ESG', 0.2719135284423828)","('NON-ESG', 0.17182111740112305)","('NON-ESG', 0.08236038684844971)"
Line 452,"96thI have opportunities to learn and grow Percentile 89thI do what I do best every day Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile92ndI have a best friend at work Percentile 97thMy opinions   matter Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile84thAccess to materials and  supplies to do my job Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile87thI know what is   expected of me Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile97thMy opinions   matter Percentile 96thI have opportunities to learn and grow Percentile92ndI have a best friend at work Percentile 89thI do what I do best every day Percentile84thAccess to materials and  supplies to do my job Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile87thI know what is   expected of me Percentile2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Our People Drive   Our Passion “ “ “What I am empowered to do each day, which is to  set the strategic direction of our sales organization, has an impact not only on the livelihood of all employees, but also on every patient who receives a diagnosis based on the surety of our products.
","('Employee_Engagement_Inclusion_And_Diversity', 0.27604836225509644)","('Employee_Health_And_Safety', 0.10629583895206451)","('Business_Model_Resilience', 0.08959618955850601)","('NON-ESG', 0.27604836225509644)","('NON-ESG', 0.10629583895206451)","('NON-ESG', 0.08959618955850601)"
Line 453,"96thI have opportunities to learn and grow Percentile 89thI do what I do best every day Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile92ndI have a best friend at work Percentile 97thMy opinions   matter Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile84thAccess to materials and  supplies to do my job Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile87thI know what is   expected of me Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile97thMy opinions   matter Percentile 96thI have opportunities to learn and grow Percentile92ndI have a best friend at work Percentile 89thI do what I do best every day Percentile84thAccess to materials and  supplies to do my job Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile87thI know what is   expected of me Percentile2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Our People Drive   Our Passion “ “ “What I am empowered to do each day, which is to  set the strategic direction of our sales organization, has an impact not only on the livelihood of all employees, but also on every patient who receives a diagnosis based on the surety of our products.
","('Employee_Health_And_Safety', 0.28701624274253845)","('Product_Design_And_Lifecycle_Management', 0.11689414083957672)","('Supply_Chain_Management', 0.11142439395189285)","('NON-ESG', 0.28701624274253845)","('NON-ESG', 0.11689414083957672)","('NON-ESG', 0.11142439395189285)"
Line 454,"96thI have opportunities to learn and grow Percentile 89thI do what I do best every day Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile92ndI have a best friend at work Percentile 97thMy opinions   matter Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile84thAccess to materials and  supplies to do my job Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile87thI know what is   expected of me Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile97thMy opinions   matter Percentile 96thI have opportunities to learn and grow Percentile92ndI have a best friend at work Percentile 89thI do what I do best every day Percentile84thAccess to materials and  supplies to do my job Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile87thI know what is   expected of me Percentile2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Our People Drive   Our Passion “ “ “What I am empowered to do each day, which is to  set the strategic direction of our sales organization, has an impact not only on the livelihood of all employees, but also on every patient who receives a diagnosis based on the surety of our products.
","('Human_Rights_And_Community_Relations', 0.9004719257354736)","('Business_Model_Resilience', 0.01219716016203165)","('Employee_Engagement_Inclusion_And_Diversity', 0.009199961088597775)","(['Community Relations'], 0.9004719257354736)","('NON-ESG', 0.01219716016203165)","('NON-ESG', 0.009199961088597775)"
Line 455,"96thI have opportunities to learn and grow Percentile 89thI do what I do best every day Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile92ndI have a best friend at work Percentile 97thMy opinions   matter Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile84thAccess to materials and  supplies to do my job Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile87thI know what is   expected of me Percentile98thMy supervisor   cares Percentile 98thI believe in the  Hologic mission Percentile98thI’ve received recognition  in the last 7 days Percentile 98thMy coworkers are  committed to quality Percentile97thMy opinions   matter Percentile 96thI have opportunities to learn and grow Percentile92ndI have a best friend at work Percentile 89thI do what I do best every day Percentile84thAccess to materials and  supplies to do my job Percentile95thI have made progress in the last six months Percentile 94thHologic encourages  development Percentile87thI know what is   expected of me Percentile2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  Our People Drive   Our Passion “ “ “What I am empowered to do each day, which is to  set the strategic direction of our sales organization, has an impact not only on the livelihood of all employees, but also on every patient who receives a diagnosis based on the surety of our products.
","('Product_Design_And_Lifecycle_Management', 0.6535592675209045)","('Selling_Practices_And_Product_Labeling', 0.15205921232700348)","('Product_Quality_And_Safety', 0.04801721125841141)","(['Product Stewardship'], 0.6535592675209045)","('NON-ESG', 0.15205921232700348)","('NON-ESG', 0.04801721125841141)"
Line 456,"When there is tight alignment between mission and performance, and the right talent in every role, engagement thrives.” Keith Reed   Vice President of Sales, Breast and Skeletal Health Solutions   Orlando, Florida I joined the organization at a time when everything in the world was uncertain due to COVID.
","('Employee_Engagement_Inclusion_And_Diversity', 0.47500601410865784)","('Business_Model_Resilience', 0.11954554170370102)","('Access_And_Affordability', 0.05222358554601669)","('NON-ESG', 0.47500601410865784)","('NON-ESG', 0.11954554170370102)","('NON-ESG', 0.05222358554601669)"
Line 457,"Hologic embraced these challenges and ensured that we felt secure in an unnerving situation.
","('Human_Rights_And_Community_Relations', 0.25283315777778625)","('Systemic_Risk_Management', 0.1378057450056076)","('Employee_Health_And_Safety', 0.07971352338790894)","('NON-ESG', 0.25283315777778625)","('NON-ESG', 0.1378057450056076)","('NON-ESG', 0.07971352338790894)"
Line 458,"We did not lose those interpersonal connections that tie our purpose to our people.
","('Customer_Privacy', 0.21681170165538788)","('Human_Rights_And_Community_Relations', 0.19294829666614532)","('Employee_Engagement_Inclusion_And_Diversity', 0.16331665217876434)","('NON-ESG', 0.21681170165538788)","('NON-ESG', 0.19294829666614532)","('NON-ESG', 0.16331665217876434)"
Line 459,"I found myself connecting more and cultivating my leadership skills, which created an excellent sense of belonging for me.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7541744709014893)","('Business_Model_Resilience', 0.03280271962285042)","('Employee_Health_And_Safety', 0.023675790056586266)","(['Human Capital Development'], 0.7541744709014893)","('NON-ESG', 0.03280271962285042)","('NON-ESG', 0.023675790056586266)"
Line 460,"I am certain that my purpose to enable healthier lives is aligned to my daily responsibilities in the organization and that growth is inevitable.”My goal in life is to leave the world a better place for having had me in it.
","('Employee_Health_And_Safety', 0.4475358724594116)","('Access_And_Affordability', 0.20315483212471008)","('Human_Rights_And_Community_Relations', 0.03958253189921379)","('NON-ESG', 0.4475358724594116)","('NON-ESG', 0.20315483212471008)","('NON-ESG', 0.03958253189921379)"
Line 461,"As a nurse, I was able to do that through direct patient care – one patient at a time.
","('Access_And_Affordability', 0.7860836386680603)","('Employee_Health_And_Safety', 0.03262300416827202)","('Critical_Incident_Risk_Management', 0.02419126220047474)","(['Health Outcome Contribution'], 0.7860836386680603)","('NON-ESG', 0.03262300416827202)","('NON-ESG', 0.02419126220047474)"
Line 462,"As someone who has worked in the medical technology industry, I’ve been able to help develop world-class treatment and diagnostic technologies that impact far more people.
","('Product_Design_And_Lifecycle_Management', 0.1829189956188202)","('Access_And_Affordability', 0.14802922308444977)","('Energy_Management', 0.1170131266117096)","('NON-ESG', 0.1829189956188202)","('NON-ESG', 0.14802922308444977)","('NON-ESG', 0.1170131266117096)"
Line 463,"Moving to Hologic was a no-brainer.
","('Business_Model_Resilience', 0.13425157964229584)","('Systemic_Risk_Management', 0.12469277530908585)","('Employee_Engagement_Inclusion_And_Diversity', 0.11171374469995499)","('NON-ESG', 0.13425157964229584)","('NON-ESG', 0.12469277530908585)","('NON-ESG', 0.11171374469995499)"
Line 464,"You’re working with amazing technology that helps to diagnose earlier, bring treatment sooner and help women in particular get back to healthy lives and their families a lot faster.” Dikeledi Khoza   Applications and Support Lead   Global Access Initiative   Johannesburg, South AfricaTanja Brycker   Vice President of International Strategic Development for Surgical, Breast and  Skeletal Health   Field, United KingdomHologic has been a great champion for the well-being of  its people and the communities where it does business.
","('Access_And_Affordability', 0.4427938759326935)","('Employee_Health_And_Safety', 0.22931991517543793)","('Human_Rights_And_Community_Relations', 0.12439806014299393)","('NON-ESG', 0.4427938759326935)","('NON-ESG', 0.22931991517543793)","('NON-ESG', 0.12439806014299393)"
Line 465,"You’re working with amazing technology that helps to diagnose earlier, bring treatment sooner and help women in particular get back to healthy lives and their families a lot faster.” Dikeledi Khoza   Applications and Support Lead   Global Access Initiative   Johannesburg, South AfricaTanja Brycker   Vice President of International Strategic Development for Surgical, Breast and  Skeletal Health   Field, United KingdomHologic has been a great champion for the well-being of  its people and the communities where it does business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17444409430027008)","('Competitive_Behavior', 0.1702694445848465)","('Business_Ethics', 0.12372849136590958)","('NON-ESG', 0.17444409430027008)","('NON-ESG', 0.1702694445848465)","('NON-ESG', 0.12372849136590958)"
Line 466,"This is a game-changer for both the employee and the company — a two-way, win-win approach.
","('Competitive_Behavior', 0.662605881690979)","('Systemic_Risk_Management', 0.053969234228134155)","('Employee_Engagement_Inclusion_And_Diversity', 0.034999780356884)","(['Business Ethics'], 0.662605881690979)","('NON-ESG', 0.053969234228134155)","('NON-ESG', 0.034999780356884)"
Line 467,"What could be more engaging than working for a company that genuinely cares about people?
","('Employee_Engagement_Inclusion_And_Diversity', 0.17957113683223724)","('Business_Model_Resilience', 0.12579084932804108)","('Human_Rights_And_Community_Relations', 0.09531709551811218)","('NON-ESG', 0.17957113683223724)","('NON-ESG', 0.12579084932804108)","('NON-ESG', 0.09531709551811218)"
Line 468,"Hologic means pride and hope.” Elidieth Gonzalez   Director, Human Resources   El Coyol, Costa RicaI love being surrounded by people I can trust, lean on  and who inspire me every day.
","('Human_Rights_And_Community_Relations', 0.2631089687347412)","('Employee_Engagement_Inclusion_And_Diversity', 0.23641160130500793)","('Business_Model_Resilience', 0.08467742800712585)","('NON-ESG', 0.2631089687347412)","('NON-ESG', 0.23641160130500793)","('NON-ESG', 0.08467742800712585)"
Line 469,"These close relationships lead to exciting moments of ideating, collaborating and problem-solving together.
","('Business_Ethics', 0.1854022741317749)","('Access_And_Affordability', 0.16347475349903107)","('Human_Rights_And_Community_Relations', 0.1634412556886673)","('NON-ESG', 0.1854022741317749)","('NON-ESG', 0.16347475349903107)","('NON-ESG', 0.1634412556886673)"
Line 470,"There is a mutual respect for each other’s perspectives and a yearning to accomplish our goals.
","('Human_Rights_And_Community_Relations', 0.5144330859184265)","('Employee_Engagement_Inclusion_And_Diversity', 0.06364843994379044)","('Customer_Privacy', 0.055432677268981934)","(['Community Relations'], 0.5144330859184265)","('NON-ESG', 0.06364843994379044)","('NON-ESG', 0.055432677268981934)"
Line 471,"Our collaborative outcome is so much greater than what I could ever dream of accomplishing alone.
","('Competitive_Behavior', 0.2580646872520447)","('Business_Model_Resilience', 0.1219601109623909)","('Management_Of_Legal_And_Regulatory_Framework', 0.08476942032575607)","('NON-ESG', 0.2580646872520447)","('NON-ESG', 0.1219601109623909)","('NON-ESG', 0.08476942032575607)"
Line 472,"” Mark Olsem   Senior Director, Brand and Healthcare Provider Marketing   Ann Arbor, Michigan “ “2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  37From Our CEO      Our Purpose      Championing  Women      Our Communities      The Environ - ment     Our People       Good Governance  I still remember when I was first diagnosed  with HSIL (cellular abnormalities) during a cervical cancer screening.
","('Human_Rights_And_Community_Relations', 0.52006995677948)","('Access_And_Affordability', 0.11726066470146179)","('Employee_Engagement_Inclusion_And_Diversity', 0.110417939722538)","(['Community Relations'], 0.52006995677948)","('NON-ESG', 0.11726066470146179)","('NON-ESG', 0.110417939722538)"
Line 473,"” Mark Olsem   Senior Director, Brand and Healthcare Provider Marketing   Ann Arbor, Michigan “ “2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  37From Our CEO      Our Purpose      Championing  Women      Our Communities      The Environ - ment     Our People       Good Governance  I still remember when I was first diagnosed  with HSIL (cellular abnormalities) during a cervical cancer screening.
","('Data_Security', 0.09912233054637909)","('Product_Design_And_Lifecycle_Management', 0.08460928499698639)","('Business_Model_Resilience', 0.06294303387403488)","('NON-ESG', 0.09912233054637909)","('NON-ESG', 0.08460928499698639)","('NON-ESG', 0.06294303387403488)"
Line 474,"When I told my colleagues, they were very supportive and ensured that I was not under too much stress, helping me in every possible way.
","('Employee_Health_And_Safety', 0.40369728207588196)","('Human_Rights_And_Community_Relations', 0.19614632427692413)","('Access_And_Affordability', 0.08310092240571976)","('NON-ESG', 0.40369728207588196)","('NON-ESG', 0.19614632427692413)","('NON-ESG', 0.08310092240571976)"
Line 475,"I am very thankful for the support system I have at Hologic.” Sandy Li  Senior Applications Specialist   Hong Kong, China Our People Deliver   Our Promise Elizabeth Coll   Marketing Manager, Surgical Solutions Division   Mississauga, CanadaI feel so proud when I speak to healthcare  professionals and patients about how Hologic has positively impacted them.
","('Access_And_Affordability', 0.23012711107730865)","('Business_Model_Resilience', 0.16515859961509705)","('Employee_Engagement_Inclusion_And_Diversity', 0.08505567908287048)","('NON-ESG', 0.23012711107730865)","('NON-ESG', 0.16515859961509705)","('NON-ESG', 0.08505567908287048)"
Line 476,"There is so much work that still needs to be done to ensure that women and girls in all corners of the world are cared for and protected.
","('Access_And_Affordability', 0.7866142988204956)","('Employee_Health_And_Safety', 0.06191374734044075)","('Human_Rights_And_Community_Relations', 0.029986046254634857)","(['Health Outcome Contribution'], 0.7866142988204956)","('NON-ESG', 0.06191374734044075)","('NON-ESG', 0.029986046254634857)"
Line 477,"Not only does Hologic support this through proven technology solutions, but also through initiatives like the Hologic Global Women’s Health Index and Project Health Equality.
","('Human_Rights_And_Community_Relations', 0.3132086992263794)","('Employee_Engagement_Inclusion_And_Diversity', 0.1858433336019516)","('Employee_Health_And_Safety', 0.09723443537950516)","('NON-ESG', 0.3132086992263794)","('NON-ESG', 0.1858433336019516)","('NON-ESG', 0.09723443537950516)"
Line 478,"I know that every day, my role at Hologic plays a part in advancing women’s health   here in Canada and beyond.”The main driving force at Mobidiag was the feeling of belonging to a team, almost a family, and this bond was one of the strongest drivers of engagement.
","('Employee_Health_And_Safety', 0.27162814140319824)","('Access_And_Affordability', 0.23226065933704376)","('Human_Rights_And_Community_Relations', 0.17406658828258514)","('NON-ESG', 0.27162814140319824)","('NON-ESG', 0.23226065933704376)","('NON-ESG', 0.17406658828258514)"
Line 479,"Extending the family circle into a larger company like Hologic requires a purpose.
","('Competitive_Behavior', 0.13644467294216156)","('Employee_Engagement_Inclusion_And_Diversity', 0.13506391644477844)","('Business_Model_Resilience', 0.12665563821792603)","('NON-ESG', 0.13644467294216156)","('NON-ESG', 0.13506391644477844)","('NON-ESG', 0.12665563821792603)"
Line 480,"Joining Hologic during COVID has really demonstrated the strong sense of purpose and dedication throughout the organization.
","('Human_Rights_And_Community_Relations', 0.2575622797012329)","('Employee_Engagement_Inclusion_And_Diversity', 0.11519363522529602)","('Employee_Health_And_Safety', 0.09556115418672562)","('NON-ESG', 0.2575622797012329)","('NON-ESG', 0.11519363522529602)","('NON-ESG', 0.09556115418672562)"
Line 481,"Knowing that our solutions help our customers better serve patients is something that drives our motivation a step further.” Yann Marcy   Vice President of R&D at Mobidiag   Acquired by Hologic in 2021 Paris, France I feel and see that who we are gets into everything.
","('Product_Design_And_Lifecycle_Management', 0.2851658761501312)","('Customer_Welfare', 0.15546642243862152)","('Business_Model_Resilience', 0.15400075912475586)","('NON-ESG', 0.2851658761501312)","('NON-ESG', 0.15546642243862152)","('NON-ESG', 0.15400075912475586)"
Line 482,"What we do.
","('Human_Rights_And_Community_Relations', 0.25359994173049927)","('Business_Ethics', 0.09983953088521957)","('Management_Of_Legal_And_Regulatory_Framework', 0.07744337618350983)","('NON-ESG', 0.25359994173049927)","('NON-ESG', 0.09983953088521957)","('NON-ESG', 0.07744337618350983)"
Line 483,"How we show up.
","('Competitive_Behavior', 0.22181421518325806)","('Business_Model_Resilience', 0.10143837332725525)","('Ecological_Impacts', 0.08205651491880417)","('NON-ESG', 0.22181421518325806)","('NON-ESG', 0.10143837332725525)","('NON-ESG', 0.08205651491880417)"
Line 484,"Engagement for me is the unspoken beauty when we truly connect.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1307661235332489)","('Customer_Privacy', 0.11950252950191498)","('Human_Rights_And_Community_Relations', 0.11477183550596237)","('NON-ESG', 0.1307661235332489)","('NON-ESG', 0.11950252950191498)","('NON-ESG', 0.11477183550596237)"
Line 485,"It’s not always easy, but it is an everyday choice we all must make.
","('Human_Rights_And_Community_Relations', 0.12860330939292908)","('Employee_Engagement_Inclusion_And_Diversity', 0.12387695908546448)","('Director_Removal', 0.09854558110237122)","('NON-ESG', 0.12860330939292908)","('NON-ESG', 0.12387695908546448)","('NON-ESG', 0.09854558110237122)"
Line 486,"I own my engagement and I work every day to expand its reach.” Veerle Dierynck   Senior Director, EMEAC Customer   and Technical Service   Brussels, Belgium “ “ ““2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  38At Hologic, we have a relentless focus on talent, performance, the experiences of  our employees and developing the best teams and leaders.
","('Human_Rights_And_Community_Relations', 0.5160431265830994)","('Employee_Engagement_Inclusion_And_Diversity', 0.28320494294166565)","('Business_Model_Resilience', 0.021619044244289398)","(['Community Relations'], 0.5160431265830994)","('NON-ESG', 0.28320494294166565)","('NON-ESG', 0.021619044244289398)"
Line 487,"With that in mind,   we created an internal resource for our employees known as the “Bar.”   What is the Bar?
","('Labor_Practices', 0.27387285232543945)","('Employee_Engagement_Inclusion_And_Diversity', 0.17857083678245544)","('Employee_Health_And_Safety', 0.08095743507146835)","('NON-ESG', 0.27387285232543945)","('NON-ESG', 0.17857083678245544)","('NON-ESG', 0.08095743507146835)"
Line 488,"A resource for self-guided content, centered around good management  practices.
","('Business_Ethics', 0.3297117054462433)","('Human_Rights_And_Community_Relations', 0.1322413831949234)","('Business_Model_Resilience', 0.05946454405784607)","('NON-ESG', 0.3297117054462433)","('NON-ESG', 0.1322413831949234)","('NON-ESG', 0.05946454405784607)"
Line 489,"The Bar acts as a digital resource for current or aspiring people managers to build  managerial muscles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5536285042762756)","('Business_Model_Resilience', 0.10403221845626831)","('Product_Design_And_Lifecycle_Management', 0.045535001903772354)","(['Human Capital Development'], 0.5536285042762756)","('NON-ESG', 0.10403221845626831)","('NON-ESG', 0.045535001903772354)"
Line 490,"Its content is continually evolving and responding to the most pressing challenges managers are facing.We help our managers by clearly setting expectations and  providing guidance on those topics that matter most to developing talent and delivering strong performance.
","('Employee_Engagement_Inclusion_And_Diversity', 0.669783353805542)","('Business_Model_Resilience', 0.06234138458967209)","('Human_Rights_And_Community_Relations', 0.04215913265943527)","(['Human Capital Development'], 0.669783353805542)","('NON-ESG', 0.06234138458967209)","('NON-ESG', 0.04215913265943527)"
Line 491,"We   aim to raise the bar on leadership practices at Hologic.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4931972026824951)","('Business_Ethics', 0.0954638347029686)","('Director_Removal', 0.04874997213482857)","('NON-ESG', 0.4931972026824951)","('NON-ESG', 0.0954638347029686)","('NON-ESG', 0.04874997213482857)"
Line 492,"Leadership Expectations • D riving personal impact on individuals and team culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7899125814437866)","('Human_Rights_And_Community_Relations', 0.039256833493709564)","('Employee_Health_And_Safety', 0.02075251005589962)","(['Human Capital Development'], 0.7899125814437866)","('NON-ESG', 0.039256833493709564)","('NON-ESG', 0.02075251005589962)"
Line 493,"• E ffectively managing individual and team performance.
","('Human_Rights_And_Community_Relations', 0.1988651603460312)","('Employee_Health_And_Safety', 0.14931872487068176)","('Employee_Engagement_Inclusion_And_Diversity', 0.11948718130588531)","('NON-ESG', 0.1988651603460312)","('NON-ESG', 0.14931872487068176)","('NON-ESG', 0.11948718130588531)"
Line 494,"• L earning how to inspire others.
","('Human_Rights_And_Community_Relations', 0.24042293429374695)","('Access_And_Affordability', 0.17173179984092712)","('Employee_Engagement_Inclusion_And_Diversity', 0.1157192587852478)","('NON-ESG', 0.24042293429374695)","('NON-ESG', 0.17173179984092712)","('NON-ESG', 0.1157192587852478)"
Line 495,"• C ultivating and motivating talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3125323951244354)","('Employee_Health_And_Safety', 0.13997595012187958)","('Human_Rights_And_Community_Relations', 0.06016099825501442)","('NON-ESG', 0.3125323951244354)","('NON-ESG', 0.13997595012187958)","('NON-ESG', 0.06016099825501442)"
Line 496,"• D efining, interpreting and sharing a vision.
","('Management_Of_Legal_And_Regulatory_Framework', 0.1990952342748642)","('Employee_Engagement_Inclusion_And_Diversity', 0.12062317132949829)","('Access_And_Affordability', 0.11504340171813965)","('NON-ESG', 0.1990952342748642)","('NON-ESG', 0.12062317132949829)","('NON-ESG', 0.11504340171813965)"
Line 497,"Employee Engagement • U nderstanding why engagement is so important.•  M easuring engagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7047325372695923)","('Employee_Health_And_Safety', 0.08823756873607635)","('Human_Rights_And_Community_Relations', 0.03277421370148659)","(['Human Capital Development'], 0.7047325372695923)","('NON-ESG', 0.08823756873607635)","('NON-ESG', 0.03277421370148659)"
Line 498,"•  H ologic’s process and the role of managers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23292413353919983)","('Director_Removal', 0.10777948051691055)","('Business_Model_Resilience', 0.10777593404054642)","('NON-ESG', 0.23292413353919983)","('NON-ESG', 0.10777948051691055)","('NON-ESG', 0.10777593404054642)"
Line 499,"Development • E ffectively using one-to-ones to build trust and drive performance.•  S etting clear expectations.
","('Competitive_Behavior', 0.42479750514030457)","('Business_Ethics', 0.14144256711006165)","('Business_Model_Resilience', 0.0860435888171196)","('NON-ESG', 0.42479750514030457)","('NON-ESG', 0.14144256711006165)","('NON-ESG', 0.0860435888171196)"
Line 500,"• L earning how to trigger development and ensure it “sticks.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4718700647354126)","('Access_And_Affordability', 0.10497304052114487)","('Ecological_Impacts', 0.07422096282243729)","('NON-ESG', 0.4718700647354126)","('NON-ESG', 0.10497304052114487)","('NON-ESG', 0.07422096282243729)"
Line 501,"” • D iscovering how to make difficult conversations productive.
","('Competitive_Behavior', 0.15341289341449738)","('Business_Ethics', 0.09489563852548599)","('Employee_Engagement_Inclusion_And_Diversity', 0.09029974043369293)","('NON-ESG', 0.15341289341449738)","('NON-ESG', 0.09489563852548599)","('NON-ESG', 0.09029974043369293)"
Line 502,"• C reating high-performing teams.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23190228641033173)","('Competitive_Behavior', 0.13771528005599976)","('Systemic_Risk_Management', 0.08972698450088501)","('NON-ESG', 0.23190228641033173)","('NON-ESG', 0.13771528005599976)","('NON-ESG', 0.08972698450088501)"
Line 503,"Onboarding • D esigning an impactful pre-joining experience.•  C reating first touchpoints once a new employee is onboard.
","('Employee_Engagement_Inclusion_And_Diversity', 0.507765531539917)","('Product_Design_And_Lifecycle_Management', 0.09173843264579773)","('Business_Model_Resilience', 0.07122819125652313)","(['Human Capital Development'], 0.507765531539917)","('NON-ESG', 0.09173843264579773)","('NON-ESG', 0.07122819125652313)"
Line 504,"Manager Processes • I ncentivizing and rewarding performance.•  S etting goals.
","('Business_Model_Resilience', 0.4838518500328064)","('Competitive_Behavior', 0.06064451113343239)","('Systemic_Risk_Management', 0.05183300003409386)","('NON-ESG', 0.4838518500328064)","('NON-ESG', 0.06064451113343239)","('NON-ESG', 0.05183300003409386)"
Line 505,"• A ssessing strengths.
","('Competitive_Behavior', 0.3403129577636719)","('Business_Model_Resilience', 0.17427483201026917)","('Systemic_Risk_Management', 0.17213796079158783)","('NON-ESG', 0.3403129577636719)","('NON-ESG', 0.17427483201026917)","('NON-ESG', 0.17213796079158783)"
Line 506,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9621993899345398)","('Business_Model_Resilience', 0.0032884986139833927)","('Labor_Practices', 0.0030306309927254915)","(['Human Capital Development'], 0.9621993899345398)","('NON-ESG', 0.0032884986139833927)","('NON-ESG', 0.0030306309927254915)"
Line 507,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8679366111755371)","('Labor_Practices', 0.043088965117931366)","('Employee_Health_And_Safety', 0.011286974884569645)","(['Human Capital Development'], 0.8679366111755371)","('NON-ESG', 0.043088965117931366)","('NON-ESG', 0.011286974884569645)"
Line 508,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9757400751113892)","('Customer_Privacy', 0.0017421490047127008)","('Human_Rights_And_Community_Relations', 0.0017270335229113698)","(['Human Capital Development'], 0.9757400751113892)","('NON-ESG', 0.0017421490047127008)","('NON-ESG', 0.0017270335229113698)"
Line 509,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9716812968254089)","('Employee_Health_And_Safety', 0.0021180682815611362)","('Customer_Privacy', 0.0020548461470752954)","(['Human Capital Development'], 0.9716812968254089)","('NON-ESG', 0.0021180682815611362)","('NON-ESG', 0.0020548461470752954)"
Line 510,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9754453897476196)","('Human_Rights_And_Community_Relations', 0.0017780637135729194)","('Employee_Health_And_Safety', 0.001700517488643527)","(['Human Capital Development'], 0.9754453897476196)","('NON-ESG', 0.0017780637135729194)","('NON-ESG', 0.001700517488643527)"
Line 511,"Raising the Bar:   Championing World-Class Managers2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  39Women at All Levels (Global) 2022 Age Diversity Global U.S. Gen Z (1996 - 2012) 12% 7% Gen Y/Millennials (1977 - 1995) 63% 50% Gen X (1965 - 1976) 20% 26% Baby Boomers (1946 - 1964) 4% 17% Other 1% 0%Employee Workforce Composition Workforce Data 2022 General Employee Data Global U.S. Full-Time Employees 6,883 4,Part-Time Employees 61 Total Full- and Part-Time Employees 6,944 4,New Hires 1,274 Total Employee Turnover 1,250 2022 Global Employees Women Men Individual Contributor 45% 55% Manager 45% 55% Director and VPs 37% 63% Global Leadership Team 33% 67% Total Company 45% 55%Progression of Workforce (Women and Multicultural) Over Time   40% 35% 30% 25% 20%29%30%31%33%33% 29% FY19 FY20 FY21 FY50% 45% 40% 35% 30% FY19 FY20 FY21 FY2243%45% 42% 42% Note: No birthday data for 29 International employees - included in “Other” category.Note: Gender data is not available for 103 employees.Multicultural (U.S. Only)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  402022 United States Workforce Composition Ethnicity Women Men Individual Contributor   (3,227 Employees)                                                                        White 27% 38% Minority Race and Ethnicity 15% 20% Gender Total 42% 58% Managers    (490 Employees)White 37% 40% Minority Race and Ethnicity 10% 13% Gender Total 47% 53% Director and VPs   (310 Employees)                                                                                   White 31% 50% Minority Race and Ethnicity 8% 11% Gender Total 39% 61% GLT*   (12 Employees)                                                                                                           White 25% 50% Minority Race and Ethnicity 8% 17% Gender Total 33% 67% Total U.S.   (4,045 Employees)White 28% 39% Minority Race and Ethnicity 14% 19% Gender Total 42% 58%Employee Workforce Composition (continued) *Global Leadership Team includes Non-U.S. Senior Leadership    N ote: Ethnicity data is not available for 48 U.S.-based employees.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  41Employee Workforce Composition (continued) 2022 Hired U.S. Population Percentages   (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9676380157470703)","('Labor_Practices', 0.002701754681766033)","('Human_Rights_And_Community_Relations', 0.0022311287466436625)","(['Human Capital Development'], 0.9676380157470703)","('NON-ESG', 0.002701754681766033)","('NON-ESG', 0.0022311287466436625)"
Line 512,"Am.* NHOPI** Two or More Female 49% 27% 2% 5% 9% 0% 1% 5% Male 51% 31% 3% 4% 9% 1% 1% 4% All 58% 4% 9% 17% 1% 1% 9%2022 Current U.S. Population Percentages Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9633128046989441)","('Water_And_Wastewater_Management', 0.0025064689107239246)","('Customer_Privacy', 0.002503751078620553)","(['Human Capital Development'], 0.9633128046989441)","('NON-ESG', 0.0025064689107239246)","('NON-ESG', 0.002503751078620553)"
Line 513,"Am.* NHOPI** Two or More Female 42% 28% 1% 4% 7% 0% 0% 2% Male 58% 39% 3% 5% 8% 0% 2% 2% All 67% 4% 8% 15% 0% 2% 4% 2022 Promoted U.S. Population  Percentages (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9646568894386292)","('Customer_Privacy', 0.0026935813948512077)","('Water_And_Wastewater_Management', 0.0022652437910437584)","(['Human Capital Development'], 0.9646568894386292)","('NON-ESG', 0.0026935813948512077)","('NON-ESG', 0.0022652437910437584)"
Line 514,"Am.* NHOPI** Two or More Female 46% 30% 1% 5% 10% 0% 0% 0% Male 54% 36% 3% 5% 7% 0% 1% 3% All 65% 3% 11% 16% 0% 1% 3%Note: No ethnicity data for 48 U.S. based employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.945201575756073)","('Customer_Privacy', 0.007944292388856411)","('Employee_Health_And_Safety', 0.0034145775716751814)","(['Human Capital Development'], 0.945201575756073)","('NON-ESG', 0.007944292388856411)","('NON-ESG', 0.0034145775716751814)"
Line 515,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 516,"* Native American** Native Hawaiian and Other Pacific Islander Note: No ethnicity data for 107 U.S. hires.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9641298055648804)","('Human_Rights_And_Community_Relations', 0.0034206572454422712)","('Customer_Privacy', 0.0031660597305744886)","(['Human Capital Development'], 0.9641298055648804)","('NON-ESG', 0.0034206572454422712)","('NON-ESG', 0.0031660597305744886)"
Line 517,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 518,"* Native American** Native Hawaiian and Other Pacific Islander Note: No ethnicity data for 39 U.S. promotions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9633479118347168)","('Customer_Privacy', 0.003432132536545396)","('Human_Rights_And_Community_Relations', 0.0034289658069610596)","(['Human Capital Development'], 0.9633479118347168)","('NON-ESG', 0.003432132536545396)","('NON-ESG', 0.0034289658069610596)"
Line 519,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 520,"* Native American** Native Hawaiian and “Other” Pacific Islander2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  42Employee Workforce Composition (continued) 2022 Terminated U.S. Population  Percentages (Incumbents by Sub-Group)Total Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9741817712783813)","('Human_Rights_And_Community_Relations', 0.002448095241561532)","('Employee_Health_And_Safety', 0.0015232132282108068)","(['Human Capital Development'], 0.9741817712783813)","('NON-ESG', 0.002448095241561532)","('NON-ESG', 0.0015232132282108068)"
Line 521,"Am.* NHOPI** Two or More Involuntary and Voluntary (All) 92% 61% 6% 8% 14% 0% 1% 2% Female 43% 30% 2% 4% 6% 0% 0% 1% Male 57% 37% 4% 5% 10% 0% 1% 1% Retirement/Death 8% 7% 1% 0% 0% 0% 0% 0% Female 43% 36% 4% 0% 2% 0% 0% 0% Male 57% 51% 2% 0% 2% 0% 0% 2% Note: No ethnicity data for 149 U.S. terminated employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9468346834182739)","('Customer_Privacy', 0.007770435884594917)","('Employee_Health_And_Safety', 0.0040362016297876835)","(['Human Capital Development'], 0.9468346834182739)","('NON-ESG', 0.007770435884594917)","('NON-ESG', 0.0040362016297876835)"
Line 522,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 523,"* Native American ** Native Hawaiian and “Other” Pacific Islander2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People       Good Governance  43Employee Workforce Composition (continued) 2022 U.S. Management Level Workforce  Representations by Sub-GroupTotal Population White Black Hispanic Asian Nat.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9751278162002563)","('Human_Rights_And_Community_Relations', 0.002202918753027916)","('Employee_Health_And_Safety', 0.0015865599270910025)","(['Human Capital Development'], 0.9751278162002563)","('NON-ESG', 0.002202918753027916)","('NON-ESG', 0.0015865599270910025)"
Line 524,"Am.* NHOPI** Two or More Individual Contributor 80% 51% 4% 8% 13% 0% 1% 3% Female 42% 27% 1% 4% 8% 0% 0% 2% Male 58% 38% 3% 6% 9% 0% 1% 2% Managers 12% 9% 0% 1% 2% 0% 0% 0% Female 47% 37% 1% 2% 6% 0% 0% 1% Male 53% 39% 2% 3% 6% 0% 1% 1% Director and VPs 8% 7% 0% 0% 1% 0% 0% 0% Female 39% 31% 1% 1% 5% 1% 0% 1% Male 61% 50% 1% 2% 6% 0% 0% 1% GLT 0% 0% 0% 0% 0% 0% 0% 0% Female 36% 27% 0% 10% 0% 0% 0% 0% Male 64% 55% 9% 0% 0% 0% 0% 0% Note: No ethnicity data for 149 U.S. terminated employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9374902248382568)","('Customer_Privacy', 0.00831668358296156)","('Competitive_Behavior', 0.004279223270714283)","(['Human Capital Development'], 0.9374902248382568)","('NON-ESG', 0.00831668358296156)","('NON-ESG', 0.004279223270714283)"
Line 525,"Numbers may not foot due to rounding.
","('Competitive_Behavior', 0.16689203679561615)","('Customer_Privacy', 0.14125707745552063)","('Employee_Engagement_Inclusion_And_Diversity', 0.1256358027458191)","('NON-ESG', 0.16689203679561615)","('NON-ESG', 0.14125707745552063)","('NON-ESG', 0.1256358027458191)"
Line 526,"* Native American ** Native Hawaiian and “Other” Pacific Islander2022 Hologic Sustainability Report 44From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  Good Governance As a leading global healthcare company, Hologic has a  responsibility to provide transparency into our business practices and operate with the highest degree of integrity.
","('Business_Ethics', 0.7497219443321228)","('Employee_Engagement_Inclusion_And_Diversity', 0.07106821984052658)","('Human_Rights_And_Community_Relations', 0.04028196632862091)","(['Business Ethics'], 0.7497219443321228)","('NON-ESG', 0.07106821984052658)","('NON-ESG', 0.04028196632862091)"
Line 527,"Our governance policies guide our work in clinical trials, supply chain management, supplier risk management, quality management, workplace health and safety as well as information security.
","('Supply_Chain_Management', 0.94806969165802)","('Labor_Practices', 0.005013602320104837)","('Employee_Health_And_Safety', 0.0042953952215611935)","(['Supply Chain Management'], 0.94806969165802)","('NON-ESG', 0.005013602320104837)","('NON-ESG', 0.0042953952215611935)"
Line 528,"Strong governance is essential to our success as a growing  company with a direct impact on the lives and health of millions of women around the world.Governance and Shareholder   Engagement    .
","('Human_Rights_And_Community_Relations', 0.5284987688064575)","('Access_And_Affordability', 0.12114615738391876)","('Management_Of_Legal_And_Regulatory_Framework', 0.058888211846351624)","(['Community Relations'], 0.5284987688064575)","('NON-ESG', 0.12114615738391876)","('NON-ESG', 0.058888211846351624)"
Line 529,"Clinical Trial Governance    .
","('Competitive_Behavior', 0.337955117225647)","('Management_Of_Legal_And_Regulatory_Framework', 0.280245840549469)","('Business_Ethics', 0.09206981956958771)","('NON-ESG', 0.337955117225647)","('NON-ESG', 0.280245840549469)","('NON-ESG', 0.09206981956958771)"
Line 530,"Supply Chain Management    .
","('Supply_Chain_Management', 0.9392426609992981)","('Physical_Impacts_Of_Climate_Change', 0.005102513823658228)","('Waste_And_Hazardous_Materials_Management', 0.004047159105539322)","(['Supply Chain Management'], 0.9392426609992981)","('NON-ESG', 0.005102513823658228)","('NON-ESG', 0.004047159105539322)"
Line 531,"Supplier Risk Management    .
","('Supply_Chain_Management', 0.9318803548812866)","('Physical_Impacts_Of_Climate_Change', 0.005599609110504389)","('Labor_Practices', 0.005187075585126877)","(['Supply Chain Management'], 0.9318803548812866)","('NON-ESG', 0.005599609110504389)","('NON-ESG', 0.005187075585126877)"
Line 532,"Quality Management Systems   .
","('Business_Ethics', 0.19319136440753937)","('Product_Quality_And_Safety', 0.1856928914785385)","('Employee_Health_And_Safety', 0.07184261828660965)","('NON-ESG', 0.19319136440753937)","('NON-ESG', 0.1856928914785385)","('NON-ESG', 0.07184261828660965)"
Line 533,"Workplace Health and Safety   .
","('Employee_Health_And_Safety', 0.9784049391746521)","('Critical_Incident_Risk_Management', 0.00388553598895669)","('Employee_Engagement_Inclusion_And_Diversity', 0.0019819028675556183)","(['Operational Eco-Efficiency'], 0.9784049391746521)","('NON-ESG', 0.00388553598895669)","('NON-ESG', 0.0019819028675556183)"
Line 534,"52Information Security Governance  .
","('Data_Security', 0.34564152359962463)","('Systemic_Risk_Management', 0.3445870876312256)","('Competitive_Behavior', 0.06445170193910599)","('NON-ESG', 0.34564152359962463)","('NON-ESG', 0.3445870876312256)","('NON-ESG', 0.06445170193910599)"
Line 535,"G overnance Policies and Procedures   .
","('Management_Of_Legal_And_Regulatory_Framework', 0.8269270062446594)","('Business_Ethics', 0.06541571766138077)","('Human_Rights_And_Community_Relations', 0.019632160663604736)","(['Corporate Governance'], 0.8269270062446594)","('NON-ESG', 0.06541571766138077)","('NON-ESG', 0.019632160663604736)"
Line 536,"Reporting Frameworks    .
","('Management_Of_Legal_And_Regulatory_Framework', 0.6491971015930176)","('Human_Rights_And_Community_Relations', 0.0611192025244236)","('Access_And_Affordability', 0.032138314098119736)","(['Corporate Governance'], 0.6491971015930176)","('NON-ESG', 0.0611192025244236)","('NON-ESG', 0.032138314098119736)"
Line 537,"Sustainability Accounting Standards   .
","('Management_Of_Legal_And_Regulatory_Framework', 0.22625166177749634)","('Product_Quality_And_Safety', 0.10509209334850311)","('Director_Removal', 0.09181080013513565)","('NON-ESG', 0.22625166177749634)","('NON-ESG', 0.10509209334850311)","('NON-ESG', 0.09181080013513565)"
Line 538,"Task Force on Climate-Related  Financial Disclosures   .
","('Physical_Impacts_Of_Climate_Change', 0.924232006072998)","('Business_Model_Resilience', 0.018597841262817383)","('GHG_Emissions', 0.010513108223676682)","(['Climate Change'], 0.924232006072998)","('NON-ESG', 0.018597841262817383)","('NON-ESG', 0.010513108223676682)"
Line 539,"Safe Harbor Statement   .
","('Customer_Privacy', 0.37226951122283936)","('Data_Security', 0.30447152256965637)","('Business_Model_Resilience', 0.03302910923957825)","('NON-ESG', 0.37226951122283936)","('NON-ESG', 0.30447152256965637)","('NON-ESG', 0.03302910923957825)"
Line 540,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance From Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  2022 Hologic Sustainability Report 45Governance and Shareholder Engagement Board Structure and Composition A nine-member team brings a mix of experience, diversity and fresh perspectives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9392999410629272)","('Human_Rights_And_Community_Relations', 0.01011570729315281)","('Business_Model_Resilience', 0.006149308290332556)","(['Human Capital Development'], 0.9392999410629272)","('NON-ESG', 0.01011570729315281)","('NON-ESG', 0.006149308290332556)"
Line 541,"Given  the Board’s smaller size, each member is highly engaged and actively contributes to an environment that fosters his or her voice to be heard, while supporting and appropriately challenging management.
","('Director_Removal', 0.6764934062957764)","('Management_Of_Legal_And_Regulatory_Framework', 0.05389776825904846)","('Business_Model_Resilience', 0.0340254046022892)","(['Anti-Crime Policy & Measures'], 0.6764934062957764)","('NON-ESG', 0.05389776825904846)","('NON-ESG', 0.0340254046022892)"
Line 542,"It has an ongoing commitment to Board refreshment and to   having highly qualified, independent voices in the boardroom — which has resulted in an e xceptionally well-balanced group.Our Board believes that good governance requires an effective set of specific  practices, as well as a culture of responsibility and accountability throughout   the organization.
","('Director_Removal', 0.41652223467826843)","('Business_Ethics', 0.11431115120649338)","('Employee_Engagement_Inclusion_And_Diversity', 0.08091767877340317)","('NON-ESG', 0.41652223467826843)","('NON-ESG', 0.11431115120649338)","('NON-ESG', 0.08091767877340317)"
Line 543,"The Board is engaged with management, with each other and with Hologic’s  shareholders.
","('Director_Removal', 0.7008995413780212)","('Management_Of_Legal_And_Regulatory_Framework', 0.05979185178875923)","('Business_Ethics', 0.027228450402617455)","(['Anti-Crime Policy & Measures'], 0.7008995413780212)","('NON-ESG', 0.05979185178875923)","('NON-ESG', 0.027228450402617455)"
Line 544,"In 2015, we implemented a year-round approach to shareholder engagement.
","('Business_Model_Resilience', 0.3059447705745697)","('Management_Of_Legal_And_Regulatory_Framework', 0.2269701510667801)","('Director_Removal', 0.0730188861489296)","('NON-ESG', 0.3059447705745697)","('NON-ESG', 0.2269701510667801)","('NON-ESG', 0.0730188861489296)"
Line 545,"In addition to conversations just before our annual meeting,   we initiate discussions during a quieter period several months later, reaching   out to a number of our largest investors to discuss business highlights,   compensation and governance matters — or whatever else is on their minds.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48942604660987854)","('Business_Model_Resilience', 0.13386012613773346)","('Systemic_Risk_Management', 0.0671834722161293)","('NON-ESG', 0.48942604660987854)","('NON-ESG', 0.13386012613773346)","('NON-ESG', 0.0671834722161293)"
Line 546,"Directors participate in these discussions as requested, and are updated on calls   for which they are not present.
","('Director_Removal', 0.6365695595741272)","('Management_Of_Legal_And_Regulatory_Framework', 0.12916170060634613)","('Business_Ethics', 0.02739529497921467)","(['Anti-Crime Policy & Measures'], 0.6365695595741272)","('NON-ESG', 0.12916170060634613)","('NON-ESG', 0.02739529497921467)"
Line 547,"Our Board takes feedback from investors seriously.
","('Business_Model_Resilience', 0.2906826436519623)","('Management_Of_Legal_And_Regulatory_Framework', 0.14374420046806335)","('Director_Removal', 0.10990408807992935)","('NON-ESG', 0.2906826436519623)","('NON-ESG', 0.14374420046806335)","('NON-ESG', 0.10990408807992935)"
Line 548,"Feedback from investors has  helped shape our compensation programs, as well as our governance structures.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9240440726280212)","('Competitive_Behavior', 0.010529867373406887)","('Business_Ethics', 0.009058771654963493)","(['Corporate Governance'], 0.9240440726280212)","('NON-ESG', 0.010529867373406887)","('NON-ESG', 0.009058771654963493)"
Line 549,"Steve MacMillan Chairman, President and Chief  Executive Officer Scott GarrettSenior Operating Partner, Water Street Healthcare Partners Sally W.
","('Business_Model_Resilience', 0.46819621324539185)","('Director_Removal', 0.11586868017911911)","('Systemic_Risk_Management', 0.05930506810545921)","('NON-ESG', 0.46819621324539185)","('NON-ESG', 0.11586868017911911)","('NON-ESG', 0.05930506810545921)"
Line 550,"CrawfordIndependent Lead Director, Former Chief Operating Officer, Healthsource Inc.
","('Customer_Welfare', 0.2162739634513855)","('Systemic_Risk_Management', 0.09898930788040161)","('Business_Model_Resilience', 0.07781261950731277)","('NON-ESG', 0.2162739634513855)","('NON-ESG', 0.09898930788040161)","('NON-ESG', 0.07781261950731277)"
Line 551,"Ludwig N.
","('Management_Of_Legal_And_Regulatory_Framework', 0.23391027748584747)","('Competitive_Behavior', 0.13678601384162903)","('Ecological_Impacts', 0.07577783614397049)","('NON-ESG', 0.23391027748584747)","('NON-ESG', 0.13678601384162903)","('NON-ESG', 0.07577783614397049)"
Line 552,"Hantson Former Chief Executive Officer,  Alexion Pharmaceuticals Inc.
","('Business_Model_Resilience', 0.1517440229654312)","('Product_Design_And_Lifecycle_Management', 0.10151331126689911)","('Competitive_Behavior', 0.08300386369228363)","('NON-ESG', 0.1517440229654312)","('NON-ESG', 0.10151331126689911)","('NON-ESG', 0.08300386369228363)"
Line 553,"Charles J.
","('Business_Ethics', 0.12702348828315735)","('Management_Of_Legal_And_Regulatory_Framework', 0.10427027940750122)","('Ecological_Impacts', 0.07274530082941055)","('NON-ESG', 0.12702348828315735)","('NON-ESG', 0.10427027940750122)","('NON-ESG', 0.07274530082941055)"
Line 554,"DockendorffFormer CFO and Executive Vice  President, Covidien plc Christiana StamoulisExecutive Vice President and Chief  Financial Officer, Incyte Corporation Namal NawanaExecutive Chairman of Sapphiros Stacey D.
","('Business_Model_Resilience', 0.42193126678466797)","('Director_Removal', 0.20398758351802826)","('Systemic_Risk_Management', 0.06017615646123886)","('NON-ESG', 0.42193126678466797)","('NON-ESG', 0.20398758351802826)","('NON-ESG', 0.06017615646123886)"
Line 555,"StewartCEO, Mothers Against Drunk Driving (MADD)Amy M.
","('Employee_Health_And_Safety', 0.3899385631084442)","('Critical_Incident_Risk_Management', 0.14857186377048492)","('Business_Ethics', 0.060923654586076736)","('NON-ESG', 0.3899385631084442)","('NON-ESG', 0.14857186377048492)","('NON-ESG', 0.060923654586076736)"
Line 556,"WendellFormer Senior Vice President, Strategy  and Business Development, Covidien plc 2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  46Governance and Shareholder Engagement (continued) Board Tenure Diversity ● Newer (≤5 yrs.)    ● Medium-tenured (6-10 yrs.)   ● Experienced (>10 yrs.) 7 years average tenure Board Diversity   Individual directors may be  included in more than one segment noted below.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8059772253036499)","('Director_Removal', 0.06196043640375137)","('Business_Model_Resilience', 0.019074421375989914)","(['Human Capital Development'], 0.8059772253036499)","('NON-ESG', 0.06196043640375137)","('NON-ESG', 0.019074421375989914)"
Line 557,"WendellFormer Senior Vice President, Strategy  and Business Development, Covidien plc 2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  46Governance and Shareholder Engagement (continued) Board Tenure Diversity ● Newer (≤5 yrs.)    ● Medium-tenured (6-10 yrs.)   ● Experienced (>10 yrs.) 7 years average tenure Board Diversity   Individual directors may be  included in more than one segment noted below.
","('Competitive_Behavior', 0.28823867440223694)","('Management_Of_Legal_And_Regulatory_Framework', 0.10752206295728683)","('Systemic_Risk_Management', 0.05714137479662895)","('NON-ESG', 0.28823867440223694)","('NON-ESG', 0.10752206295728683)","('NON-ESG', 0.05714137479662895)"
Line 558,"● Female ● Born outside of U.S.   ● Underrepresented minority Gender, geographic and  demographic background diversityBoard Independence● Independent    ● Not Independent Approximately 89% of our   Board is IndependentBoard Age Diversity● 50s    ● 60s   ● 70s Median age is 60Board Composition The Board is composed of a majority of independent directors, and each of the three Board committees   (Audit and Finance, Compensation, and Nominating and Corporate Governance) is composed entirely of  independent directors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9586468935012817)","('Director_Removal', 0.003755310783162713)","('Business_Model_Resilience', 0.0030501126311719418)","(['Human Capital Development'], 0.9586468935012817)","('NON-ESG', 0.003755310783162713)","('NON-ESG', 0.0030501126311719418)"
Line 559,"● Female ● Born outside of U.S.   ● Underrepresented minority Gender, geographic and  demographic background diversityBoard Independence● Independent    ● Not Independent Approximately 89% of our   Board is IndependentBoard Age Diversity● 50s    ● 60s   ● 70s Median age is 60Board Composition The Board is composed of a majority of independent directors, and each of the three Board committees   (Audit and Finance, Compensation, and Nominating and Corporate Governance) is composed entirely of  independent directors.
","('Customer_Welfare', 0.09410855174064636)","('Competitive_Behavior', 0.08379676938056946)","('Access_And_Affordability', 0.07291565090417862)","('NON-ESG', 0.09410855174064636)","('NON-ESG', 0.08379676938056946)","('NON-ESG', 0.07291565090417862)"
Line 560,"The current membership of our Board and each committee is listed below.
","('Director_Removal', 0.6381359100341797)","('Management_Of_Legal_And_Regulatory_Framework', 0.06166110932826996)","('Employee_Engagement_Inclusion_And_Diversity', 0.03822724148631096)","(['Anti-Crime Policy & Measures'], 0.6381359100341797)","('NON-ESG', 0.06166110932826996)","('NON-ESG', 0.03822724148631096)"
Line 561,"Director and Principal Occupation Age Since Independent Current Committee Membership Steve MacMillan   Chairman, President and   Chief Executive Officer, Hologic Inc.59 2013 •  N /A Sally W.
","('Director_Removal', 0.6720576286315918)","('Employee_Engagement_Inclusion_And_Diversity', 0.05668334290385246)","('Labor_Practices', 0.04534333199262619)","(['Anti-Crime Policy & Measures'], 0.6720576286315918)","('NON-ESG', 0.05668334290385246)","('NON-ESG', 0.04534333199262619)"
Line 562,"Crawford   Former Chief Operating Officer,   Healthsource Inc.69 2007 ✓ •  L ead Independent Director  •  C ompensation  •  N ominating and Corporate Governance  (CHAIR) Charles J.
","('Business_Model_Resilience', 0.31806105375289917)","('Systemic_Risk_Management', 0.1508297175168991)","('Director_Removal', 0.12728840112686157)","('NON-ESG', 0.31806105375289917)","('NON-ESG', 0.1508297175168991)","('NON-ESG', 0.12728840112686157)"
Line 563,"Dockendorff   Former Chief Financial Officer and   Executive Vice President, Covidien plc68 2017 ✓ •  A udit and Finance (CHAIR) Scott T.
","('Business_Model_Resilience', 0.4309857189655304)","('Director_Removal', 0.1497456431388855)","('Systemic_Risk_Management', 0.10816550254821777)","('NON-ESG', 0.4309857189655304)","('NON-ESG', 0.1497456431388855)","('NON-ESG', 0.10816550254821777)"
Line 564,"Garrett   Senior Operating Partner,   Water Street Healthcare Partners71 2013 ✓ •  C ompensation (CHAIR)  •  N ominating and Corporate Governance  Ludwig N.
","('Systemic_Risk_Management', 0.34866267442703247)","('Management_Of_Legal_And_Regulatory_Framework', 0.14631639420986176)","('Business_Model_Resilience', 0.13465799391269684)","('NON-ESG', 0.34866267442703247)","('NON-ESG', 0.14631639420986176)","('NON-ESG', 0.13465799391269684)"
Line 565,"Hantson Former Chief Executive Officer   Alexion Pharmaceuticals Inc.60 2018 ✓ •  C ompensation •  N ominating and Corporate Governance Namal Nawana   Executive Chairman, Sapphiros52 2018 ✓ •  C ompensation  •  N ominating and Corporate Governance Christiana Stamoulis   Executive Vice President and   Chief Financial Officer, Incyte Corporation52 2011 ✓ •  A udit and Finance Stacey D.
","('Business_Model_Resilience', 0.28229373693466187)","('Systemic_Risk_Management', 0.15515638887882233)","('Director_Removal', 0.13124103844165802)","('NON-ESG', 0.28229373693466187)","('NON-ESG', 0.15515638887882233)","('NON-ESG', 0.13124103844165802)"
Line 566,"Stewart   CEO, Mothers Against Drunk   Driving (MADD)58 2023 ✓ •  A udit and Finance Amy M.
","('Employee_Health_And_Safety', 0.257712185382843)","('Critical_Incident_Risk_Management', 0.14681127667427063)","('Business_Ethics', 0.09605635702610016)","('NON-ESG', 0.257712185382843)","('NON-ESG', 0.14681127667427063)","('NON-ESG', 0.09605635702610016)"
Line 567,"Wendell   Former Senior Vice President,   Strategy & BD&L, Covidien plc62 2016 ✓ •  A udit and Finance422022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  Governance and Shareholder Engagement (continued) Roles of the Board The Board assesses risk, evaluates management’s performance, plans for successors   and provides overall guidance and direction.
","('Director_Removal', 0.3514822721481323)","('Business_Model_Resilience', 0.1681566685438156)","('Management_Of_Legal_And_Regulatory_Framework', 0.0848366990685463)","('NON-ESG', 0.3514822721481323)","('NON-ESG', 0.1681566685438156)","('NON-ESG', 0.0848366990685463)"
Line 568,"Committee Risk Oversight: •   T he Audit and Finance Committee focuses on cybersecurity risk, financial risk and   internal controls.
","('Business_Ethics', 0.39541101455688477)","('Systemic_Risk_Management', 0.3133247494697571)","('Data_Security', 0.1190900206565857)","('NON-ESG', 0.39541101455688477)","('NON-ESG', 0.3133247494697571)","('NON-ESG', 0.1190900206565857)"
Line 569,"• T he Compensation Committee focuses on risks related to compensation.
","('Labor_Practices', 0.3474787473678589)","('Business_Ethics', 0.24904823303222656)","('Systemic_Risk_Management', 0.09171749651432037)","('NON-ESG', 0.3474787473678589)","('NON-ESG', 0.24904823303222656)","('NON-ESG', 0.09171749651432037)"
Line 570,"•   T he Nominating and Governance Committee oversees all our governance processes,   including Hologic’s reporting and efforts related to sustainability.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7748861312866211)","('Director_Removal', 0.046699222177267075)","('Business_Model_Resilience', 0.021791094914078712)","(['Corporate Governance'], 0.7748861312866211)","('NON-ESG', 0.046699222177267075)","('NON-ESG', 0.021791094914078712)"
Line 571,"Each year, the Board also reviews an enterprise risk management report compiled by   business leaders who have assessed risks throughout the organization over a three-year  horizon, focusing on financial risk, legal/compliance risk and operational/strategic risk.
","('Systemic_Risk_Management', 0.9474874138832092)","('Business_Model_Resilience', 0.010427122935652733)","('Physical_Impacts_Of_Climate_Change', 0.005931919440627098)","(['Risk & Crisis Management'], 0.9474874138832092)","('NON-ESG', 0.010427122935652733)","('NON-ESG', 0.005931919440627098)"
Line 572,"The report details Hologic’s top 10 risks, as well as mitigating actions and plans relating   to those risks.
","('Systemic_Risk_Management', 0.8530958294868469)","('Physical_Impacts_Of_Climate_Change', 0.04282825067639351)","('Business_Model_Resilience', 0.0297718346118927)","(['Risk & Crisis Management'], 0.8530958294868469)","('NON-ESG', 0.04282825067639351)","('NON-ESG', 0.0297718346118927)"
Line 573,"Board Compensation Philosophy and Structure The design of our executive compensation program and the decisions made by the  Board’s Compensation Committee are guided by these principles:  •   P ay for performance.
","('Labor_Practices', 0.5855125784873962)","('Employee_Engagement_Inclusion_And_Diversity', 0.1534825563430786)","('Director_Removal', 0.039958011358976364)","(['Labor Practice Indicators'], 0.5855125784873962)","('NON-ESG', 0.1534825563430786)","('NON-ESG', 0.039958011358976364)"
Line 574,"•    Competitive pay.
","('Competitive_Behavior', 0.8913267254829407)","('Business_Ethics', 0.025636764243245125)","('Management_Of_Legal_And_Regulatory_Framework', 0.008992449380457401)","(['Business Ethics'], 0.8913267254829407)","('NON-ESG', 0.025636764243245125)","('NON-ESG', 0.008992449380457401)"
Line 575,"•   A f ocus on total direct compensation.
","('Labor_Practices', 0.36810144782066345)","('Business_Ethics', 0.1809479296207428)","('Management_Of_Legal_And_Regulatory_Framework', 0.15759502351284027)","('NON-ESG', 0.36810144782066345)","('NON-ESG', 0.1809479296207428)","('NON-ESG', 0.15759502351284027)"
Line 576,"Further, Hologic is focused on growth, efficient use of capital and shareholder value.
","('Business_Model_Resilience', 0.6036851406097412)","('Competitive_Behavior', 0.106612429022789)","('Systemic_Risk_Management', 0.04390069842338562)","(['Codes of Business Conduct'], 0.6036851406097412)","('NON-ESG', 0.106612429022789)","('NON-ESG', 0.04390069842338562)"
Line 577,"Consequently, we use measures of adjusted revenue, adjusted EPS (earnings per share),  ROIC (return on invested capital), adjusted free cash flow and relative TSR (total shareholder return) that align management’s interest to shareholders are structured to drive performance.
","('Competitive_Behavior', 0.2518290877342224)","('Systemic_Risk_Management', 0.22702999413013458)","('Business_Model_Resilience', 0.21656687557697296)","('NON-ESG', 0.2518290877342224)","('NON-ESG', 0.22702999413013458)","('NON-ESG', 0.21656687557697296)"
Line 578,"Our Board believes that our directors and officers should hold a meaningful financial stake   in Hologic to further align their interests with those of our stockholders.
","('Director_Removal', 0.6822784543037415)","('Business_Model_Resilience', 0.04506450891494751)","('Management_Of_Legal_And_Regulatory_Framework', 0.0367109477519989)","(['Anti-Crime Policy & Measures'], 0.6822784543037415)","('NON-ESG', 0.04506450891494751)","('NON-ESG', 0.0367109477519989)"
Line 579,"•   E ach non-employee director is expected to achieve equity ownership in Hologic with a value   of five times annual base cash retainer within five years of his or her election to the Board.
","('Director_Removal', 0.772415041923523)","('Labor_Practices', 0.030240889638662338)","('Employee_Engagement_Inclusion_And_Diversity', 0.025538213551044464)","(['Anti-Crime Policy & Measures'], 0.772415041923523)","('NON-ESG', 0.030240889638662338)","('NON-ESG', 0.025538213551044464)"
Line 580,"•   O ur CEO is expected to achieve equity ownership in Hologic with a value of five times his   then-current base salary.
","('Systemic_Risk_Management', 0.2519441246986389)","('Competitive_Behavior', 0.2403544932603836)","('Business_Model_Resilience', 0.11421291530132294)","('NON-ESG', 0.2519441246986389)","('NON-ESG', 0.2403544932603836)","('NON-ESG', 0.11421291530132294)"
Line 581,"•   E ach of our other executive officers is expected to achieve equity ownership in Hologic with   a value of two times his or her then current base salary, within five years.
","('Director_Removal', 0.7379212975502014)","('Management_Of_Legal_And_Regulatory_Framework', 0.029080705717206)","('Employee_Engagement_Inclusion_And_Diversity', 0.028852101415395737)","(['Anti-Crime Policy & Measures'], 0.7379212975502014)","('NON-ESG', 0.029080705717206)","('NON-ESG', 0.028852101415395737)"
Line 582,"All our non-employee directors and all of our executive officers who have been subject to   these guidelines for over five years have achieved ownership in excess of them.* Mr. MacMillan owns equity in the company that makes him one of our 25 largest stockholders.
","('Director_Removal', 0.7881423234939575)","('Labor_Practices', 0.01828448288142681)","('Management_Of_Legal_And_Regulatory_Framework', 0.01821875385940075)","(['Anti-Crime Policy & Measures'], 0.7881423234939575)","('NON-ESG', 0.01828448288142681)","('NON-ESG', 0.01821875385940075)"
Line 583,"He purchased approximately 11% of his shares in the open market.
","('Competitive_Behavior', 0.6905755996704102)","('Systemic_Risk_Management', 0.053332749754190445)","('Management_Of_Legal_And_Regulatory_Framework', 0.04292780160903931)","(['Business Ethics'], 0.6905755996704102)","('NON-ESG', 0.053332749754190445)","('NON-ESG', 0.04292780160903931)"
Line 584,"Mr. MacMillan’s interests are well-aligned with those of our stockholders.
","('Competitive_Behavior', 0.6885578036308289)","('Systemic_Risk_Management', 0.051204051822423935)","('Business_Model_Resilience', 0.04391726851463318)","(['Business Ethics'], 0.6885578036308289)","('NON-ESG', 0.051204051822423935)","('NON-ESG', 0.04391726851463318)"
Line 585,"*  O nly shares of stock issued and outstanding (or vested and deferred under our deferred equity plan) are credited towards   the ownership goals.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5421195030212402)","('Systemic_Risk_Management', 0.08386007696390152)","('Director_Removal', 0.07977722585201263)","(['Corporate Governance'], 0.5421195030212402)","('NON-ESG', 0.08386007696390152)","('NON-ESG', 0.07977722585201263)"
Line 586,"No unvested RSUs or PSUs or outstanding stock options (regardless of whether or not vested) are  credited towards the ownership goals.NACD Directorship 100™   Names Hologic Board Member   Sally W.
","('Director_Removal', 0.4780573546886444)","('Management_Of_Legal_And_Regulatory_Framework', 0.13387389481067657)","('Business_Model_Resilience', 0.06493759155273438)","('NON-ESG', 0.4780573546886444)","('NON-ESG', 0.13387389481067657)","('NON-ESG', 0.06493759155273438)"
Line 587,"Crawford as an Honoree Hologic Lead Independent Director, Sally W.
","('Director_Removal', 0.5698149800300598)","('Business_Model_Resilience', 0.06201079487800598)","('Business_Ethics', 0.041427966207265854)","(['Anti-Crime Policy & Measures'], 0.5698149800300598)","('NON-ESG', 0.06201079487800598)","('NON-ESG', 0.041427966207265854)"
Line 588,"Crawford, was recognized by the  National Association of Corporate Directors (NACD) as part of its 2022 NACD Directorship 100™ — honoring the most influential peer-nominated leaders in the boardroom and corporate governance community.
","('Director_Removal', 0.7277390956878662)","('Management_Of_Legal_And_Regulatory_Framework', 0.033240366727113724)","('Business_Model_Resilience', 0.028467543423175812)","(['Anti-Crime Policy & Measures'], 0.7277390956878662)","('NON-ESG', 0.033240366727113724)","('NON-ESG', 0.028467543423175812)"
Line 589,"Now in its 16th year, the NACD evaluates nominees in four key categories: integrity,  mature confidence, informed judgment and high-performance standards.
","('Business_Ethics', 0.9556147456169128)","('Competitive_Behavior', 0.004658777732402086)","('Management_Of_Legal_And_Regulatory_Framework', 0.004059393424540758)","(['Business Ethics'], 0.9556147456169128)","('NON-ESG', 0.004658777732402086)","('NON-ESG', 0.004059393424540758)"
Line 590,"A selection committee reviews the nominees’ histories of advancing board  performance and leading corporate governance practices in accordance with established NACD principles.
","('Director_Removal', 0.37155961990356445)","('Management_Of_Legal_And_Regulatory_Framework', 0.20341427624225616)","('Business_Model_Resilience', 0.06743258982896805)","('NON-ESG', 0.37155961990356445)","('NON-ESG', 0.20341427624225616)","('NON-ESG', 0.06743258982896805)"
Line 591,"The principles provide a framework that encourages excellence in areas that include risk oversight, corporate strategy, compensation   and transparency.Steve MacMillan with Sally Crawford at NASDAQ for   Breast Cancer Awareness Month.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  48Clinical Trial Governance Hologic is committed to preserving the health   and dignity of individuals with whom we interact.
","('Business_Ethics', 0.7357965707778931)","('Human_Rights_And_Community_Relations', 0.1260991394519806)","('Management_Of_Legal_And_Regulatory_Framework', 0.025686880573630333)","(['Business Ethics'], 0.7357965707778931)","('NON-ESG', 0.1260991394519806)","('NON-ESG', 0.025686880573630333)"
Line 592,"The principles provide a framework that encourages excellence in areas that include risk oversight, corporate strategy, compensation   and transparency.Steve MacMillan with Sally Crawford at NASDAQ for   Breast Cancer Awareness Month.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  48Clinical Trial Governance Hologic is committed to preserving the health   and dignity of individuals with whom we interact.
","('Human_Rights_And_Community_Relations', 0.19774091243743896)","('Employee_Engagement_Inclusion_And_Diversity', 0.13496217131614685)","('Customer_Privacy', 0.12048104405403137)","('NON-ESG', 0.19774091243743896)","('NON-ESG', 0.13496217131614685)","('NON-ESG', 0.12048104405403137)"
Line 593,"This includes conducting our clinical trials in compliance with the highest scientific, ethical   and regulatory standards.
","('Business_Ethics', 0.8415628671646118)","('Management_Of_Legal_And_Regulatory_Framework', 0.058288589119911194)","('Product_Quality_And_Safety', 0.026710692793130875)","(['Business Ethics'], 0.8415628671646118)","('NON-ESG', 0.058288589119911194)","('NON-ESG', 0.026710692793130875)"
Line 594,"All clinical trials comply with applicable U.S. and international  regulations, standards and guidelines for Human Subjects Protection and Ethical Review of Clinical Trials.
","('Management_Of_Legal_And_Regulatory_Framework', 0.45059382915496826)","('Business_Ethics', 0.2642609775066376)","('Competitive_Behavior', 0.10639449208974838)","('NON-ESG', 0.45059382915496826)","('NON-ESG', 0.2642609775066376)","('NON-ESG', 0.10639449208974838)"
Line 595,"This includes obtaining participants’ free and prior informed consent before they participate in any clinical trial.
","('Access_And_Affordability', 0.19480463862419128)","('Competitive_Behavior', 0.1457817107439041)","('Management_Of_Legal_And_Regulatory_Framework', 0.12575849890708923)","('NON-ESG', 0.19480463862419128)","('NON-ESG', 0.1457817107439041)","('NON-ESG', 0.12575849890708923)"
Line 596,"When we can use leftover remnant samples for which we do not know the identity of the individual who provided it in our clinical studies, we ensure  the samples are collected ethically.
","('Customer_Privacy', 0.18605346977710724)","('Selling_Practices_And_Product_Labeling', 0.15514546632766724)","('Product_Quality_And_Safety', 0.09236205369234085)","('NON-ESG', 0.18605346977710724)","('NON-ESG', 0.15514546632766724)","('NON-ESG', 0.09236205369234085)"
Line 597,"All clinical trial protocols are reviewed by an Independent  Institutional Review Board (IRB) or Ethics Committees (EC) as required for each region.
","('Management_Of_Legal_And_Regulatory_Framework', 0.401020884513855)","('Business_Ethics', 0.35288745164871216)","('Director_Removal', 0.06395943462848663)","('NON-ESG', 0.401020884513855)","('NON-ESG', 0.35288745164871216)","('NON-ESG', 0.06395943462848663)"
Line 598,"These IRBs and ECs have the authority to approve, modify or stop clinical trials.
","('Competitive_Behavior', 0.21079741418361664)","('Management_Of_Legal_And_Regulatory_Framework', 0.17708896100521088)","('Customer_Welfare', 0.08841685950756073)","('NON-ESG', 0.21079741418361664)","('NON-ESG', 0.17708896100521088)","('NON-ESG', 0.08841685950756073)"
Line 599,"We have departments of highly trained employees dedicated  to conducting clinical trials in the U.S. and globally.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3103688359260559)","('Access_And_Affordability', 0.12129567563533783)","('Customer_Welfare', 0.08451516181230545)","('NON-ESG', 0.3103688359260559)","('NON-ESG', 0.12129567563533783)","('NON-ESG', 0.08451516181230545)"
Line 600,"These personnel are governed by Hologic policies and procedures designed to meet regulations, standards and best practices  in clinical trials.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8271986842155457)","('Business_Ethics', 0.04076052084565163)","('Product_Quality_And_Safety', 0.03421768546104431)","(['Corporate Governance'], 0.8271986842155457)","('NON-ESG', 0.04076052084565163)","('NON-ESG', 0.03421768546104431)"
Line 601,"Confidentiality and Privacy Assurance and Grievance  Mechanisms for Clinical Trial Participants     Hologic recognizes the importance of maintaining the privacy of an individual’s health information when participating in a clinical trial.
","('Customer_Privacy', 0.445141464471817)","('Data_Security', 0.4302372932434082)","('Business_Ethics', 0.02215367741882801)","('NON-ESG', 0.445141464471817)","('NON-ESG', 0.4302372932434082)","('NON-ESG', 0.02215367741882801)"
Line 602,"We comply with U.S. and international regulations such as those limiting the health information we are allowed to collect for our trials, and those requiring strong security of clinical trial databases.
","('Data_Security', 0.35631659626960754)","('Customer_Privacy', 0.27291831374168396)","('Management_Of_Legal_And_Regulatory_Framework', 0.10344111174345016)","('NON-ESG', 0.35631659626960754)","('NON-ESG', 0.27291831374168396)","('NON-ESG', 0.10344111174345016)"
Line 603,"A Principal Investigator at clinical sites is responsible for participant care with Hologic’s Technical Support and Clinical Affairs available as first-line contacts for our investigational clinical sites.
","('Access_And_Affordability', 0.3833180069923401)","('Customer_Welfare', 0.1087244302034378)","('Management_Of_Legal_And_Regulatory_Framework', 0.0484987236559391)","('NON-ESG', 0.3833180069923401)","('NON-ESG', 0.1087244302034378)","('NON-ESG', 0.0484987236559391)"
Line 604,"Reporting on Violations in Clinical Trials and   Corrective Actions Some of our clinical trials are subject to clinical trial site and  sponsor audits under global regulatory bodies including FDA’s Biomedical Research Program.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38874271512031555)","('Competitive_Behavior', 0.225014328956604)","('Product_Quality_And_Safety', 0.04819931834936142)","('NON-ESG', 0.38874271512031555)","('NON-ESG', 0.225014328956604)","('NON-ESG', 0.04819931834936142)"
Line 605,"Regulatory audits and inspections of clinical trials have resulted in no major findings at either the clinical site or Hologic.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6338309645652771)","('Business_Ethics', 0.09747809171676636)","('Competitive_Behavior', 0.044339943677186966)","(['Corporate Governance'], 0.6338309645652771)","('NON-ESG', 0.09747809171676636)","('NON-ESG', 0.044339943677186966)"
Line 606,"Hologic is committed to a quality system approach and conducts regular internal audits of procedures and policies.
","('Business_Ethics', 0.6691570281982422)","('Management_Of_Legal_And_Regulatory_Framework', 0.19873115420341492)","('Director_Removal', 0.015317656099796295)","(['Business Ethics'], 0.6691570281982422)","('NON-ESG', 0.19873115420341492)","('NON-ESG', 0.015317656099796295)"
Line 607,"Risk Management Prior to and During Ongoing   Clinical Trials Our clinical trials are managed by Hologic’s Clinical Affairs  department.
","('Customer_Welfare', 0.15161435306072235)","('Access_And_Affordability', 0.15034699440002441)","('Competitive_Behavior', 0.07126976549625397)","('NON-ESG', 0.15161435306072235)","('NON-ESG', 0.15034699440002441)","('NON-ESG', 0.07126976549625397)"
Line 608,"The Clinical Affairs teams, in partnership with R&D, ensure compliance with product development procedures, which include phase exit reviews.
","('Selling_Practices_And_Product_Labeling', 0.43068259954452515)","('Product_Quality_And_Safety', 0.2006630301475525)","('Customer_Welfare', 0.09545943140983582)","('NON-ESG', 0.43068259954452515)","('NON-ESG', 0.2006630301475525)","('NON-ESG', 0.09545943140983582)"
Line 609,"In addition, our core teams have internal department-level documents that contain risk mitigation processes.
","('Systemic_Risk_Management', 0.643674910068512)","('Business_Model_Resilience', 0.10776162892580032)","('Physical_Impacts_Of_Climate_Change', 0.0835975855588913)","(['Risk & Crisis Management'], 0.643674910068512)","('NON-ESG', 0.10776162892580032)","('NON-ESG', 0.0835975855588913)"
Line 610,"Clinical Trial Data Transparency Registration of Clinical Trials in Publicly Available Databases When required, we register clinical trial data and results,  including terminated clinical trials, on public websites such as ClinicalTrials.gov .
","('Customer_Privacy', 0.25608739256858826)","('Competitive_Behavior', 0.18673080205917358)","('Selling_Practices_And_Product_Labeling', 0.06857108324766159)","('NON-ESG', 0.25608739256858826)","('NON-ESG', 0.18673080205917358)","('NON-ESG', 0.06857108324766159)"
Line 611,"This transparency helps our  customers make informed decisions about the safety and efficacy of our products.
","('Product_Quality_And_Safety', 0.6478530764579773)","('Selling_Practices_And_Product_Labeling', 0.1659144014120102)","('Product_Design_And_Lifecycle_Management', 0.04842609912157059)","(['Product Quality & Recall Management'], 0.6478530764579773)","('NON-ESG', 0.1659144014120102)","('NON-ESG', 0.04842609912157059)"
Line 612,"Animal Research Policy Animal studies are sometimes required by regulatory agencies to better understand treatment outcomes and to ensure surgical procedures or medical devices are safe and effective.
","('Employee_Health_And_Safety', 0.2261764407157898)","('Access_And_Affordability', 0.18573175370693207)","('Product_Quality_And_Safety', 0.10018383711576462)","('NON-ESG', 0.2261764407157898)","('NON-ESG', 0.18573175370693207)","('NON-ESG', 0.10018383711576462)"
Line 613,"Hologic conducts mandatory animal testing for the development of products primarily related to breast health, skeletal health and gynecological surgery.
","('Product_Quality_And_Safety', 0.31364139914512634)","('Customer_Welfare', 0.2255786806344986)","('Selling_Practices_And_Product_Labeling', 0.0895407497882843)","('NON-ESG', 0.31364139914512634)","('NON-ESG', 0.2255786806344986)","('NON-ESG', 0.0895407497882843)"
Line 614,"FDA approval is required prior to marketing such products, which must be supported by data including preclinical animal studies to demonstrate safety and effectiveness of the products and their designs.
","('Product_Quality_And_Safety', 0.605770468711853)","('Selling_Practices_And_Product_Labeling', 0.2113923281431198)","('Customer_Welfare', 0.026656074449419975)","(['Product Quality & Recall Management'], 0.605770468711853)","('NON-ESG', 0.2113923281431198)","('NON-ESG', 0.026656074449419975)"
Line 615,"Hologic is committed to complying with currently applicable scientific, legal, regulatory and ethical requirements, guidelines and policies to ensure animal welfare.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3525506854057312)","('Ecological_Impacts', 0.11286671459674835)","('Selling_Practices_And_Product_Labeling', 0.07002294808626175)","('NON-ESG', 0.3525506854057312)","('NON-ESG', 0.11286671459674835)","('NON-ESG', 0.07002294808626175)"
Line 616,"Studies are carried out by individuals who are trained and qualified in the proper care, handling and use of animals, including experience with the species being studied.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  Supplier Diversity Hologic continuously pursues supplier diversity, both  voluntarily and through a range of federal, state and local regulations that require we develop and track efforts to  use suppliers that are minority-owned, veteran-owned  and woman-owned.
","('Supply_Chain_Management', 0.3292652666568756)","('Employee_Engagement_Inclusion_And_Diversity', 0.1606999933719635)","('Labor_Practices', 0.061026349663734436)","('NON-ESG', 0.3292652666568756)","('NON-ESG', 0.1606999933719635)","('NON-ESG', 0.061026349663734436)"
Line 617,"Studies are carried out by individuals who are trained and qualified in the proper care, handling and use of animals, including experience with the species being studied.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  Supplier Diversity Hologic continuously pursues supplier diversity, both  voluntarily and through a range of federal, state and local regulations that require we develop and track efforts to  use suppliers that are minority-owned, veteran-owned  and woman-owned.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9341145157814026)","('Labor_Practices', 0.009498839266598225)","('Competitive_Behavior', 0.007517748046666384)","(['Human Capital Development'], 0.9341145157814026)","('NON-ESG', 0.009498839266598225)","('NON-ESG', 0.007517748046666384)"
Line 618,"Approximately 10% of Hologic’s  2022 total supplier spend was with diverse suppliers.
","('Supply_Chain_Management', 0.9225549101829529)","('Product_Design_And_Lifecycle_Management', 0.01392795704305172)","('Labor_Practices', 0.006206825841218233)","(['Supply Chain Management'], 0.9225549101829529)","('NON-ESG', 0.01392795704305172)","('NON-ESG', 0.006206825841218233)"
Line 619,"Supplier Compliance Supplier Code of Conduct   All suppliers must comply with the laws of their respective countries related to the environment, child labor, wages and hours, discrimination and gifts.Supplier Non-Disclosure   and Confidentiality   All Hologic suppliers are required  to sign and adhere to non-disclosure agreements.
","('Labor_Practices', 0.9145914316177368)","('Supply_Chain_Management', 0.017972135916352272)","('Employee_Health_And_Safety', 0.006102383136749268)","(['Labor Practice Indicators'], 0.9145914316177368)","('NON-ESG', 0.017972135916352272)","('NON-ESG', 0.006102383136749268)"
Line 620,"This includes, but is not limited  to, any information concerning current or planned products, designs or volumes.Supplier Notification   Suppliers must notify Hologic  in a timely manner of any event  that could impact the supply or quality of product.Supplier Use of   Intellectual Property   Information that is provided to suppliers and/or developed by  a supplier and paid for by Hologic  is considered the property  of Hologic.Business Continuity and   Risk Management   We ensure that our suppliers (and their suppliers) have well-defined, documented plans to identify and mitigate supply chain risks.Supply Chain Management Hologic recognizes that proper governance,  oversight and compliance with regulations  related to procurement are critical to the sustainability of our businesses and to meeting customer expectations.
","('Supply_Chain_Management', 0.7643442749977112)","('Product_Design_And_Lifecycle_Management', 0.08585236221551895)","('Selling_Practices_And_Product_Labeling', 0.018742989748716354)","(['Supply Chain Management'], 0.7643442749977112)","('NON-ESG', 0.08585236221551895)","('NON-ESG', 0.018742989748716354)"
Line 621,"This includes, but is not limited  to, any information concerning current or planned products, designs or volumes.Supplier Notification   Suppliers must notify Hologic  in a timely manner of any event  that could impact the supply or quality of product.Supplier Use of   Intellectual Property   Information that is provided to suppliers and/or developed by  a supplier and paid for by Hologic  is considered the property  of Hologic.Business Continuity and   Risk Management   We ensure that our suppliers (and their suppliers) have well-defined, documented plans to identify and mitigate supply chain risks.Supply Chain Management Hologic recognizes that proper governance,  oversight and compliance with regulations  related to procurement are critical to the sustainability of our businesses and to meeting customer expectations.
","('Supply_Chain_Management', 0.9515089988708496)","('Labor_Practices', 0.00423853425309062)","('Product_Design_And_Lifecycle_Management', 0.003564342623576522)","(['Supply Chain Management'], 0.9515089988708496)","('NON-ESG', 0.00423853425309062)","('NON-ESG', 0.003564342623576522)"
Line 622,"Hologic team members celebrate the opening of a new distribution center in our Asia-Pacific region.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  50Our suppliers are classified based on their potential risk   level.
","('Supply_Chain_Management', 0.856744110584259)","('Business_Model_Resilience', 0.02622114308178425)","('Systemic_Risk_Management', 0.018680425360798836)","(['Supply Chain Management'], 0.856744110584259)","('NON-ESG', 0.02622114308178425)","('NON-ESG', 0.018680425360798836)"
Line 623,"These classifications influence how we interact with  our suppliers and how critical suppliers are identified.
","('Supply_Chain_Management', 0.9500983953475952)","('Physical_Impacts_Of_Climate_Change', 0.003942600917071104)","('Water_And_Wastewater_Management', 0.003921406343579292)","(['Supply Chain Management'], 0.9500983953475952)","('NON-ESG', 0.003942600917071104)","('NON-ESG', 0.003921406343579292)"
Line 624,"We track the annual spend with our most critical suppliers.
","('Supply_Chain_Management', 0.9282054901123047)","('Physical_Impacts_Of_Climate_Change', 0.006983600556850433)","('GHG_Emissions', 0.006325969938188791)","(['Supply Chain Management'], 0.9282054901123047)","('NON-ESG', 0.006983600556850433)","('NON-ESG', 0.006325969938188791)"
Line 625,"Periodically, or as needed, our supply chain teams review  our current supplier segmentation to determine if any  changes are warranted.
","('Supply_Chain_Management', 0.9524396061897278)","('Labor_Practices', 0.003966719843447208)","('Physical_Impacts_Of_Climate_Change', 0.0036249158438295126)","(['Supply Chain Management'], 0.9524396061897278)","('NON-ESG', 0.003966719843447208)","('NON-ESG', 0.0036249158438295126)"
Line 626,"Strategic Suppliers We evaluate whether these suppliers meet and/or exceed the requirements of preferred suppliers, plus are willing to make investments at risk to provide access to cutting-edge technology or services that provide Hologic a marketplace advantage.
","('Supply_Chain_Management', 0.9343772530555725)","('Customer_Welfare', 0.005462258588522673)","('Water_And_Wastewater_Management', 0.005150646902620792)","(['Supply Chain Management'], 0.9343772530555725)","('NON-ESG', 0.005462258588522673)","('NON-ESG', 0.005150646902620792)"
Line 627,"Preferred Suppliers These suppliers provide best-in-class pricing, prototyping, technical support and innovation.
","('Supply_Chain_Management', 0.8970360159873962)","('Product_Design_And_Lifecycle_Management', 0.02010592631995678)","('Customer_Welfare', 0.007695039268583059)","(['Supply Chain Management'], 0.8970360159873962)","('NON-ESG', 0.02010592631995678)","('NON-ESG', 0.007695039268583059)"
Line 628,"Preferred suppliers are allowed to work with R&D and sustain engineering on new projects and changes.
","('Supply_Chain_Management', 0.8230589628219604)","('GHG_Emissions', 0.023646781221032143)","('Energy_Management', 0.01934557594358921)","(['Supply Chain Management'], 0.8230589628219604)","('NON-ESG', 0.023646781221032143)","('NON-ESG', 0.01934557594358921)"
Line 629,"Core Suppliers These suppliers meet an acceptable level of quality, delivery, service and cost.
","('Supply_Chain_Management', 0.9175845980644226)","('Product_Design_And_Lifecycle_Management', 0.015292821452021599)","('Water_And_Wastewater_Management', 0.0069576590321958065)","(['Supply Chain Management'], 0.9175845980644226)","('NON-ESG', 0.015292821452021599)","('NON-ESG', 0.0069576590321958065)"
Line 630,"New suppliers start at this level.
","('Supply_Chain_Management', 0.9193150401115417)","('Product_Design_And_Lifecycle_Management', 0.007635283749550581)","('Systemic_Risk_Management', 0.006359909661114216)","(['Supply Chain Management'], 0.9193150401115417)","('NON-ESG', 0.007635283749550581)","('NON-ESG', 0.006359909661114216)"
Line 631,"Restricted Suppliers Restricted suppliers do not meet the business needs of Hologic or are a potential new supplier eligible for use in limited capacity.
","('Supply_Chain_Management', 0.9255591034889221)","('GHG_Emissions', 0.006351875141263008)","('Labor_Practices', 0.006309266667813063)","(['Supply Chain Management'], 0.9255591034889221)","('NON-ESG', 0.006351875141263008)","('NON-ESG', 0.006309266667813063)"
Line 632,"Management authorization is required before any new business is awarded.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4282302260398865)","('Business_Ethics', 0.18862153589725494)","('Competitive_Behavior', 0.09216557443141937)","('NON-ESG', 0.4282302260398865)","('NON-ESG', 0.18862153589725494)","('NON-ESG', 0.09216557443141937)"
Line 633,"Unapproved Suppliers These suppliers do not meet Hologic’s quality and  business expectations.Supplier Risk Management  We have a formal process to identify potential risks in the supply chain.
","('Supply_Chain_Management', 0.9473134279251099)","('Labor_Practices', 0.005343298893421888)","('Waste_And_Hazardous_Materials_Management', 0.004103954415768385)","(['Supply Chain Management'], 0.9473134279251099)","('NON-ESG', 0.005343298893421888)","('NON-ESG', 0.004103954415768385)"
Line 634,"Our supplier risk assessments are performed from three vantage points: quality risk,   supply continuity risk and information services data risk.
","('Supply_Chain_Management', 0.9366948008537292)","('Product_Design_And_Lifecycle_Management', 0.007828647270798683)","('Labor_Practices', 0.004656116012483835)","(['Supply Chain Management'], 0.9366948008537292)","('NON-ESG', 0.007828647270798683)","('NON-ESG', 0.004656116012483835)"
Line 635,"We maintain tracking metrics on the percentage of the supply chain covered by risk assessments.
","('Supply_Chain_Management', 0.9490373730659485)","('Physical_Impacts_Of_Climate_Change', 0.004474932327866554)","('Product_Design_And_Lifecycle_Management', 0.003654556116089225)","(['Supply Chain Management'], 0.9490373730659485)","('NON-ESG', 0.004474932327866554)","('NON-ESG', 0.003654556116089225)"
Line 636,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  51Quality Management Systems The purpose of Hologic’s Quality Management System (QMS) is to consistently  meet customer requirements and enhance customer satisfaction.
","('Business_Ethics', 0.32566410303115845)","('Human_Rights_And_Community_Relations', 0.12902775406837463)","('Employee_Engagement_Inclusion_And_Diversity', 0.11150611937046051)","('NON-ESG', 0.32566410303115845)","('NON-ESG', 0.12902775406837463)","('NON-ESG', 0.11150611937046051)"
Line 637,"QMS performance is documented and maintained to ensure its effectiveness in accordance with applicable standards and regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.915166974067688)","('Product_Quality_And_Safety', 0.018657496199011803)","('Business_Ethics', 0.013748767785727978)","(['Corporate Governance'], 0.915166974067688)","('NON-ESG', 0.018657496199011803)","('NON-ESG', 0.013748767785727978)"
Line 638,"The Hologic QMS includes multiple regulatory certifications, such as the  current ISO 13485:2016 certifications, which are held at each of our sites  along with EU MDR and IVDR certifications.Procedures and Compliance Field Action Procedure This defines the requirements and conditions  under which a recall (field correction or removal), customer notification, safety alert, market withdrawal and/or field safety corrective action take place.
","('Product_Quality_And_Safety', 0.6018157005310059)","('Employee_Health_And_Safety', 0.25695687532424927)","('Product_Design_And_Lifecycle_Management', 0.01659119315445423)","(['Product Quality & Recall Management'], 0.6018157005310059)","('NON-ESG', 0.25695687532424927)","('NON-ESG', 0.01659119315445423)"
Line 639,"All Hologic entities follow the minimum requirements defined in our Corporate Standard  Operating Procedures.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6689872741699219)","('Business_Ethics', 0.07993710786104202)","('Competitive_Behavior', 0.06534266471862793)","(['Corporate Governance'], 0.6689872741699219)","('NON-ESG', 0.07993710786104202)","('NON-ESG', 0.06534266471862793)"
Line 640,"Complaint Handling Procedure This includes complaint handling for  marketed products in accordance with established regulations across all sites  that are governed by our corporate  quality system.
","('Product_Quality_And_Safety', 0.6740927696228027)","('Selling_Practices_And_Product_Labeling', 0.06762492656707764)","('Business_Ethics', 0.04951801896095276)","(['Product Quality & Recall Management'], 0.6740927696228027)","('NON-ESG', 0.06762492656707764)","('NON-ESG', 0.04951801896095276)"
Line 641,"The requirements of  these procedures apply to all finished products manufactured or distributed  by Hologic.
","('Product_Design_And_Lifecycle_Management', 0.9481931328773499)","('Product_Quality_And_Safety', 0.00975947454571724)","('Selling_Practices_And_Product_Labeling', 0.008564519695937634)","(['Product Stewardship'], 0.9481931328773499)","('NON-ESG', 0.00975947454571724)","('NON-ESG', 0.008564519695937634)"
Line 642,"Quality Audit Procedure Internal audits are conducted to ensure our QMS at all global sites and regions complies with applicable internal and external requirements.
","('Business_Ethics', 0.6927372217178345)","('Management_Of_Legal_And_Regulatory_Framework', 0.199501171708107)","('Systemic_Risk_Management', 0.014251462183892727)","(['Business Ethics'], 0.6927372217178345)","('NON-ESG', 0.199501171708107)","('NON-ESG', 0.014251462183892727)"
Line 643,"All Hologic employees are required to complete training in Quality System requirements and to acknowledge  and adhere to our Hologic Quality Policy.
","('Product_Quality_And_Safety', 0.2935648560523987)","('Employee_Engagement_Inclusion_And_Diversity', 0.22569793462753296)","('Business_Ethics', 0.06906893104314804)","('NON-ESG', 0.2935648560523987)","('NON-ESG', 0.22569793462753296)","('NON-ESG', 0.06906893104314804)"
Line 644,"Chemical Compliance To comply with applicable chemical regulations, Hologic has implemented a process and system to ensure all substances controlled by chemical regulations within Hologic products are identified, monitored and reported as applicable.
","('Product_Quality_And_Safety', 0.444832980632782)","('Selling_Practices_And_Product_Labeling', 0.2784070074558258)","('Waste_And_Hazardous_Materials_Management', 0.05544928461313248)","('NON-ESG', 0.444832980632782)","('NON-ESG', 0.2784070074558258)","('NON-ESG', 0.05544928461313248)"
Line 645,"Note: Class I recall: a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will  cause serious adverse health consequences or death.
","('Product_Quality_And_Safety', 0.6849052906036377)","('Employee_Health_And_Safety', 0.05829358473420143)","('Selling_Practices_And_Product_Labeling', 0.05775577202439308)","(['Product Quality & Recall Management'], 0.6849052906036377)","('NON-ESG', 0.05829358473420143)","('NON-ESG', 0.05775577202439308)"
Line 646,"Class II recall: a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
","('Product_Quality_And_Safety', 0.5659617185592651)","('Employee_Health_And_Safety', 0.22829154133796692)","('Product_Design_And_Lifecycle_Management', 0.032948412001132965)","(['Product Quality & Recall Management'], 0.5659617185592651)","('NON-ESG', 0.22829154133796692)","('NON-ESG', 0.032948412001132965)"
Line 647,"https://www.fda.gov/safety/industry-guidance-recalls/recalls-background-and-definitionsRecall Metrics FY’18 FY’19 FY’20 FY’21 FY’Class I 0 0 0 0 Class II 2 3 2 1 Hologic team members perform quality control checks.2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  52Workplace Health and Safety Every day, Hologic employees strive for zero health and safety incidents in their workplaces.
","('Employee_Health_And_Safety', 0.9609440565109253)","('Product_Quality_And_Safety', 0.010228443890810013)","('Employee_Engagement_Inclusion_And_Diversity', 0.0029214448295533657)","(['Operational Eco-Efficiency'], 0.9609440565109253)","('NON-ESG', 0.010228443890810013)","('NON-ESG', 0.0029214448295533657)"
Line 648,"We collaborate to improve safety, increase productivity   and reduce waste.
","('Waste_And_Hazardous_Materials_Management', 0.9647903442382812)","('Employee_Health_And_Safety', 0.006540685426443815)","('Air_Quality', 0.002663631225004792)","(['Operational Eco-Efficiency'], 0.9647903442382812)","('NON-ESG', 0.006540685426443815)","('NON-ESG', 0.002663631225004792)"
Line 649,"Three of our manufacturing sites are ISO 14001/ISO 45001-certified, and all other sites are audited annually against the concepts   of the ISO 14001/ISO 45001 standards.
","('Product_Quality_And_Safety', 0.46572059392929077)","('Management_Of_Legal_And_Regulatory_Framework', 0.12954692542552948)","('Product_Design_And_Lifecycle_Management', 0.06506363302469254)","('NON-ESG', 0.46572059392929077)","('NON-ESG', 0.12954692542552948)","('NON-ESG', 0.06506363302469254)"
Line 650,"Hologic maintains health and safety programs conforming to best practices in the industry and all applicable regulations.
","('Product_Quality_And_Safety', 0.6325626373291016)","('Employee_Health_And_Safety', 0.24466170370578766)","('Product_Design_And_Lifecycle_Management', 0.01173663791269064)","(['Product Quality & Recall Management'], 0.6325626373291016)","('NON-ESG', 0.24466170370578766)","('NON-ESG', 0.01173663791269064)"
Line 651,"Safety rules and procedures   are in place to prevent behaviors and work practices that can lead to accidents and injuries.
","('Employee_Health_And_Safety', 0.9774929285049438)","('Critical_Incident_Risk_Management', 0.006880621425807476)","('Employee_Engagement_Inclusion_And_Diversity', 0.0011635090922936797)","(['Operational Eco-Efficiency'], 0.9774929285049438)","('NON-ESG', 0.006880621425807476)","('NON-ESG', 0.0011635090922936797)"
Line 652,"Safety performance is assessed throughout the year by   management and during annual performance reviews.
","('Product_Quality_And_Safety', 0.7623132467269897)","('Employee_Health_And_Safety', 0.11560258269309998)","('Product_Design_And_Lifecycle_Management', 0.01188336405903101)","(['Product Quality & Recall Management'], 0.7623132467269897)","('NON-ESG', 0.11560258269309998)","('NON-ESG', 0.01188336405903101)"
Line 653,"Hologic rewards positive safety   performance and encourages   employees to: Refuse Employees are directed to stop work when an unsafe   condition or incident occurs.
","('Employee_Health_And_Safety', 0.9807974696159363)","('Critical_Incident_Risk_Management', 0.0029422377701848745)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015835019294172525)","(['Operational Eco-Efficiency'], 0.9807974696159363)","('NON-ESG', 0.0029422377701848745)","('NON-ESG', 0.0015835019294172525)"
Line 654,"They are empowered to  inform and/or correct the unsafe condition.
","('Employee_Health_And_Safety', 0.7664880752563477)","('Product_Quality_And_Safety', 0.07248911261558533)","('Waste_And_Hazardous_Materials_Management', 0.0478154756128788)","(['Operational Eco-Efficiency'], 0.7664880752563477)","('NON-ESG', 0.07248911261558533)","('NON-ESG', 0.0478154756128788)"
Line 655,"Report Employees must report unsafe acts and conditions,  safety incidents and injuries to their management  and EH&S immediately.
","('Employee_Health_And_Safety', 0.9811971783638)","('Critical_Incident_Risk_Management', 0.003034998429939151)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015603237552568316)","(['Operational Eco-Efficiency'], 0.9811971783638)","('NON-ESG', 0.003034998429939151)","('NON-ESG', 0.0015603237552568316)"
Line 656,"Remind Employees are encouraged to remind each other  to work safely.
","('Employee_Health_And_Safety', 0.9105404615402222)","('Labor_Practices', 0.01880756951868534)","('Human_Rights_And_Community_Relations', 0.007905644364655018)","(['Operational Eco-Efficiency'], 0.9105404615402222)","('NON-ESG', 0.01880756951868534)","('NON-ESG', 0.007905644364655018)"
Line 657,"*TRIR = Total Recordable Incident Rate Industry Average provided by U.S. Bureau of Labor Statistics (BLS)  (https://www.bls.gov/iif/oshsum.htm )   2022 compared to 2021 BLS data for private industry >1000 employees; 2021 compared to 2020 BLS data for private industry >1000 employees; 2020 compared to 2019 BLS data for private industry >1000 employees; 2019 compared to 2018 BLS data for private industry >1000 employees; 2017 & 2018 compared to 2017 BLS Data for private industry >1000 employees; 2016 compared to 2016 BLS Data for private industry >1000 employeesYear Hologic TRIR* Industry Avg.
","('Labor_Practices', 0.7697277069091797)","('Employee_Health_And_Safety', 0.08722648024559021)","('Employee_Engagement_Inclusion_And_Diversity', 0.0445578433573246)","(['Labor Practice Indicators'], 0.7697277069091797)","('NON-ESG', 0.08722648024559021)","('NON-ESG', 0.0445578433573246)"
Line 658,"*TRIR = Total Recordable Incident Rate Industry Average provided by U.S. Bureau of Labor Statistics (BLS)  (https://www.bls.gov/iif/oshsum.htm )   2022 compared to 2021 BLS data for private industry >1000 employees; 2021 compared to 2020 BLS data for private industry >1000 employees; 2020 compared to 2019 BLS data for private industry >1000 employees; 2019 compared to 2018 BLS data for private industry >1000 employees; 2017 & 2018 compared to 2017 BLS Data for private industry >1000 employees; 2016 compared to 2016 BLS Data for private industry >1000 employeesYear Hologic TRIR* Industry Avg.
","('Supply_Chain_Management', 0.1803193837404251)","('Employee_Engagement_Inclusion_And_Diversity', 0.12339679896831512)","('Labor_Practices', 0.11065346747636795)","('NON-ESG', 0.1803193837404251)","('NON-ESG', 0.12339679896831512)","('NON-ESG', 0.11065346747636795)"
Line 659,"TRIR* 2016 1.6 3.2017 1.2 3.2018 1.0 3.2019 0.8 3.2020 0.9 2.2021 0.7 2.2022 0.8 2.82022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  53Regular Employee Training on Cybersecurity Issues All Hologic employees, contractors and consultants are  required to undergo annual cybersecurity training and education.
","('Data_Security', 0.7255948185920715)","('Business_Ethics', 0.05191163718700409)","('Systemic_Risk_Management', 0.033779192715883255)","(['Information Security/Cybersecurity & System Availability'], 0.7255948185920715)","('NON-ESG', 0.05191163718700409)","('NON-ESG', 0.033779192715883255)"
Line 660,"Training is communicated:  •  A t the onset for new employees, contractors and consultants.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5085100531578064)","('Labor_Practices', 0.1558236926794052)","('Employee_Health_And_Safety', 0.1358000934123993)","(['Human Capital Development'], 0.5085100531578064)","('NON-ESG', 0.1558236926794052)","('NON-ESG', 0.1358000934123993)"
Line 661,"• W hen required by information system changes.
","('Customer_Privacy', 0.6402645111083984)","('Data_Security', 0.23326821625232697)","('Director_Removal', 0.01209593191742897)","(['Privacy Protection'], 0.6402645111083984)","('NON-ESG', 0.23326821625232697)","('NON-ESG', 0.01209593191742897)"
Line 662,"•  O n an annual basis.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7916855216026306)","('Labor_Practices', 0.034114763140678406)","('GHG_Emissions', 0.017346858978271484)","(['Corporate Governance'], 0.7916855216026306)","('NON-ESG', 0.034114763140678406)","('NON-ESG', 0.017346858978271484)"
Line 663,"Examples of Employee Training: • E nabling and using secure authentication.
","('Data_Security', 0.9100768566131592)","('Business_Ethics', 0.019741438329219818)","('Customer_Privacy', 0.00951232947409153)","(['Information Security/Cybersecurity & System Availability'], 0.9100768566131592)","('NON-ESG', 0.019741438329219818)","('NON-ESG', 0.00951232947409153)"
Line 664,"•   I dentifying and reporting different forms of social  engineering attacks, such as phishing, phone scams   and impersonation calls.
","('Data_Security', 0.8189291954040527)","('Business_Ethics', 0.08374319970607758)","('Customer_Privacy', 0.012771762907505035)","(['Information Security/Cybersecurity & System Availability'], 0.8189291954040527)","('NON-ESG', 0.08374319970607758)","('NON-ESG', 0.012771762907505035)"
Line 665,"•   R ecognizing and reporting potential indicators of   insider threats.
","('Data_Security', 0.5053769946098328)","('Systemic_Risk_Management', 0.1707271933555603)","('Business_Ethics', 0.15154418349266052)","(['Information Security/Cybersecurity & System Availability'], 0.5053769946098328)","('NON-ESG', 0.1707271933555603)","('NON-ESG', 0.15154418349266052)"
Line 666,"•   I dentifying and properly storing, transferring, archiving and  destroying protected information based on the Information Protection Policy.
","('Data_Security', 0.5225779414176941)","('Customer_Privacy', 0.332974910736084)","('Waste_And_Hazardous_Materials_Management', 0.015422460623085499)","(['Information Security/Cybersecurity & System Availability'], 0.5225779414176941)","('NON-ESG', 0.332974910736084)","('NON-ESG', 0.015422460623085499)"
Line 667,"•   A wareness of unintentional data exposures, such as losing  mobile devices or emailing the wrong person due to autocomplete in email.
","('Data_Security', 0.7483828067779541)","('Customer_Privacy', 0.11255083978176117)","('Business_Ethics', 0.03276332467794418)","(['Information Security/Cybersecurity & System Availability'], 0.7483828067779541)","('NON-ESG', 0.11255083978176117)","('NON-ESG', 0.03276332467794418)"
Line 668,"Information Management System Aligned to Standards Data privacy protection is covered in our employee Code of  Conduct and is regularly reviewed by Hologic’s Internal Audit Department and external experts.
","('Data_Security', 0.8935785293579102)","('Customer_Privacy', 0.05095308646559715)","('Business_Ethics', 0.00602400628849864)","(['Information Security/Cybersecurity & System Availability'], 0.8935785293579102)","('NON-ESG', 0.05095308646559715)","('NON-ESG', 0.00602400628849864)"
Line 669,"We also conduct weekly internal vulnerability assessments  and engage with a third-party testing organization to support annual assessments.
","('Data_Security', 0.9341778755187988)","('Systemic_Risk_Management', 0.01223565824329853)","('Physical_Impacts_Of_Climate_Change', 0.004938064608722925)","(['Information Security/Cybersecurity & System Availability'], 0.9341778755187988)","('NON-ESG', 0.01223565824329853)","('NON-ESG', 0.004938064608722925)"
Line 670,"Internal policies that govern employee behavior and educate  employees on how to effectively manage risks include:  •  I nformation Protection Policy.
","('Business_Ethics', 0.6944344639778137)","('Employee_Health_And_Safety', 0.05559922009706497)","('Labor_Practices', 0.03782786428928375)","(['Business Ethics'], 0.6944344639778137)","('NON-ESG', 0.05559922009706497)","('NON-ESG', 0.03782786428928375)"
Line 671,"• I nformation Security Policy.
","('Data_Security', 0.9052503108978271)","('Customer_Privacy', 0.009765050373971462)","('Director_Removal', 0.009138897992670536)","(['Information Security/Cybersecurity & System Availability'], 0.9052503108978271)","('NON-ESG', 0.009765050373971462)","('NON-ESG', 0.009138897992670536)"
Line 672,"• I nformation Security Management Policy.
","('Data_Security', 0.8814985156059265)","('Management_Of_Legal_And_Regulatory_Framework', 0.011177115142345428)","('Systemic_Risk_Management', 0.010367317125201225)","(['Information Security/Cybersecurity & System Availability'], 0.8814985156059265)","('NON-ESG', 0.011177115142345428)","('NON-ESG', 0.010367317125201225)"
Line 673,"•  S ocial Media Policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5649731159210205)","('Competitive_Behavior', 0.1728356033563614)","('Human_Rights_And_Community_Relations', 0.044919732958078384)","(['Corporate Governance'], 0.5649731159210205)","('NON-ESG', 0.1728356033563614)","('NON-ESG', 0.044919732958078384)"
Line 674,"•  A cceptable Use Policy for Technology.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6557736992835999)","('Product_Design_And_Lifecycle_Management', 0.07168902456760406)","('Data_Security', 0.03150547295808792)","(['Corporate Governance'], 0.6557736992835999)","('NON-ESG', 0.07168902456760406)","('NON-ESG', 0.03150547295808792)"
Line 675,"• C ybersecurity Training, Education and Awareness Policy.
","('Data_Security', 0.16833825409412384)","('Product_Quality_And_Safety', 0.1419571340084076)","('Access_And_Affordability', 0.11187896132469177)","('NON-ESG', 0.16833825409412384)","('NON-ESG', 0.1419571340084076)","('NON-ESG', 0.11187896132469177)"
Line 676,"• I T Risk Management Policy.
","('Systemic_Risk_Management', 0.6713449954986572)","('Business_Model_Resilience', 0.06059928983449936)","('Management_Of_Legal_And_Regulatory_Framework', 0.05189080536365509)","(['Risk & Crisis Management'], 0.6713449954986572)","('NON-ESG', 0.06059928983449936)","('NON-ESG', 0.05189080536365509)"
Line 677,"Intellectual Property and Data Privacy Protection   Hologic is not currently certified to ISO 27001 standards,  however our cybersecurity program is aligned with the National Institute of Technology (NIST) Cybersecurity Framework (CSF).
","('Data_Security', 0.9577324390411377)","('Customer_Privacy', 0.004589049145579338)","('Business_Ethics', 0.004472631495445967)","(['Information Security/Cybersecurity & System Availability'], 0.9577324390411377)","('NON-ESG', 0.004589049145579338)","('NON-ESG', 0.004472631495445967)"
Line 678,"The NIST CSF offers a simple, yet effective construct that represents a set of cybersecurity practices and outcomes, as well as technical, operational and managerial security controls designed to support the five risk management functions: identify, protect, detect, respond and recover.
","('Data_Security', 0.9241406917572021)","('Systemic_Risk_Management', 0.01975223980844021)","('Business_Ethics', 0.008579742163419724)","(['Information Security/Cybersecurity & System Availability'], 0.9241406917572021)","('NON-ESG', 0.01975223980844021)","('NON-ESG', 0.008579742163419724)"
Line 679,"The Hologic Information Technology (IT)  Department is responsible for developing, maintaining and revising policies, procedures and standards that pertain to the security   and protection of Hologic’s information assets and services.
","('Data_Security', 0.9381619691848755)","('Customer_Privacy', 0.013542437925934792)","('Management_Of_Legal_And_Regulatory_Framework', 0.0045436169020831585)","(['Information Security/Cybersecurity & System Availability'], 0.9381619691848755)","('NON-ESG', 0.013542437925934792)","('NON-ESG', 0.0045436169020831585)"
Line 680,"The governance structure of   the IT organization is designed to ensure   that Hologic’s technology investments are aligned with strategic and cross-functional business objectives.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6184545755386353)","('Business_Model_Resilience', 0.09848019480705261)","('Director_Removal', 0.04741159453988075)","(['Corporate Governance'], 0.6184545755386353)","('NON-ESG', 0.09848019480705261)","('NON-ESG', 0.04741159453988075)"
Line 681,"The decision-making structure for Hologic’s information  security governance includes: Hologic’s Chief Information Officer, Chief Information Security Officer, IT senior leadership, IT investment council, IT risk management committee and IT project management office leadership committee.
","('Data_Security', 0.8870247602462769)","('Systemic_Risk_Management', 0.01444736123085022)","('Management_Of_Legal_And_Regulatory_Framework', 0.013200398534536362)","(['Information Security/Cybersecurity & System Availability'], 0.8870247602462769)","('NON-ESG', 0.01444736123085022)","('NON-ESG', 0.013200398534536362)"
Line 682,"Our IT department established the Hologic Information  Technology Risk Management framework to identify the risks associated with Hologic information resources and IT processes and operations and to mitigate those risks.
","('Systemic_Risk_Management', 0.8349838852882385)","('Data_Security', 0.046980857849121094)","('Physical_Impacts_Of_Climate_Change', 0.019116953015327454)","(['Risk & Crisis Management'], 0.8349838852882385)","('NON-ESG', 0.046980857849121094)","('NON-ESG', 0.019116953015327454)"
Line 683,"Information Security Governance The two main components of Hologic’s Information Security Governance are:  •    T he creation of decision-making mechanisms, whether  committees, review boards or written policies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5961973071098328)","('Data_Security', 0.1537739783525467)","('Business_Ethics', 0.08503728359937668)","(['Corporate Governance'], 0.5961973071098328)","('NON-ESG', 0.1537739783525467)","('NON-ESG', 0.08503728359937668)"
Line 684,"•   T he assignment of decision-making authority   and accountability.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4225598871707916)","('Business_Ethics', 0.3093762993812561)","('Director_Removal', 0.05703108757734299)","('NON-ESG', 0.4225598871707916)","('NON-ESG', 0.3093762993812561)","('NON-ESG', 0.05703108757734299)"
Line 685,"Information Security Governance Decision-Making StructureData Privacy Protection Cybersecurity Training2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  54Governance Policies and Procedures  Diversity Policy Our approach to diversity is supported internally through our  global Anti-Discrimination and Anti-Harassment Policy, which explicitly prohibits any form of discrimination, harassment, sexual harassment or retaliation.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9471513628959656)","('Employee_Health_And_Safety', 0.007944650948047638)","('Labor_Practices', 0.00588445458561182)","(['Human Capital Development'], 0.9471513628959656)","('NON-ESG', 0.007944650948047638)","('NON-ESG', 0.00588445458561182)"
Line 686,"Information Security Governance Decision-Making StructureData Privacy Protection Cybersecurity Training2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  54Governance Policies and Procedures  Diversity Policy Our approach to diversity is supported internally through our  global Anti-Discrimination and Anti-Harassment Policy, which explicitly prohibits any form of discrimination, harassment, sexual harassment or retaliation.
","('Business_Ethics', 0.3075479567050934)","('Employee_Health_And_Safety', 0.2055966556072235)","('Employee_Engagement_Inclusion_And_Diversity', 0.13156911730766296)","('NON-ESG', 0.3075479567050934)","('NON-ESG', 0.2055966556072235)","('NON-ESG', 0.13156911730766296)"
Line 687,"All employees are required  to undertake biannual anti-harassment and anti-discrimination training and to acknowledge and adhere to our Anti-Discrimination   and Anti-Harassment Policy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6988615393638611)","('Employee_Health_And_Safety', 0.06641851365566254)","('Labor_Practices', 0.05779964476823807)","(['Human Capital Development'], 0.6988615393638611)","('NON-ESG', 0.06641851365566254)","('NON-ESG', 0.05779964476823807)"
Line 688,"Hologic is committed to the principle that those we interact with, whether employee, vendor, partner or customer, will be treated with respect, dignity and professionalism.
","('Business_Ethics', 0.481189489364624)","('Human_Rights_And_Community_Relations', 0.14947010576725006)","('Labor_Practices', 0.07245923578739166)","('NON-ESG', 0.481189489364624)","('NON-ESG', 0.14947010576725006)","('NON-ESG', 0.07245923578739166)"
Line 689,"Human Rights and Fair Working Conditions Hologic supports fundamental human rights globally and is committed to a work environment that is free from human trafficking and slavery.
","('Human_Rights_And_Community_Relations', 0.8663890957832336)","('Labor_Practices', 0.04392770677804947)","('Employee_Health_And_Safety', 0.011131537146866322)","(['Community Relations'], 0.8663890957832336)","('NON-ESG', 0.04392770677804947)","('NON-ESG', 0.011131537146866322)"
Line 690,"We do not allow child or forced labor, nor do we knowingly work with business partners that employ children or forced labor.
","('Labor_Practices', 0.976699948310852)","('Director_Removal', 0.002291083103045821)","('Waste_And_Hazardous_Materials_Management', 0.0018424685113132)","(['Labor Practice Indicators'], 0.976699948310852)","('NON-ESG', 0.002291083103045821)","('NON-ESG', 0.0018424685113132)"
Line 691,"We also follow all applicable laws governing wages and working hours.
","('Labor_Practices', 0.9760836362838745)","('Director_Removal', 0.002158431801944971)","('Waste_And_Hazardous_Materials_Management', 0.002103823237121105)","(['Labor Practice Indicators'], 0.9760836362838745)","('NON-ESG', 0.002158431801944971)","('NON-ESG', 0.002103823237121105)"
Line 692,"For more information, please review Hologic’s International Modern Slavery Policy .Our Code of Conduct  outlines Hologic’s commitment to integrity and ethical conduct.
","('Business_Ethics', 0.9634267687797546)","('Management_Of_Legal_And_Regulatory_Framework', 0.004481388721615076)","('Competitive_Behavior', 0.0036349166184663773)","(['Business Ethics'], 0.9634267687797546)","('NON-ESG', 0.004481388721615076)","('NON-ESG', 0.0036349166184663773)"
Line 693,"All employees must  read and understand the Code of Conduct, as well as our other policies and procedures.
","('Business_Ethics', 0.5416320562362671)","('Management_Of_Legal_And_Regulatory_Framework', 0.18242961168289185)","('Labor_Practices', 0.04546032473444939)","(['Business Ethics'], 0.5416320562362671)","('NON-ESG', 0.18242961168289185)","('NON-ESG', 0.04546032473444939)"
Line 694,"They must strive   to uphold the principles of integrity and ethics in our written standards.
","('Business_Ethics', 0.9661855101585388)","('Customer_Privacy', 0.0028585048858076334)","('Competitive_Behavior', 0.0025207470171153545)","(['Business Ethics'], 0.9661855101585388)","('NON-ESG', 0.0028585048858076334)","('NON-ESG', 0.0025207470171153545)"
Line 695,"Antitrust and Competition Laws Compliance   Hologic requires all employees to comply with all applicable antitrust laws.
","('Business_Ethics', 0.726463258266449)","('Competitive_Behavior', 0.15337194502353668)","('Management_Of_Legal_And_Regulatory_Framework', 0.044027380645275116)","(['Business Ethics'], 0.726463258266449)","('NON-ESG', 0.15337194502353668)","('NON-ESG', 0.044027380645275116)"
Line 696,"We are committed to prohibiting any actions that result in unfair methods of competition or restraint of trade.
","('Competitive_Behavior', 0.9522407650947571)","('Business_Ethics', 0.009836029261350632)","('Management_Of_Legal_And_Regulatory_Framework', 0.005575955845415592)","(['Business Ethics'], 0.9522407650947571)","('NON-ESG', 0.009836029261350632)","('NON-ESG', 0.005575955845415592)"
Line 697,"Formal Grievance Escalation Process We encourage employees to feel comfortable approaching their supervisor or management in instances where they believe violations of policies or standards have occurred.
","('Business_Ethics', 0.8582389950752258)","('Management_Of_Legal_And_Regulatory_Framework', 0.02915455400943756)","('Labor_Practices', 0.018037449568510056)","(['Business Ethics'], 0.8582389950752258)","('NON-ESG', 0.02915455400943756)","('NON-ESG', 0.018037449568510056)"
Line 698,"However, in situations where employees prefer to place an anonymous grievance in confidence, they are encouraged  to use our hotline provider, which is hosted by a third party.
","('Business_Ethics', 0.733534038066864)","('Management_Of_Legal_And_Regulatory_Framework', 0.09485355764627457)","('Competitive_Behavior', 0.02209862880408764)","(['Business Ethics'], 0.733534038066864)","('NON-ESG', 0.09485355764627457)","('NON-ESG', 0.02209862880408764)"
Line 699,"The information provided is sent to Hologic on a confidential and anonymous basis at the discretion of the employee.Honesty.
","('Customer_Privacy', 0.7444681525230408)","('Business_Ethics', 0.10147711634635925)","('Data_Security', 0.044045161455869675)","(['Privacy Protection'], 0.7444681525230408)","('NON-ESG', 0.10147711634635925)","('NON-ESG', 0.044045161455869675)"
Line 700,"Being truthful and upfront with  co-workers, customers, communities,  suppliers, distributors and shareholders.
","('Labor_Practices', 0.7616341710090637)","('Supply_Chain_Management', 0.053905777633190155)","('Human_Rights_And_Community_Relations', 0.032985005527734756)","(['Labor Practice Indicators'], 0.7616341710090637)","('NON-ESG', 0.053905777633190155)","('NON-ESG', 0.032985005527734756)"
Line 701,"Integrity.
","('Business_Ethics', 0.9331973195075989)","('Data_Security', 0.007701708469539881)","('Customer_Privacy', 0.005591574124991894)","(['Business Ethics'], 0.9331973195075989)","('NON-ESG', 0.007701708469539881)","('NON-ESG', 0.005591574124991894)"
Line 702,"Delivering what Hologic  promises and standing up for what is right.
","('Human_Rights_And_Community_Relations', 0.18100681900978088)","('Business_Model_Resilience', 0.11112183332443237)","('Business_Ethics', 0.10718917846679688)","('NON-ESG', 0.18100681900978088)","('NON-ESG', 0.11112183332443237)","('NON-ESG', 0.10718917846679688)"
Line 703,"Respect.
","('Business_Ethics', 0.3709418475627899)","('Customer_Privacy', 0.08224555850028992)","('Human_Rights_And_Community_Relations', 0.0785180851817131)","('NON-ESG', 0.3709418475627899)","('NON-ESG', 0.08224555850028992)","('NON-ESG', 0.0785180851817131)"
Line 704,"Treating each other with fairness  and dignity and appreciating the unique  abilities and strengths of each individual, as well as the advantages of diversity.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8356465697288513)","('Human_Rights_And_Community_Relations', 0.02707424946129322)","('Competitive_Behavior', 0.026609813794493675)","(['Human Capital Development'], 0.8356465697288513)","('NON-ESG', 0.02707424946129322)","('NON-ESG', 0.026609813794493675)"
Line 705,"Trust.
","('Customer_Privacy', 0.20819707214832306)","('Data_Security', 0.1725788116455078)","('Business_Ethics', 0.13219000399112701)","('NON-ESG', 0.20819707214832306)","('NON-ESG', 0.1725788116455078)","('NON-ESG', 0.13219000399112701)"
Line 706,"Building team spirit and confidence  by communicating openly and honestly.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2597852647304535)","('Human_Rights_And_Community_Relations', 0.22502000629901886)","('Employee_Health_And_Safety', 0.0769457072019577)","('NON-ESG', 0.2597852647304535)","('NON-ESG', 0.22502000629901886)","('NON-ESG', 0.0769457072019577)"
Line 707,"Citizenship.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6397018432617188)","('Human_Rights_And_Community_Relations', 0.05851714685559273)","('Customer_Privacy', 0.05569850653409958)","(['Human Capital Development'], 0.6397018432617188)","('NON-ESG', 0.05851714685559273)","('NON-ESG', 0.05569850653409958)"
Line 708,"Obeying the laws  of all the jurisdictions where the  company does business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9370033740997314)","('Business_Ethics', 0.00911344587802887)","('Competitive_Behavior', 0.007840671576559544)","(['Corporate Governance'], 0.9370033740997314)","('NON-ESG', 0.00911344587802887)","('NON-ESG', 0.007840671576559544)"
Line 709,"Responsibility.
","('Human_Rights_And_Community_Relations', 0.6312938928604126)","('Customer_Privacy', 0.04350808635354042)","('Director_Removal', 0.03311646729707718)","(['Community Relations'], 0.6312938928604126)","('NON-ESG', 0.04350808635354042)","('NON-ESG', 0.03311646729707718)"
Line 710,"Taking the initiative  to speak up and report concerns  regarding ethical conduct and seeking reliable guidance in cases of doubt.Hologic Employee Shared Values2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  55Governance Policies and Procedures (continued) Ethics in Sales and Marketing We prioritize integrity as a fundamental aspect of our sales and marketing practices.
","('Business_Ethics', 0.9676415920257568)","('Product_Quality_And_Safety', 0.0028876664582639933)","('Competitive_Behavior', 0.0027560165617614985)","(['Business Ethics'], 0.9676415920257568)","('NON-ESG', 0.0028876664582639933)","('NON-ESG', 0.0027560165617614985)"
Line 711,"Our  products are tightly regulated by government agencies, health ministries and regulatory authorities worldwide.
","('Product_Quality_And_Safety', 0.2431173026561737)","('Selling_Practices_And_Product_Labeling', 0.1874462068080902)","('Management_Of_Legal_And_Regulatory_Framework', 0.18547257781028748)","('NON-ESG', 0.2431173026561737)","('NON-ESG', 0.1874462068080902)","('NON-ESG', 0.18547257781028748)"
Line 712,"Hologic is committed to conducting its business ethically and in compliance with all applicable laws and regulations, including the U.S. Foreign Corrupt Practices Act and other laws that prohibit improper payments to obtain a business advantage.
","('Business_Ethics', 0.9742164015769958)","('Management_Of_Legal_And_Regulatory_Framework', 0.003253593808040023)","('Competitive_Behavior', 0.0025771816726773977)","(['Business Ethics'], 0.9742164015769958)","('NON-ESG', 0.003253593808040023)","('NON-ESG', 0.0025771816726773977)"
Line 713,"In addition, as a medical products manufacturer, Hologic has the added responsibility of ensuring that representations regarding our products are consistent with the approved label.
","('Selling_Practices_And_Product_Labeling', 0.7439257502555847)","('Product_Quality_And_Safety', 0.06627651304006577)","('Product_Design_And_Lifecycle_Management', 0.059061504900455475)","(['Marketing Practices'], 0.7439257502555847)","('NON-ESG', 0.06627651304006577)","('NON-ESG', 0.059061504900455475)"
Line 714,"Our commitment to ethics is part of everything we do, and we take the following steps to ensure our employees understand how to achieve business objectives with transparency, honesty and integrity.
","('Business_Ethics', 0.9667393565177917)","('Employee_Engagement_Inclusion_And_Diversity', 0.0024461010470986366)","('Customer_Privacy', 0.002433181507512927)","(['Business Ethics'], 0.9667393565177917)","('NON-ESG', 0.0024461010470986366)","('NON-ESG', 0.002433181507512927)"
Line 715,"Ethical Interactions With Healthcare Professionals Strict regulations govern our interactions with healthcare professionals, which include physicians, nurses and hospital or medical office administrators.
","('Business_Ethics', 0.924781084060669)","('Management_Of_Legal_And_Regulatory_Framework', 0.018580077216029167)","('Competitive_Behavior', 0.0065923891961574554)","(['Business Ethics'], 0.924781084060669)","('NON-ESG', 0.018580077216029167)","('NON-ESG', 0.0065923891961574554)"
Line 716,"We ensure our employees are aware of the potential compliance risks inherent in these interactions.
","('Business_Ethics', 0.7544700503349304)","('Management_Of_Legal_And_Regulatory_Framework', 0.11446540802717209)","('Product_Quality_And_Safety', 0.019102390855550766)","(['Business Ethics'], 0.7544700503349304)","('NON-ESG', 0.11446540802717209)","('NON-ESG', 0.019102390855550766)"
Line 717,"Our policies and robust employee training programs ensure that any interaction Hologic employees have with a healthcare professional serves an appropriate and ethical business purpose, does not interfere with the healthcare professional’s independent medical judgment and does not violate local law or regulation.
","('Business_Ethics', 0.3664180636405945)","('Labor_Practices', 0.19301441311836243)","('Management_Of_Legal_And_Regulatory_Framework', 0.11811806261539459)","('NON-ESG', 0.3664180636405945)","('NON-ESG', 0.19301441311836243)","('NON-ESG', 0.11811806261539459)"
Line 718,"We disclose payments and transfers of value made to physicians and other healthcare entities in every state and country where disclosure is required by law.
","('Business_Ethics', 0.6706842184066772)","('Management_Of_Legal_And_Regulatory_Framework', 0.09256315231323242)","('Customer_Privacy', 0.05688682571053505)","(['Business Ethics'], 0.6706842184066772)","('NON-ESG', 0.09256315231323242)","('NON-ESG', 0.05688682571053505)"
Line 719,"In the United States, this information is published on the Centers for Medicare and Medicaid Services Open Payments site.
","('Management_Of_Legal_And_Regulatory_Framework', 0.34371015429496765)","('Access_And_Affordability', 0.27945131063461304)","('Systemic_Risk_Management', 0.057881955057382584)","('NON-ESG', 0.34371015429496765)","('NON-ESG', 0.27945131063461304)","('NON-ESG', 0.057881955057382584)"
Line 720,"Our internal policies include: •   M edical Education and Healthcare Professional Interaction Policy.
","('Access_And_Affordability', 0.5488726496696472)","('Management_Of_Legal_And_Regulatory_Framework', 0.09288042038679123)","('Employee_Engagement_Inclusion_And_Diversity', 0.07123113423585892)","(['Health Outcome Contribution'], 0.5488726496696472)","('NON-ESG', 0.09288042038679123)","('NON-ESG', 0.07123113423585892)"
Line 721,"•   S tate Healthcare Professional Interactions Policy.
","('Human_Rights_And_Community_Relations', 0.12793873250484467)","('Management_Of_Legal_And_Regulatory_Framework', 0.12048068642616272)","('Access_And_Affordability', 0.11899109184741974)","('NON-ESG', 0.12793873250484467)","('NON-ESG', 0.12048068642616272)","('NON-ESG', 0.11899109184741974)"
Line 722,"•   G ifts and Other Incentives Policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9421223998069763)","('Competitive_Behavior', 0.006788279861211777)","('Business_Ethics', 0.005765771958976984)","(['Corporate Governance'], 0.9421223998069763)","('NON-ESG', 0.006788279861211777)","('NON-ESG', 0.005765771958976984)"
Line 723,"•   H ealthcare Anti-Inducement and Anti-Kickback Policy.
","('Business_Ethics', 0.6340351700782776)","('Management_Of_Legal_And_Regulatory_Framework', 0.17282696068286896)","('Competitive_Behavior', 0.06800851970911026)","(['Business Ethics'], 0.6340351700782776)","('NON-ESG', 0.17282696068286896)","('NON-ESG', 0.06800851970911026)"
Line 724,"•   U .S.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2931046485900879)","('GHG_Emissions', 0.1579560786485672)","('Competitive_Behavior', 0.0635477602481842)","('NON-ESG', 0.2931046485900879)","('NON-ESG', 0.1579560786485672)","('NON-ESG', 0.0635477602481842)"
Line 725,"Foreign Corrupt Practices Act and Other International Bribery Laws Policy.
","('Business_Ethics', 0.9724823236465454)","('Management_Of_Legal_And_Regulatory_Framework', 0.003499060170724988)","('Competitive_Behavior', 0.0023501943796873093)","(['Business Ethics'], 0.9724823236465454)","('NON-ESG', 0.003499060170724988)","('NON-ESG', 0.0023501943796873093)"
Line 726,"•   S unshine Act Policy .
","('Management_Of_Legal_And_Regulatory_Framework', 0.9014132022857666)","('Human_Rights_And_Community_Relations', 0.01216297410428524)","('Business_Ethics', 0.009325983002781868)","(['Corporate Governance'], 0.9014132022857666)","('NON-ESG', 0.01216297410428524)","('NON-ESG', 0.009325983002781868)"
Line 727,"Other Policies and Commitments:  AdvaMed Code of Ethics Hologic is a proud supporter of the ideals and values articulated by AdvaMed and a signatory   to the 2022 AdvaMed Code of Ethics .
","('Business_Ethics', 0.9424117803573608)","('Management_Of_Legal_And_Regulatory_Framework', 0.01607905700802803)","('Director_Removal', 0.005050759296864271)","(['Business Ethics'], 0.9424117803573608)","('NON-ESG', 0.01607905700802803)","('NON-ESG', 0.005050759296864271)"
Line 728,"Conflict Minerals Hologic supports the goal of ending human rights violations, violence and harmful environmental impacts in the covered countries and around the globe.
","('Human_Rights_And_Community_Relations', 0.9442529082298279)","('Critical_Incident_Risk_Management', 0.004206430166959763)","('Labor_Practices', 0.003996807616204023)","(['Community Relations'], 0.9442529082298279)","('NON-ESG', 0.004206430166959763)","('NON-ESG', 0.003996807616204023)"
Line 729,"Management Oversight Our compliance team has responsibility for monitoring and following up on matters to senior management, as well as to the Board of Directors.
","('Director_Removal', 0.6740965247154236)","('Management_Of_Legal_And_Regulatory_Framework', 0.08573751896619797)","('Business_Ethics', 0.03920050710439682)","(['Anti-Crime Policy & Measures'], 0.6740965247154236)","('NON-ESG', 0.08573751896619797)","('NON-ESG', 0.03920050710439682)"
Line 730,"The Hologic Corporate Quality Manual  covers management responsibility, which includes our commitment to ensure the suitability, adequacy and effectiveness of the QMS.
","('Business_Ethics', 0.339089572429657)","('Business_Model_Resilience', 0.1492016613483429)","('Systemic_Risk_Management', 0.12684088945388794)","('NON-ESG', 0.339089572429657)","('NON-ESG', 0.1492016613483429)","('NON-ESG', 0.12684088945388794)"
Line 731,"These processes ensure compliance of all marketing materials and product claims.
","('Selling_Practices_And_Product_Labeling', 0.7218626141548157)","('Product_Quality_And_Safety', 0.09250729531049728)","('Product_Design_And_Lifecycle_Management', 0.046534400433301926)","(['Marketing Practices'], 0.7218626141548157)","('NON-ESG', 0.09250729531049728)","('NON-ESG', 0.046534400433301926)"
Line 732,"Risk Assessments Hologic uses a risk-based approach, as per ISO 14971, for product risk management and these risk assessments are governed by our risk management procedure.
","('Systemic_Risk_Management', 0.8747515082359314)","('Business_Model_Resilience', 0.01948324590921402)","('Physical_Impacts_Of_Climate_Change', 0.016030604019761086)","(['Risk & Crisis Management'], 0.8747515082359314)","('NON-ESG', 0.01948324590921402)","('NON-ESG', 0.016030604019761086)"
Line 733,"This risk-based approach applies control to processes related to the oversight of marketing materials and product claims.
","('Selling_Practices_And_Product_Labeling', 0.682715892791748)","('Product_Design_And_Lifecycle_Management', 0.11024396121501923)","('Product_Quality_And_Safety', 0.04585719481110573)","(['Marketing Practices'], 0.682715892791748)","('NON-ESG', 0.11024396121501923)","('NON-ESG', 0.04585719481110573)"
Line 734,"Compliance Monitoring and External Audits Hologic conducts internal audits using a risk-based approach at planned intervals to determine whether the QMS, which covers ethical marketing materials, is functioning as required.
","('Business_Ethics', 0.9390631318092346)","('Management_Of_Legal_And_Regulatory_Framework', 0.013923552818596363)","('Product_Quality_And_Safety', 0.008640541695058346)","(['Business Ethics'], 0.9390631318092346)","('NON-ESG', 0.013923552818596363)","('NON-ESG', 0.008640541695058346)"
Line 735,"Additionally, announced and unannounced external audits are conducted by third parties, such  as the FDA and Notified Body, in accordance with their individual regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9279536008834839)","('Business_Ethics', 0.011760675348341465)","('Product_Quality_And_Safety', 0.007763071451336145)","(['Corporate Governance'], 0.9279536008834839)","('NON-ESG', 0.011760675348341465)","('NON-ESG', 0.007763071451336145)"
Line 736,"Reporting of Violations and Incident Investigations/Corrective Actions Our Hologic corporate field action procedure governs the process for managing field actions that apply to all products manufactured by or for Hologic.
","('Product_Quality_And_Safety', 0.6330821514129639)","('Business_Ethics', 0.08106283843517303)","('Selling_Practices_And_Product_Labeling', 0.07986447215080261)","(['Product Quality & Recall Management'], 0.6330821514129639)","('NON-ESG', 0.08106283843517303)","('NON-ESG', 0.07986447215080261)"
Line 737,"Hologic’s Corrective and Preventive Action Procedure This procedure provides the minimum requirements for initiating, investigating and completing corrective and preventive actions.
","('Critical_Incident_Risk_Management', 0.40541520714759827)","('Human_Rights_And_Community_Relations', 0.16695435345172882)","('Management_Of_Legal_And_Regulatory_Framework', 0.1149907261133194)","('NON-ESG', 0.40541520714759827)","('NON-ESG', 0.16695435345172882)","('NON-ESG', 0.1149907261133194)"
Line 738,"The corrective and preventive action system is intended to identify actions needed to correct and prevent recurrence of nonconforming product or other quality problems.
","('Product_Design_And_Lifecycle_Management', 0.7264567017555237)","('Product_Quality_And_Safety', 0.15741322934627533)","('Selling_Practices_And_Product_Labeling', 0.02156517468392849)","(['Product Stewardship'], 0.7264567017555237)","('NON-ESG', 0.15741322934627533)","('NON-ESG', 0.02156517468392849)"
Line 739,"2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  56Topic SASB Code SASB Metrics Response Affordability  & PricingHC-MS-240a.1Ratio of weighted average rate of net price increases to the  annual increase in the U.S. Consumer Price IndexHologic operates primarily in mature markets, with stable pricing.
","('Competitive_Behavior', 0.8645207285881042)","('Business_Model_Resilience', 0.018376560881733894)","('Systemic_Risk_Management', 0.015989309176802635)","(['Business Ethics'], 0.8645207285881042)","('NON-ESG', 0.018376560881733894)","('NON-ESG', 0.015989309176802635)"
Line 740,"This disclosure is not relevant to  our business and therefore we do not consider this information to be material to our investors or  external stakeholders.
","('Business_Model_Resilience', 0.2722032070159912)","('Management_Of_Legal_And_Regulatory_Framework', 0.16941441595554352)","('Customer_Privacy', 0.10858891904354095)","('NON-ESG', 0.2722032070159912)","('NON-ESG', 0.16941441595554352)","('NON-ESG', 0.10858891904354095)"
Line 741,"HC-MS-240a.2Description of how price information for each product is disclosed to customersHologic competes vigorously, fairly and ethically.
","('Selling_Practices_And_Product_Labeling', 0.616974949836731)","('Product_Quality_And_Safety', 0.060441870242357254)","('Customer_Welfare', 0.05508393421769142)","(['Marketing Practices'], 0.616974949836731)","('NON-ESG', 0.060441870242357254)","('NON-ESG', 0.05508393421769142)"
Line 742,"This includes providing transparent and accurate pricing  to our customers, and not discussing the agreed upon terms or pricing with any external party, including  other customers.
","('Competitive_Behavior', 0.8026046752929688)","('Management_Of_Legal_And_Regulatory_Framework', 0.05484999343752861)","('Business_Ethics', 0.020801706239581108)","(['Business Ethics'], 0.8026046752929688)","('NON-ESG', 0.05484999343752861)","('NON-ESG', 0.020801706239581108)"
Line 743,"Product SafetyHC-MS-250a.1 Number of recalls issues, total units recalledMetric is summarized in the Quality Management Systems section on page 51.
","('Product_Quality_And_Safety', 0.8793786764144897)","('Employee_Health_And_Safety', 0.02430489845573902)","('Selling_Practices_And_Product_Labeling', 0.01011781208217144)","(['Product Quality & Recall Management'], 0.8793786764144897)","('NON-ESG', 0.02430489845573902)","('NON-ESG', 0.01011781208217144)"
Line 744,"There were three (3) recalls involving Hologic products reported in FDA’s Medical Device Recalls database for fiscal 2022: •  Panther Fusion® Extraction Reagent-X [ID-Z-0750-2022].•  Panther Fusion® GBS [ID-Z-0877-2022].•  BioZorb® 3D Bioabsorbable Marker [ID-Z1858-2022].
","('Product_Quality_And_Safety', 0.6079739928245544)","('Selling_Practices_And_Product_Labeling', 0.07326290756464005)","('Product_Design_And_Lifecycle_Management', 0.057423289865255356)","(['Product Quality & Recall Management'], 0.6079739928245544)","('NON-ESG', 0.07326290756464005)","('NON-ESG', 0.057423289865255356)"
Line 745,"HC-MS-250a.2List of product listed in FDA's MedWatch Safety Alerts for   Human Medical Products DatabaseThere are zero (0) Hologic products listed in FDA’s MedWatch Safety Alerts database for fiscal 2022 to date.
","('Product_Quality_And_Safety', 0.8917378187179565)","('Selling_Practices_And_Product_Labeling', 0.01945991814136505)","('Product_Design_And_Lifecycle_Management', 0.009403585456311703)","(['Product Quality & Recall Management'], 0.8917378187179565)","('NON-ESG', 0.01945991814136505)","('NON-ESG', 0.009403585456311703)"
Line 746,"This is reported in the Quality Management Systems section.
","('Product_Quality_And_Safety', 0.2547348141670227)","('Supply_Chain_Management', 0.14377228915691376)","('Product_Design_And_Lifecycle_Management', 0.06369621306657791)","('NON-ESG', 0.2547348141670227)","('NON-ESG', 0.14377228915691376)","('NON-ESG', 0.06369621306657791)"
Line 747,"HC-MS-250a.3Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device ExperienceMetric is reported in the Quality Management Systems section.
","('Employee_Health_And_Safety', 0.8141415119171143)","('Product_Quality_And_Safety', 0.06524797528982162)","('Product_Design_And_Lifecycle_Management', 0.03645350784063339)","(['Operational Eco-Efficiency'], 0.8141415119171143)","('NON-ESG', 0.06524797528982162)","('NON-ESG', 0.03645350784063339)"
Line 748,"We reported one fatality for the fiscal year related to Hologic products: •  MyoSure® Lite Tissue Removal Device [ID-1222780-2022-00176].It was not possible to confirm a relationship between the device and the issue reported and a definitive root  cause for the reported event could not be determined.
","('Employee_Health_And_Safety', 0.9647600650787354)","('Critical_Incident_Risk_Management', 0.010724280029535294)","('Employee_Engagement_Inclusion_And_Diversity', 0.0020230982918292284)","(['Operational Eco-Efficiency'], 0.9647600650787354)","('NON-ESG', 0.010724280029535294)","('NON-ESG', 0.0020230982918292284)"
Line 749,"HC-MS-250a.4Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by typeHologic has not been a subject of any enforcement actions (e.g., untitled letters, warning letters, seizures, injunctions or criminal prosecution) in fiscal 2022 for any of the divisions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7997379302978516)","('Business_Ethics', 0.09032381325960159)","('Competitive_Behavior', 0.016292596235871315)","(['Corporate Governance'], 0.7997379302978516)","('NON-ESG', 0.09032381325960159)","('NON-ESG', 0.016292596235871315)"
Line 750,"This information is reported in the Quality Management Systems section on page 51.
","('Product_Quality_And_Safety', 0.4188666045665741)","('Management_Of_Legal_And_Regulatory_Framework', 0.10704712569713593)","('Business_Ethics', 0.06755617260932922)","('NON-ESG', 0.4188666045665741)","('NON-ESG', 0.10704712569713593)","('NON-ESG', 0.06755617260932922)"
Line 751,"Ethical MarketingHC-MS-270a.1Total amount of monetary losses as a result of legal proceedings associated with false marketing claimsThere have been no monetary losses as a result of legal proceedings associated with false marketing claims.
","('Business_Ethics', 0.5642441511154175)","('Competitive_Behavior', 0.11171264946460724)","('Selling_Practices_And_Product_Labeling', 0.08976814895868301)","(['Business Ethics'], 0.5642441511154175)","('NON-ESG', 0.11171264946460724)","('NON-ESG', 0.08976814895868301)"
Line 752,"This is also reported in the ethical marketing summary within our Governance, Policies and Procedures section on page 54.
","('Business_Ethics', 0.8626604676246643)","('Management_Of_Legal_And_Regulatory_Framework', 0.029093410819768906)","('Product_Quality_And_Safety', 0.020857807248830795)","(['Business Ethics'], 0.8626604676246643)","('NON-ESG', 0.029093410819768906)","('NON-ESG', 0.020857807248830795)"
Line 753,"HC-MS-270a.2Description of code of ethics governing of off-label use  of productsReported in the ethical marketing summary within our Governance, Policies and Procedures section  on page 54.Reporting Frameworks Hologic’s sustainability reporting is aligned with the Sustainability Accounting Standard Board (SASB) reporting standards.
","('Selling_Practices_And_Product_Labeling', 0.4605695307254791)","('Product_Quality_And_Safety', 0.16099263727664948)","('Business_Ethics', 0.08019522577524185)","('NON-ESG', 0.4605695307254791)","('NON-ESG', 0.16099263727664948)","('NON-ESG', 0.08019522577524185)"
Line 754,"In 2022, we expanded   our sustainability reporting to include adhering to the Task Force on Climate-Related Financial Disclosures (TCFD) framework for the first time.
","('Physical_Impacts_Of_Climate_Change', 0.8780055642127991)","('Business_Model_Resilience', 0.039992351084947586)","('GHG_Emissions', 0.016796952113509178)","(['Climate Change'], 0.8780055642127991)","('NON-ESG', 0.039992351084947586)","('NON-ESG', 0.016796952113509178)"
Line 755,"Sustainability Accounting Standards (SASB)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  57Topic SASB Code SASB Metrics Response Product Design  & Lifecycle ManagementHC-MS-410a.1Discussion of process to assess and manage environmental  and human health considerations associated with chemicals in products, and meet demand for sustainable productsReported in the Good Governance Workplace Health & Safety section on page 52.
","('Product_Design_And_Lifecycle_Management', 0.9482163190841675)","('Product_Quality_And_Safety', 0.012777002528309822)","('Selling_Practices_And_Product_Labeling', 0.004065345041453838)","(['Product Stewardship'], 0.9482163190841675)","('NON-ESG', 0.012777002528309822)","('NON-ESG', 0.004065345041453838)"
Line 756,"Sustainability Accounting Standards (SASB)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  57Topic SASB Code SASB Metrics Response Product Design  & Lifecycle ManagementHC-MS-410a.1Discussion of process to assess and manage environmental  and human health considerations associated with chemicals in products, and meet demand for sustainable productsReported in the Good Governance Workplace Health & Safety section on page 52.
","('Product_Quality_And_Safety', 0.46721920371055603)","('Employee_Health_And_Safety', 0.3556545674800873)","('Product_Design_And_Lifecycle_Management', 0.020000772550702095)","('NON-ESG', 0.46721920371055603)","('NON-ESG', 0.3556545674800873)","('NON-ESG', 0.020000772550702095)"
Line 757,"A chemical compliance process is in place following corporate procedures for REACH CORP-00147 and corporate procedure for  RoHS Compliance CORP-00146, EUMDR regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8811667561531067)","('Business_Ethics', 0.06003011018037796)","('Product_Quality_And_Safety', 0.006298597436398268)","(['Corporate Governance'], 0.8811667561531067)","('NON-ESG', 0.06003011018037796)","('NON-ESG', 0.006298597436398268)"
Line 758,"There is a corporate procedure on hazardous substances (CMR/EDs) CORP-00425.
","('Waste_And_Hazardous_Materials_Management', 0.9601321220397949)","('Air_Quality', 0.0059178173542022705)","('Selling_Practices_And_Product_Labeling', 0.0029420540668070316)","(['Operational Eco-Efficiency'], 0.9601321220397949)","('NON-ESG', 0.0059178173542022705)","('NON-ESG', 0.0029420540668070316)"
Line 759,"We work with a third party responsible for the collection of EU REACH, EU RoHS, EU MDR/IVDR Hazardous Substances and California Proposition 65 information on Hologic products.
","('Waste_And_Hazardous_Materials_Management', 0.7509623765945435)","('Product_Quality_And_Safety', 0.0695270523428917)","('Selling_Practices_And_Product_Labeling', 0.04646334797143936)","(['Operational Eco-Efficiency'], 0.7509623765945435)","('NON-ESG', 0.0695270523428917)","('NON-ESG', 0.04646334797143936)"
Line 760,"We also report to the EU WFD (SCIP) SVHCs above threshold.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6056979298591614)","('GHG_Emissions', 0.07047683745622635)","('Access_And_Affordability', 0.06584731489419937)","(['Corporate Governance'], 0.6056979298591614)","('NON-ESG', 0.07047683745622635)","('NON-ESG', 0.06584731489419937)"
Line 761,"We continue a process improvement project, with the goal of expanding oversight on the identification of hazardous substances and to ensure our compliance with California Prop 65 and global environmental regulations.
","('Waste_And_Hazardous_Materials_Management', 0.8521987199783325)","('Product_Quality_And_Safety', 0.022268924862146378)","('Air_Quality', 0.02019217424094677)","(['Operational Eco-Efficiency'], 0.8521987199783325)","('NON-ESG', 0.022268924862146378)","('NON-ESG', 0.02019217424094677)"
Line 762,"HC-MS-410a.2Total amount of products accepted for take-back and reused, recycled, or donatedReported in the Good Governance Workplace Health & Safety section on page 52, quantified below: •  Breast & Skeletal Health: remanufactured/refurbished (3,985), returns (9,732).•  Molecular Diagnostics: remanufactured/refurbished (121), returns (198).•  GYN Surgical: remanufactured/refurbished (1,072), returns (1,275).
","('Product_Design_And_Lifecycle_Management', 0.6588717103004456)","('Product_Quality_And_Safety', 0.20647315680980682)","('Employee_Health_And_Safety', 0.02582699991762638)","(['Product Stewardship'], 0.6588717103004456)","('NON-ESG', 0.20647315680980682)","('NON-ESG', 0.02582699991762638)"
Line 763,"Supply Chain  ManagementHC-MS-430a.1Percentage of entity's facilities and Tier 1 supplier's  facilities participating in third-party audit programs for manufacturing and product qualityReported in the Supply Chain Management and Supply Chain Risk Management Supplier compliance and classifications reported on pages 49-50.
","('Supply_Chain_Management', 0.9498513340950012)","('Product_Design_And_Lifecycle_Management', 0.0046825893223285675)","('Labor_Practices', 0.0040978980250656605)","(['Supply Chain Management'], 0.9498513340950012)","('NON-ESG', 0.0046825893223285675)","('NON-ESG', 0.0040978980250656605)"
Line 764,"HC-MS-430a.2Description of efforts to maintain traceability within  the supply chainReported in the Supply Chain Management and Supply Chain Risk Management sections on pages 49-50.
","('Supply_Chain_Management', 0.953532338142395)","('Product_Design_And_Lifecycle_Management', 0.003401450114324689)","('Physical_Impacts_Of_Climate_Change', 0.00336585589684546)","(['Supply Chain Management'], 0.953532338142395)","('NON-ESG', 0.003401450114324689)","('NON-ESG', 0.00336585589684546)"
Line 765,"HC-MS-430a.3Description of the management of risks associated  with use of critical materialsReported in the Supply Chain Management and Supply Chain Risk Management sections on pages 49-50.
","('Supply_Chain_Management', 0.9513891339302063)","('Waste_And_Hazardous_Materials_Management', 0.004332326352596283)","('Physical_Impacts_Of_Climate_Change', 0.003941061440855265)","(['Supply Chain Management'], 0.9513891339302063)","('NON-ESG', 0.004332326352596283)","('NON-ESG', 0.003941061440855265)"
Line 766,"Business EthicsHC-MS-510a.1Total amount of monetary losses as a result of legal proceedings associated with bribery or corruptionThere have been no monetary losses as a result of legal proceedings associated with bribery or corruption.
","('Business_Ethics', 0.9735112190246582)","('Management_Of_Legal_And_Regulatory_Framework', 0.0021381338592618704)","('Product_Quality_And_Safety', 0.002067823428660631)","(['Business Ethics'], 0.9735112190246582)","('NON-ESG', 0.0021381338592618704)","('NON-ESG', 0.002067823428660631)"
Line 767,"This is also reported in the Good Governance section’s outline of ethical interactions with healthcare professionals.
","('Business_Ethics', 0.942450225353241)","('Competitive_Behavior', 0.008146101608872414)","('Human_Rights_And_Community_Relations', 0.005224855616688728)","(['Business Ethics'], 0.942450225353241)","('NON-ESG', 0.008146101608872414)","('NON-ESG', 0.005224855616688728)"
Line 768,"HC-MS-510a.2Description of code of ethics governing interactions with  healthcare professionals Reported in the Good Governance section’s outline of ethical interactions with healthcare professionals on page 55.
","('Business_Ethics', 0.966937243938446)","('Management_Of_Legal_And_Regulatory_Framework', 0.003245021915063262)","('Competitive_Behavior', 0.0030532691162079573)","(['Business Ethics'], 0.966937243938446)","('NON-ESG', 0.003245021915063262)","('NON-ESG', 0.0030532691162079573)"
Line 769,"This is also covered within the Hologic Code of Conduct .SASB (continued)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  58Topic Recommended Disclosure Response GovernanceDescribe the Board’s oversight of   climate-related risks and opportunities.Led by our senior management team and overseen by our Nominating and Corporate Governance Committee along with the Board of Directors, Hologic’s sustainability efforts are founded on the principle that virtually all business decisions have economic, environmental and social implications.
","('Physical_Impacts_Of_Climate_Change', 0.9284837245941162)","('Business_Model_Resilience', 0.019138718023896217)","('Supply_Chain_Management', 0.006350842770189047)","(['Climate Change'], 0.9284837245941162)","('NON-ESG', 0.019138718023896217)","('NON-ESG', 0.006350842770189047)"
Line 770,"This is also covered within the Hologic Code of Conduct .SASB (continued)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  58Topic Recommended Disclosure Response GovernanceDescribe the Board’s oversight of   climate-related risks and opportunities.Led by our senior management team and overseen by our Nominating and Corporate Governance Committee along with the Board of Directors, Hologic’s sustainability efforts are founded on the principle that virtually all business decisions have economic, environmental and social implications.
","('Human_Rights_And_Community_Relations', 0.6947104334831238)","('Business_Model_Resilience', 0.054256632924079895)","('Management_Of_Legal_And_Regulatory_Framework', 0.038926877081394196)","(['Community Relations'], 0.6947104334831238)","('NON-ESG', 0.054256632924079895)","('NON-ESG', 0.038926877081394196)"
Line 771,"We believe that integrating these considerations into our business strategy and decisions is an important part of growing the long-term success of the company and benefits our stockholders, customers and employees.
","('Business_Model_Resilience', 0.8203146457672119)","('Product_Design_And_Lifecycle_Management', 0.03465054929256439)","('Supply_Chain_Management', 0.015626398846507072)","(['Codes of Business Conduct'], 0.8203146457672119)","('NON-ESG', 0.03465054929256439)","('NON-ESG', 0.015626398846507072)"
Line 772,"Describe management’s role in assessing and managing risks and opportunities.Risk oversight is handled by the full Board as well as at the individual committee level, with the Board focusing on the evolving business and risk landscape as described on page 47.
","('Systemic_Risk_Management', 0.8902751803398132)","('Business_Model_Resilience', 0.03490479290485382)","('Physical_Impacts_Of_Climate_Change', 0.010278460569679737)","(['Risk & Crisis Management'], 0.8902751803398132)","('NON-ESG', 0.03490479290485382)","('NON-ESG', 0.010278460569679737)"
Line 773,"Hologic’s risk management process focuses on a comprehensive but targeted annual ERM report, which is presented to the Board, as well as periodic reports on evolving risks and mitigating actions, as warranted.
","('Systemic_Risk_Management', 0.7888320684432983)","('Business_Model_Resilience', 0.07802823185920715)","('Physical_Impacts_Of_Climate_Change', 0.05458587408065796)","(['Risk & Crisis Management'], 0.7888320684432983)","('NON-ESG', 0.07802823185920715)","('NON-ESG', 0.05458587408065796)"
Line 774,"Additionally, the executive leadership team’s individual performance objectives are aligned with the top risks identified in the annual enterprise risk management process.
","('Systemic_Risk_Management', 0.916320264339447)","('Business_Model_Resilience', 0.022745711728930473)","('Physical_Impacts_Of_Climate_Change', 0.013867144472897053)","(['Risk & Crisis Management'], 0.916320264339447)","('NON-ESG', 0.022745711728930473)","('NON-ESG', 0.013867144472897053)"
Line 775,"StrategyDescribe the climate-related risks and opportunities the organization has identified over the short, medium and long term.Hologic considers a variety of risks, as described on pages 32 and 47, when evaluating what is relevant to our climate assessment, including: policy, legal, technology, reputational, acute physical and chronic physical risk.
","('Physical_Impacts_Of_Climate_Change', 0.9509053230285645)","('Business_Model_Resilience', 0.01011611893773079)","('GHG_Emissions', 0.004527799319475889)","(['Climate Change'], 0.9509053230285645)","('NON-ESG', 0.01011611893773079)","('NON-ESG', 0.004527799319475889)"
Line 776,"Short-term risks include (1) acute physical risk from extreme weather events, (2) transition risks emanating from potential regulation  or utilization of alternative energy sources and (3) reputational risk as we continue to refine our sustainability strategy.
","('Business_Model_Resilience', 0.33879944682121277)","('Physical_Impacts_Of_Climate_Change', 0.27974629402160645)","('Systemic_Risk_Management', 0.1902633011341095)","('NON-ESG', 0.33879944682121277)","('NON-ESG', 0.27974629402160645)","('NON-ESG', 0.1902633011341095)"
Line 777,"All of which may necessitate additional capital expenditures or operating costs.
","('Energy_Management', 0.28698039054870605)","('Management_Of_Legal_And_Regulatory_Framework', 0.11225518584251404)","('Supply_Chain_Management', 0.10877031087875366)","('NON-ESG', 0.28698039054870605)","('NON-ESG', 0.11225518584251404)","('NON-ESG', 0.10877031087875366)"
Line 778,"Medium-term and long-term risks include chronic physical risk from longer-term changes in climate patterns, which may disrupt  supply chains or commercial activity.
","('Supply_Chain_Management', 0.9326518177986145)","('Physical_Impacts_Of_Climate_Change', 0.013499410822987556)","('Business_Model_Resilience', 0.00703803775832057)","(['Supply Chain Management'], 0.9326518177986145)","('NON-ESG', 0.013499410822987556)","('NON-ESG', 0.00703803775832057)"
Line 779,"Chronic physical risk also may increase capital expenditures, operating expenses or insurance claims liability.
","('Systemic_Risk_Management', 0.8146880865097046)","('Business_Ethics', 0.0490538589656353)","('Physical_Impacts_Of_Climate_Change', 0.019145390018820763)","(['Risk & Crisis Management'], 0.8146880865097046)","('NON-ESG', 0.0490538589656353)","('NON-ESG', 0.019145390018820763)"
Line 780,"Describe the impact of climate-related risks and opportunities on the organization’s businesses, strategy and financial planning.Short-term opportunities described on page 32 include resource efficiency by utilizing more efficient production and distribution processes, which may contribute to operating and emissions savings and reputational benefits.
","('Physical_Impacts_Of_Climate_Change', 0.8683056235313416)","('Business_Model_Resilience', 0.026968345046043396)","('Supply_Chain_Management', 0.023343192413449287)","(['Climate Change'], 0.8683056235313416)","('NON-ESG', 0.026968345046043396)","('NON-ESG', 0.023343192413449287)"
Line 781,"Medium-term and long-term opportunities include (1) energy source, by utilizing lower emission sources of energy, which may  contribute to operational efficiencies and reputational benefits and (2) products and services developed with lower emissions may improve our competitive position, reputation and generate efficiencies.
","('Product_Design_And_Lifecycle_Management', 0.8875746130943298)","('Energy_Management', 0.026816576719284058)","('Customer_Welfare', 0.011870961636304855)","(['Product Stewardship'], 0.8875746130943298)","('NON-ESG', 0.026816576719284058)","('NON-ESG', 0.011870961636304855)"
Line 782,"Hologic believes that integrating climate-related risks and opportunities into our business strategy and decisions is an important part  of growing the long-term success of the company and benefits our stockholders, customers and employees.
","('Physical_Impacts_Of_Climate_Change', 0.9251046776771545)","('Business_Model_Resilience', 0.02001134678721428)","('Systemic_Risk_Management', 0.010442717000842094)","(['Climate Change'], 0.9251046776771545)","('NON-ESG', 0.02001134678721428)","('NON-ESG', 0.010442717000842094)"
Line 783,"In the short-term, Hologic’s climate strategy is related to evaluating the preparedness of our physical facilities for extreme weather  events, as well as making sure our products benefit from efficient production and distribution processes.
","('Product_Design_And_Lifecycle_Management', 0.9154098629951477)","('Supply_Chain_Management', 0.012528383173048496)","('Business_Model_Resilience', 0.01202969066798687)","(['Product Stewardship'], 0.9154098629951477)","('NON-ESG', 0.012528383173048496)","('NON-ESG', 0.01202969066798687)"
Line 784,"In the long-term, Hologic’s climate strategy is focused on maximizing returns for all of our stakeholders and is integrated into thought  process around long-term environmental targets, operations, supply chain, as well as the related financial implications to revenue, direct and indirect costs and capital expenditures.
","('Supply_Chain_Management', 0.9226667284965515)","('Product_Design_And_Lifecycle_Management', 0.013005786575376987)","('Business_Model_Resilience', 0.010996638797223568)","(['Supply Chain Management'], 0.9226667284965515)","('NON-ESG', 0.013005786575376987)","('NON-ESG', 0.010996638797223568)"
Line 785,"Describe the resilience of the organization’s strategy, taking into consideration different climate-related scenarios, including a 2°C or lower scenario.Hologic understands the significant challenges that climate change presents.
","('Physical_Impacts_Of_Climate_Change', 0.4880971908569336)","('Business_Model_Resilience', 0.3964468538761139)","('Supply_Chain_Management', 0.014372001402080059)","('NON-ESG', 0.4880971908569336)","('NON-ESG', 0.3964468538761139)","('NON-ESG', 0.014372001402080059)"
Line 786,"We will continue to work to understand different  climate-related scenarios and how to align environmental goals to avoid worldwide average temperatures increasing more than  2°C, recognizing the importance of the United Nations Climate Agreement.Task Force on Climate-Related Financial Disclosures Index2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  59Topic Recommended Disclosure Response Risk ManagementDescribe the organization’s processes for identifying   and assessing climate-related risks.Hologic’s risk management process focuses on a comprehensive but targeted annual enterprise risk management assessment, which involves an enterprise risk management (ERM) report compiled by business leaders who have assessed risk throughout the business over a three-year horizon, focusing on financial risk, legal/compliance risk and operational/strategic risk.
","('Physical_Impacts_Of_Climate_Change', 0.9339876174926758)","('Business_Model_Resilience', 0.01598924584686756)","('GHG_Emissions', 0.008663158863782883)","(['Climate Change'], 0.9339876174926758)","('NON-ESG', 0.01598924584686756)","('NON-ESG', 0.008663158863782883)"
Line 787,"We will continue to work to understand different  climate-related scenarios and how to align environmental goals to avoid worldwide average temperatures increasing more than  2°C, recognizing the importance of the United Nations Climate Agreement.Task Force on Climate-Related Financial Disclosures Index2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  59Topic Recommended Disclosure Response Risk ManagementDescribe the organization’s processes for identifying   and assessing climate-related risks.Hologic’s risk management process focuses on a comprehensive but targeted annual enterprise risk management assessment, which involves an enterprise risk management (ERM) report compiled by business leaders who have assessed risk throughout the business over a three-year horizon, focusing on financial risk, legal/compliance risk and operational/strategic risk.
","('Physical_Impacts_Of_Climate_Change', 0.91285240650177)","('Business_Model_Resilience', 0.022602977231144905)","('Systemic_Risk_Management', 0.0195030365139246)","(['Climate Change'], 0.91285240650177)","('NON-ESG', 0.022602977231144905)","('NON-ESG', 0.0195030365139246)"
Line 788,"The ERM report details Hologic’s top ten risks as well as mitigating actions and plans relating to those risks.
","('Systemic_Risk_Management', 0.8539065718650818)","('Physical_Impacts_Of_Climate_Change', 0.0455479770898819)","('Business_Model_Resilience', 0.028927205130457878)","(['Risk & Crisis Management'], 0.8539065718650818)","('NON-ESG', 0.0455479770898819)","('NON-ESG', 0.028927205130457878)"
Line 789,"The ERM report, presented to and discussed with the Board each year, includes a rolling three-year evaluation period that reflects mitigation activity progress and risk rating changes.
","('Business_Model_Resilience', 0.5386818647384644)","('Systemic_Risk_Management', 0.17718760669231415)","('Physical_Impacts_Of_Climate_Change', 0.10040061175823212)","(['Codes of Business Conduct'], 0.5386818647384644)","('NON-ESG', 0.17718760669231415)","('NON-ESG', 0.10040061175823212)"
Line 790,"See pages 32 and 47 for more information.
","('Customer_Privacy', 0.12188323587179184)","('Management_Of_Legal_And_Regulatory_Framework', 0.09282812476158142)","('Data_Security', 0.08925507962703705)","('NON-ESG', 0.12188323587179184)","('NON-ESG', 0.09282812476158142)","('NON-ESG', 0.08925507962703705)"
Line 791,"Describe the organization’s processes for managing climate-related risks.Risk oversight, as described on pages 32 and 47, is handled by the full Board as well as at the individual committee level, with the Board focusing on the evolving business and risk landscape.
","('Physical_Impacts_Of_Climate_Change', 0.9444395303726196)","('Business_Model_Resilience', 0.013646218925714493)","('Systemic_Risk_Management', 0.004597002174705267)","(['Climate Change'], 0.9444395303726196)","('NON-ESG', 0.013646218925714493)","('NON-ESG', 0.004597002174705267)"
Line 792,"Additionally, the executive leadership team’s individual performance objectives are aligned with the top risks identified in the annual enterprise risk management process.
","('Systemic_Risk_Management', 0.916320264339447)","('Business_Model_Resilience', 0.022745711728930473)","('Physical_Impacts_Of_Climate_Change', 0.013867144472897053)","(['Risk & Crisis Management'], 0.916320264339447)","('NON-ESG', 0.022745711728930473)","('NON-ESG', 0.013867144472897053)"
Line 793,"Describe how processes for identifying, assessing,  and managing climate-related risks are integrated into the organization’s overall risk management.Risk oversight, as described on pages 32 and 47, is handled by the full Board as well as at the individual committee level, with the Board focusing on the evolving business and risk landscape.
","('Physical_Impacts_Of_Climate_Change', 0.9248074889183044)","('Business_Model_Resilience', 0.0217550341039896)","('Systemic_Risk_Management', 0.010767539031803608)","(['Climate Change'], 0.9248074889183044)","('NON-ESG', 0.0217550341039896)","('NON-ESG', 0.010767539031803608)"
Line 794,"The company’s ERM report is presented annually to the Board along with periodic reports on evolving risks and mitigating actions, as warranted.
","('Systemic_Risk_Management', 0.707092821598053)","('Business_Model_Resilience', 0.09090278297662735)","('Physical_Impacts_Of_Climate_Change', 0.0851060301065445)","(['Risk & Crisis Management'], 0.707092821598053)","('NON-ESG', 0.09090278297662735)","('NON-ESG', 0.0851060301065445)"
Line 795,"Metrics & TargetsDisclose the metrics used by the organization to assess climate-related risks and opportunities in line with its strategy and risk management process.Hologic monitors and reports on greenhouse gas emissions.
","('GHG_Emissions', 0.9641393423080444)","('Air_Quality', 0.004130922723561525)","('Physical_Impacts_Of_Climate_Change', 0.0038209494668990374)","(['Climate Change'], 0.9641393423080444)","('NON-ESG', 0.004130922723561525)","('NON-ESG', 0.0038209494668990374)"
Line 796,"We also track internal projects, such as installing solar panels at our Costa Rica facility, which are intended to reduce our carbon footprint, as described on page 30.
","('Energy_Management', 0.8563115000724792)","('GHG_Emissions', 0.02537805773317814)","('Physical_Impacts_Of_Climate_Change', 0.01920442096889019)","(['Operational Eco-Efficiency'], 0.8563115000724792)","('NON-ESG', 0.02537805773317814)","('NON-ESG', 0.01920442096889019)"
Line 797,"Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 GHG emissions, and the related risks.2022 Scope 1 & 2 GHG emissions: 7,427 Metric Ton CO 2e Scope 1 and 12,512 Metric Ton CO2e Scope 2, as described   on page 28.
","('GHG_Emissions', 0.9673689007759094)","('Air_Quality', 0.004276936873793602)","('Ecological_Impacts', 0.0033547307830303907)","(['Climate Change'], 0.9673689007759094)","('NON-ESG', 0.004276936873793602)","('NON-ESG', 0.0033547307830303907)"
Line 798,"We have focused on Scope 1 and 2 emissions to inform our energy sourcing initiatives.
","('Energy_Management', 0.9025396704673767)","('GHG_Emissions', 0.02101488597691059)","('Product_Design_And_Lifecycle_Management', 0.009704209864139557)","(['Operational Eco-Efficiency'], 0.9025396704673767)","('NON-ESG', 0.02101488597691059)","('NON-ESG', 0.009704209864139557)"
Line 799,"As we continue to develop Hologic’s  sustainability program we will baseline our Scope 3 emissions.
","('GHG_Emissions', 0.8490808606147766)","('Air_Quality', 0.03614649921655655)","('Energy_Management', 0.027692003175616264)","(['Climate Change'], 0.8490808606147766)","('NON-ESG', 0.03614649921655655)","('NON-ESG', 0.027692003175616264)"
Line 800,"Describe the targets used by the organization to  manage climate-related risks and opportunities  and performance against targets.•  Achieve a 15% reduction in non-hazardous/non-recyclable waste by 2025.
","('Waste_And_Hazardous_Materials_Management', 0.9798531532287598)","('Product_Design_And_Lifecycle_Management', 0.0019243163987994194)","('Water_And_Wastewater_Management', 0.0015290265437215567)","(['Operational Eco-Efficiency'], 0.9798531532287598)","('NON-ESG', 0.0019243163987994194)","('NON-ESG', 0.0015290265437215567)"
Line 801,"•  Achieve a 30% reduction of Scope 1 & 2 emissions by 2030.•  Achieve a 40% reliance on self-generated renewable energy on owned sites by 2030.•  Convert to 50% renewable electricity by 2030 and 75% renewable electricity by 2035.All reduction targets use a 2020 baseline.
","('Energy_Management', 0.9479855895042419)","('Management_Of_Legal_And_Regulatory_Framework', 0.01677500084042549)","('GHG_Emissions', 0.0066673485562205315)","(['Operational Eco-Efficiency'], 0.9479855895042419)","('NON-ESG', 0.01677500084042549)","('NON-ESG', 0.0066673485562205315)"
Line 802,"The preceding goals pertain to Operational Sites and are expressed as a   percentage of revenue.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4319155216217041)","('Energy_Management', 0.10880543291568756)","('Business_Model_Resilience', 0.07085665315389633)","('NON-ESG', 0.4319155216217041)","('NON-ESG', 0.10880543291568756)","('NON-ESG', 0.07085665315389633)"
Line 803,"Details appear on pages 28-29.Task Force on Climate-Related Financial Disclosures Index (continued)2022 Hologic Sustainability ReportFrom Our CEO      Our Purpose      Championing Women      Our Communities      The Environment     Our People      Good Governance  60This report contains forward-looking information that involves risks and uncertainties, including  statements about the company’s plans, objectives, expectations and intentions.
","('Physical_Impacts_Of_Climate_Change', 0.9197198152542114)","('Business_Model_Resilience', 0.023447943851351738)","('Systemic_Risk_Management', 0.008621493354439735)","(['Climate Change'], 0.9197198152542114)","('NON-ESG', 0.023447943851351738)","('NON-ESG', 0.008621493354439735)"
Line 804,"Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the company’s outlook and financial and other guidance.
","('Business_Model_Resilience', 0.8440408706665039)","('Systemic_Risk_Management', 0.03169528767466545)","('Physical_Impacts_Of_Climate_Change', 0.017446639016270638)","(['Codes of Business Conduct'], 0.8440408706665039)","('NON-ESG', 0.03169528767466545)","('NON-ESG', 0.017446639016270638)"
Line 805,"These forward-looking statements are based upon assumptions made by the company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from  those anticipated.
","('Systemic_Risk_Management', 0.9266126751899719)","('Business_Model_Resilience', 0.010108924470841885)","('Supply_Chain_Management', 0.008244175463914871)","(['Risk & Crisis Management'], 0.9266126751899719)","('NON-ESG', 0.010108924470841885)","('NON-ESG', 0.008244175463914871)"
Line 806,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Systemic_Risk_Management', 0.9489806294441223)","('Business_Model_Resilience', 0.011622508056461811)","('Physical_Impacts_Of_Climate_Change', 0.006193095818161964)","(['Risk & Crisis Management'], 0.9489806294441223)","('NON-ESG', 0.011622508056461811)","('NON-ESG', 0.006193095818161964)"
Line 807,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Supply_Chain_Management', 0.6723631024360657)","('Product_Design_And_Lifecycle_Management', 0.18624931573867798)","('Selling_Practices_And_Product_Labeling', 0.014186903834342957)","(['Supply Chain Management'], 0.6723631024360657)","('NON-ESG', 0.18624931573867798)","('NON-ESG', 0.014186903834342957)"
Line 808,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Product_Design_And_Lifecycle_Management', 0.42681175470352173)","('Competitive_Behavior', 0.27901244163513184)","('Supply_Chain_Management', 0.07274871319532394)","('NON-ESG', 0.42681175470352173)","('NON-ESG', 0.27901244163513184)","('NON-ESG', 0.07274871319532394)"
Line 809,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Data_Security', 0.791785717010498)","('Systemic_Risk_Management', 0.07414934784173965)","('Physical_Impacts_Of_Climate_Change', 0.030684778466820717)","(['Information Security/Cybersecurity & System Availability'], 0.791785717010498)","('NON-ESG', 0.07414934784173965)","('NON-ESG', 0.030684778466820717)"
Line 810,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Employee_Engagement_Inclusion_And_Diversity', 0.44553908705711365)","('Business_Model_Resilience', 0.1672057956457138)","('Director_Removal', 0.052366822957992554)","('NON-ESG', 0.44553908705711365)","('NON-ESG', 0.1672057956457138)","('NON-ESG', 0.052366822957992554)"
Line 811,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Product_Design_And_Lifecycle_Management', 0.5954583883285522)","('Product_Quality_And_Safety', 0.153825044631958)","('Selling_Practices_And_Product_Labeling', 0.08743695914745331)","(['Product Stewardship'], 0.5954583883285522)","('NON-ESG', 0.153825044631958)","('NON-ESG', 0.08743695914745331)"
Line 812,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48418864607810974)","('Selling_Practices_And_Product_Labeling', 0.1504906862974167)","('Product_Quality_And_Safety', 0.1275448203086853)","('NON-ESG', 0.48418864607810974)","('NON-ESG', 0.1504906862974167)","('NON-ESG', 0.1275448203086853)"
Line 813,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Systemic_Risk_Management', 0.872636616230011)","('Competitive_Behavior', 0.03627675026655197)","('Business_Model_Resilience', 0.023033035919070244)","(['Risk & Crisis Management'], 0.872636616230011)","('NON-ESG', 0.03627675026655197)","('NON-ESG', 0.023033035919070244)"
Line 814,"Risks and uncertainties that could adversely affect the company’s business and prospects,  and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, the war in Ukraine, other economic disruptions and U.S. and global recession concerns, on the company’s customers and suppliers and on the company’s business, financial condition, results of operations and cash flows and the company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the company’s products in certain countries, or increase the costs the company may incur to purchase materials, parts and equipment from its suppliers; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, including semiconductor chips, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the company’s sole source third-party manufacturers fail to supply the company; the development of new competitive technologies and products and competition; the company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the company’s COVID-19 assays; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic and any future public health crises; potential cybersecurity threats and targeted computer crime; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the company may complete in the future; the ability to consolidate certain of the company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the company to successfully manage leadership and organizational changes, including the ability of the company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain regulatory approvals and clearances for the company’s products, including the implementation of the European Union Medical Device Regulations, and to maintain compliance with complex and evolving regulations; the company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the company’s international activities and businesses; the early stage of market development for certain of the company’s products; the company’s leverage risks, including the company’s obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; and technical innovations that could render products marketed or under development by the company obsolete.
","('Product_Design_And_Lifecycle_Management', 0.5752390623092651)","('Competitive_Behavior', 0.09659584611654282)","('Product_Quality_And_Safety', 0.04739433526992798)","(['Product Stewardship'], 0.5752390623092651)","('NON-ESG', 0.09659584611654282)","('NON-ESG', 0.04739433526992798)"
Line 815,"The risks included above are not exhaustive.
","('Systemic_Risk_Management', 0.8874745965003967)","('Physical_Impacts_Of_Climate_Change', 0.019915934652090073)","('Supply_Chain_Management', 0.011615498922765255)","(['Risk & Crisis Management'], 0.8874745965003967)","('NON-ESG', 0.019915934652090073)","('NON-ESG', 0.011615498922765255)"
Line 816,"Other factors that could adversely affect the  company’s business and prospects are described in the filings made by the company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
","('Business_Model_Resilience', 0.45723503828048706)","('Systemic_Risk_Management', 0.2816503942012787)","('Physical_Impacts_Of_Climate_Change', 0.044409241527318954)","('NON-ESG', 0.45723503828048706)","('NON-ESG', 0.2816503942012787)","('NON-ESG', 0.044409241527318954)"
Line 817,"The company expressly disclaims any obligation or undertaking to release publicly any updates  or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5998368859291077)","('Business_Model_Resilience', 0.10425471514463425)","('Physical_Impacts_Of_Climate_Change', 0.05167609080672264)","(['Corporate Governance'], 0.5998368859291077)","('NON-ESG', 0.10425471514463425)","('NON-ESG', 0.05167609080672264)"
Line 818,"Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc.
","('Competitive_Behavior', 0.26489466428756714)","('Customer_Privacy', 0.1875765472650528)","('Selling_Practices_And_Product_Labeling', 0.08955670893192291)","('NON-ESG', 0.26489466428756714)","('NON-ESG', 0.1875765472650528)","('NON-ESG', 0.08955670893192291)"
Line 819,"and/or its subsidiaries in the United States and/or other countries.
","('Customer_Privacy', 0.16120721399784088)","('Director_Removal', 0.12255706638097763)","('Business_Model_Resilience', 0.11338447034358978)","('NON-ESG', 0.16120721399784088)","('NON-ESG', 0.12255706638097763)","('NON-ESG', 0.11338447034358978)"
Line 820,"This report contains certain financial measures that have not been prepared in accordance   with U.S. generally accepted accounting principles (“GAAP”).
","('Management_Of_Legal_And_Regulatory_Framework', 0.8585952520370483)","('Systemic_Risk_Management', 0.03896179795265198)","('GHG_Emissions', 0.011257861740887165)","(['Corporate Governance'], 0.8585952520370483)","('NON-ESG', 0.03896179795265198)","('NON-ESG', 0.011257861740887165)"
Line 821,"The non-GAAP financial measures  used in this report adjust for specified items that can be highly variable or difficult to predict.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7965552806854248)","('Systemic_Risk_Management', 0.0938064306974411)","('Physical_Impacts_Of_Climate_Change', 0.00949796661734581)","(['Corporate Governance'], 0.7965552806854248)","('NON-ESG', 0.0938064306974411)","('NON-ESG', 0.00949796661734581)"
Line 822,"The company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Hologic’s historical operating results, comparison to competitors’ operating results and determination of management  incentive compensation.
","('Competitive_Behavior', 0.6556926369667053)","('Systemic_Risk_Management', 0.0966663733124733)","('Management_Of_Legal_And_Regulatory_Framework', 0.07625366747379303)","(['Business Ethics'], 0.6556926369667053)","('NON-ESG', 0.0966663733124733)","('NON-ESG', 0.07625366747379303)"
Line 823,"These non-GAAP financial measures reflect an additional way of viewing aspects of the company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of  factors and trends affecting Hologic’s business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3742188811302185)","('Systemic_Risk_Management', 0.3502865433692932)","('Business_Model_Resilience', 0.07761167734861374)","('NON-ESG', 0.3742188811302185)","('NON-ESG', 0.3502865433692932)","('NON-ESG', 0.07761167734861374)"
Line 824,"These non-GAAP financial measures should be considered supplemental to, and not a substitute  for, financial information prepared in accordance with GAAP.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9404072165489197)","('Systemic_Risk_Management', 0.005733624566346407)","('Business_Ethics', 0.005355366505682468)","(['Corporate Governance'], 0.9404072165489197)","('NON-ESG', 0.005733624566346407)","('NON-ESG', 0.005355366505682468)"
Line 825,"The company’s definition of these non-GAAP measures may differ from similarly titled measures used by others.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8691589832305908)","('Systemic_Risk_Management', 0.02772902324795723)","('Competitive_Behavior', 0.01154869794845581)","(['Corporate Governance'], 0.8691589832305908)","('NON-ESG', 0.02772902324795723)","('NON-ESG', 0.01154869794845581)"
Line 826,"Because non-GAAP financial measures exclude the effect of items that will increase or decrease  the company’s reported results of operations, management strongly encourages you to review the company’s consolidated financial statements and publicly filed reports in their entirety.
","('Management_Of_Legal_And_Regulatory_Framework', 0.601787269115448)","('Systemic_Risk_Management', 0.13726767897605896)","('Business_Model_Resilience', 0.05967286601662636)","(['Corporate Governance'], 0.601787269115448)","('NON-ESG', 0.13726767897605896)","('NON-ESG', 0.05967286601662636)"
Line 827,"A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9298750162124634)","('Systemic_Risk_Management', 0.014007584191858768)","('Business_Ethics', 0.00810275599360466)","(['Corporate Governance'], 0.9298750162124634)","('NON-ESG', 0.014007584191858768)","('NON-ESG', 0.00810275599360466)"
Line 828,"Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc.
","('Competitive_Behavior', 0.26489466428756714)","('Customer_Privacy', 0.1875765472650528)","('Selling_Practices_And_Product_Labeling', 0.08955670893192291)","('NON-ESG', 0.26489466428756714)","('NON-ESG', 0.1875765472650528)","('NON-ESG', 0.08955670893192291)"
Line 829,"and/or its subsidiaries in the United States and/or other countries.
","('Customer_Privacy', 0.16120721399784088)","('Director_Removal', 0.12255706638097763)","('Business_Model_Resilience', 0.11338447034358978)","('NON-ESG', 0.16120721399784088)","('NON-ESG', 0.12255706638097763)","('NON-ESG', 0.11338447034358978)"
Line 830,"Safe Harbor Statement61Enabling healthier lives everywhere, every day.
","('Employee_Health_And_Safety', 0.6994667649269104)","('Critical_Incident_Risk_Management', 0.0970175489783287)","('Access_And_Affordability', 0.03266114369034767)","(['Operational Eco-Efficiency'], 0.6994667649269104)","('NON-ESG', 0.0970175489783287)","('NON-ESG', 0.03266114369034767)"
Line 831,"Follow Hologic’s sustainability journey at  hologic.com/sustainabilityInvestor Relations: Ryan Simon   Vice President, Investor Relations   858.410.8514   ryan.simon@hologic.comMedia Relations:Jane Mazur   Vice President, Communications   508.263.8764   jane.mazur@hologic.com MISC-08685 © 2023 Hologic Inc.
","('Business_Model_Resilience', 0.5515254735946655)","('Product_Design_And_Lifecycle_Management', 0.07339178770780563)","('Director_Removal', 0.04437753185629845)","(['Codes of Business Conduct'], 0.5515254735946655)","('NON-ESG', 0.07339178770780563)","('NON-ESG', 0.04437753185629845)"
Line 832,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 833,"Hologic and The Science of Sure are trademarks of Hologic Inc.
","('Competitive_Behavior', 0.273227721452713)","('Selling_Practices_And_Product_Labeling', 0.08718230575323105)","('Customer_Welfare', 0.06838022917509079)","('NON-ESG', 0.273227721452713)","('NON-ESG', 0.08718230575323105)","('NON-ESG', 0.06838022917509079)"
Line 834,"Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries  include, but are not limited to, the following: ThinPrep, 3D Mammography, Genius, 3Dimensions, Genius 3D, Panther Fusion, Aptima, Novodiag, SmartCurve, Affirm, Clarity HD+ 3D, Aptima Combo 2, MyoSure, Tigris, DTS, NovaSure, Rapid fFN, Selenia, Breast Cancer Index, Dimensions, Acessa, and Acessa ProVu. All other trademarks, registered trademarks and product names are the property of their respective owners.","('Competitive_Behavior', 0.2564328908920288)","('Customer_Privacy', 0.1754886358976364)","('Business_Ethics', 0.09754349291324615)","('NON-ESG', 0.2564328908920288)","('NON-ESG', 0.1754886358976364)","('NON-ESG', 0.09754349291324615)"
Line 835,"Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries  include, but are not limited to, the following: ThinPrep, 3D Mammography, Genius, 3Dimensions, Genius 3D, Panther Fusion, Aptima, Novodiag, SmartCurve, Affirm, Clarity HD+ 3D, Aptima Combo 2, MyoSure, Tigris, DTS, NovaSure, Rapid fFN, Selenia, Breast Cancer Index, Dimensions, Acessa, and Acessa ProVu. All other trademarks, registered trademarks and product names are the property of their respective owners.","('Management_Of_Legal_And_Regulatory_Framework', 0.14228960871696472)","('Customer_Privacy', 0.08745519816875458)","('Product_Design_And_Lifecycle_Management', 0.08007341623306274)","('NON-ESG', 0.14228960871696472)","('NON-ESG', 0.08745519816875458)","('NON-ESG', 0.08007341623306274)"
